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SUMMARY 
 
Cardiovascular disease (CVD) causes 45% of on-duty firefighter fatalities, a high 
fraction even when compared to the risk of CVD found in other first-responder 
professions like police work and emergency medical services. Monitoring and managing 
firefighter cardiac health is important for both individual health and public safety. In our 
study, we are interested in assessing the utility of the most commonly used risk 
assessment scoring, known as the Framingham Risk Score, in evaluating the 
atherosclerotic risk in asymptomatic firefighters. To this end we determined FRS for 159 
male firefighters from Gwinnett County, Georgia, and compared their risk categorization 
against their known atherosclerotic burden as determined by CIMT and CAC. While the 
20% FRS threshold, corresponding to medium risk, had a high specificity for both CAC 
and CIMT, it also had a low sensitivity (17% and 40%, respectively), indicating that a 
large percentage of individuals with clinically significant atherosclerosis are being 
misclassified. By adjusting the FRS threshold downward, we were able to raise the 
sensitivity greatly with only a modest loss of specificity.  
 
Following percutaneous transluminal coronary angioplasty for the treatment of 
coronary artery disease, stents are commonly implanted at the treatment site to prevent 
recoil and negative remodeling. To combat in-stent restenosis, an arterial healing 
response that results in luminal loss in stented arteries, anti-restenotic drugs like sirolimus 
(SES) and zotarolimus (ZES) are commonly eluted by stents to suppress cell proliferation 
at the treatment site. While comparative studies have revealed significant difference 
 xii 
between bare metal stents (BMS), SES, and ZES in both clinical and histological arterial 
response, the molecular basis of these differences remains poorly understood. We 
conducted a comparative gene expression profiling study using microarrays to examine 
differences in gene expression and pathway function in coronary arteries exposed to ZES, 
SES, and BMS in a porcine animal model. These molecular profiles suggest a model of 
delayed restenosis, resulting from a drug-induced suppression of inflammatory responses 
and proliferative processes, rather than an elimination of restenosis.  
 
microRNAs play a regulatory role in metastasis-related epithelial to mesenchymal 
transitions and mesenchymal to epithelial transitions in ovarian cancer cells. We 
previously showed that over-expression of miR-429 in ovarian cancer cells drove a 
transition from mesenchymal phenotypes to epithelial phenotypes both in morphology 
and expression of markers like ZEB1, ZEB2, and E-cadherin. Our study represents the 
first time course analysis of miR-429-induced MET in ovarian cancer cells. We 
transfected Hey cells with miR-429 and assayed gene expression over the course of 144 
hours at regular intervals. The cell morphology and gene expression of our transfected 
cells changed to become more epithelial-like at 24 and 48 hours and then became more 
mesenchymal-like by 144 hours.  By 144 hours the average gene expression levels for 
98.6% of our genes were not significantly different from the levels they started from at 0 
hours when we adjusted for baseline expression changes observed in our negative control 
treated cells. This suggests the use of microRNAs as cancer therapies and driving cancer 
cells to a more drug susceptible state.
CHAPTER	  1	  
INTRODUCTION	  
	  
	  
	  
1.1	  Gene	  expression	  
	   Transcriptional	  regulation	  and	  the	  post-­‐transcriptional	  processing	  of	  
messenger	  RNAs	  (mRNA)	  are	  early	  steps	  in	  the	  regulation	  of	  gene	  expression,	  
controlling	  the	  types	  and	  amounts	  of	  proteins	  produced	  by	  cells	  via	  control	  of	  mRNA	  
content	  and	  quantity.	  Transcriptional	  regulation	  through	  the	  direct	  action	  of	  
activators,	  repressors,	  enhancers,	  and	  transcription	  factors	  alter	  transcription	  rates	  
and	  have	  a	  large	  influence	  on	  transcript	  abundance.	  Post-­‐transcriptional	  regulation	  
and	  processing	  also	  influences	  the	  abundance	  and	  content	  of	  transcripts.	  Capping	  
and	  polyadenylation	  protect	  mRNA	  from	  degradation,	  extending	  their	  expressive	  
life	  spans.	  Splicing	  both	  removes	  intronic	  material	  from	  transcripts	  and	  can	  
generate	  alternative	  transcripts,	  where	  different	  proteins	  can	  be	  generated	  from	  
one	  complex	  transcription	  unit,	  altering	  the	  balance	  of	  content	  in	  mRNAs.	  RNA	  
interference	  and	  microRNAs	  can	  also	  drive	  the	  silencing	  and	  degradation	  of	  mRNA	  
signals	  post-­‐transcriptionally.	  The	  ensemble	  of	  mRNA	  molecules	  in	  a	  cell	  is	  
described	  as	  the	  transcriptome.	  Although	  changes	  in	  the	  amounts	  of	  specific	  mRNAs	  
are	  not	  always	  directly	  related	  to	  the	  amount	  of	  the	  protein	  product	  encoded	  by	  the	  
message,	  ensemble	  changes	  in	  mRNAs	  can	  be	  linked	  to	  ensemble	  changes	  in	  protein	  
abundance	  and	  shifts	  in	  metabolic	  pathway	  component	  expression	  and	  phenotypic	  
changes.	  Thus	  the	  abundance	  of	  transcripts	  is	  a	  quantitative	  trait	  that	  connects	  DNA	  
sequence	  variation	  with	  phenotype.	  	  
	   Transcriptomic	  analysis	  with	  expression	  microarrays,	  RT-­‐PCR	  and	  RNA-­‐Seq	  
makes	  it	  possible	  to	  link	  the	  state	  of	  a	  cell	  to	  a	  high-­‐resolution	  signature	  of	  mRNA	  
abundances.	  Genes	  linked	  to	  particular	  mRNAs	  whose	  abundances	  change	  in	  
response	  to	  a	  stimulus	  can	  be	  grouped	  together	  by	  their	  expression	  changes	  using	  
covariance	  analysis,	  ontologically-­‐driven	  pathway	  analyses,	  or	  network	  analyses	  
using	  no	  a	  priori	  knowledge.	  Moreover,	  the	  ability	  of	  mRNAs	  to	  be	  sequenced	  or	  
assayed	  with	  microarrays,	  generating	  “linear”	  data	  for	  many	  mRNAs	  in	  parallel,	  
render	  them	  more	  convenient	  to	  measure	  than	  the	  proteins	  of	  the	  same	  genes,	  
which	  are	  unstable,	  have	  detailed	  3D	  conformations,	  and	  form	  multi-­‐protein	  
complexes.	  This	  ability	  to	  quantify	  tens	  of	  thousands	  of	  mRNAs	  at	  once	  is	  the	  
primary	  advantage	  that	  new	  transcriptomic	  assays	  provide	  over	  the	  classic	  
Northern	  blot.	  It	  permits	  sampling	  of	  expression	  across	  the	  genome,	  allowing	  for	  the	  
unsupervised	  determination	  of	  differentially	  expressed	  genes	  rather	  than	  relying	  on	  
a	  pre-­‐determined	  set	  of	  genes	  or	  pathways	  that	  would	  limit	  the	  scope	  of	  analysis,	  
facilitating	  their	  use	  in	  hypothesis-­‐generation.	  It	  also	  allows	  for	  the	  detection	  of	  
differential	  expression	  in	  complex	  pathways	  and	  systems	  containing	  many	  genes,	  
particularly	  in	  those	  cases	  where	  small	  expression	  differences	  and	  network	  effects	  
may	  drive	  changes.	  	  
	   The	  Affymetrix	  GeneChip	  expression	  analysis	  platform	  used	  both	  in	  our	  time-­‐
course	  work	  in	  tracking	  the	  mesenchymal-­‐epithelial	  transition	  in	  ovarian	  cancer	  
cells	  as	  well	  as	  our	  analysis	  of	  coronary	  artery	  changes	  in	  response	  to	  different	  
drug-­‐eluting	  coronary	  stents	  is	  one	  of	  the	  most	  commonly	  used	  gene	  expression	  
microarrays	  used	  in	  gene	  expression	  studies.	  Affymetrix	  arrays	  are	  produced	  by	  in	  
situ	  synthesis	  of	  24mer	  oligonucleotides	  probes	  at	  high	  densities	  where	  individual	  
feature	  sizes	  can	  be	  as	  small	  as	  8	  µm	  (Lockhart	  et	  al.	  1996).	  Typically	  11	  perfect	  
match	  probes	  complementary	  to	  different	  positions	  along	  each	  mRNA	  transcript	  
measure	  relative	  expression	  while	  a	  set	  of	  mismatch	  probes	  that	  are	  identical	  to	  the	  
perfect	  match	  probes	  except	  for	  a	  single	  base	  modification	  in	  the	  middle	  position	  
detect	  non-­‐specific	  hybridizations	  (Dalma-­‐Weiszhausz	  et	  al.	  2006).	  The	  GeneChip	  
Human	  Genome	  U133	  Plus	  2.0	  Array	  is	  comprised	  of	  1.3	  million	  oligonucleotide	  
features	  to	  assay	  the	  relative	  expression	  levels	  of	  54,000	  transcripts.	  These	  types	  of	  
oligonucleotide	  arrays	  have	  the	  advantage	  of	  being	  relatively	  high	  density,	  have	  
good	  reproducibility	  compared	  to	  spotted	  arrays,	  and	  ease	  of	  preparation.	  However	  
compared	  to	  RNA-­‐Seq	  approaches	  made	  possible	  by	  next-­‐generation	  sequencing,	  
these	  microarrays	  are	  expensive	  and	  limited	  to	  known	  gene	  targets	  (Baginsky	  et	  al.	  
2010).	  	  
1.1.1	  Interpretation	  
To	  extract	  useful	  information	  from	  normalized	  gene	  expression	  data,	  we	  must	  apply	  
the	  appropriate	  statistical	  tests	  to	  determine	  if	  expression	  levels	  are	  significantly	  
different	  between	  treatments.	  Here	  the	  large	  number	  of	  gene	  transcripts	  measured	  
at	  once	  for	  each	  sample	  presents	  a	  challenge	  where	  a	  large	  number	  of	  variables	  are	  
measured	  for	  relatively	  few	  samples	  per	  treatment	  as	  well	  as	  an	  advantage	  where	  
greater	  insight	  can	  be	  had	  into	  more	  complex	  biological	  systems.	  Whatever	  the	  level	  
of	  detail	  desired,	  successful	  gene	  expression	  studies	  must	  be	  carefully	  planned	  so	  
that	  the	  experimental	  design	  is	  capable	  of	  answering	  the	  questions	  posed	  with	  
appropriate	  sample	  sizes	  across	  groups,	  and	  well-­‐chosen	  controls.	  Given	  the	  high	  
cost	  of	  gene	  expression	  studies,	  failure	  to	  consider	  statistical	  analyses	  during	  the	  
planning	  stage	  can	  lead	  to	  results	  with	  low	  discriminatory	  power	  and	  a	  poor	  ability	  
to	  support	  strong	  conclusions.	  	  	  
In	  the	  past,	  fold	  change	  values	  were	  used	  to	  describe	  differences	  between	  
two	  treatment	  groups,	  typically	  a	  case	  and	  control	  group,	  using	  a	  chosen	  threshold	  
for	  determining	  significant	  differences	  or	  a	  ranked	  fold	  change	  list	  to	  describe	  
expression	  patterns	  found	  between	  the	  two	  groups.	  This	  approach	  suffered	  from	  
fold-­‐change	  thresholds	  that	  were	  subjective	  choices,	  as	  well	  as	  a	  lack	  of	  accounting	  
for	  within-­‐system	  variance,	  where	  genes	  can	  have	  large	  fold-­‐changes	  that	  may	  
actually	  be	  insignificant	  when	  considered	  in	  the	  context	  of	  highly	  variable	  data.	  A	  
more	  sound	  approach	  utilizes	  statistical	  tests	  like	  t-­‐tests	  that	  describe	  the	  difference	  
in	  estimated	  means	  of	  each	  group	  relative	  to	  the	  amount	  of	  variance	  found	  in	  both	  
groups.	  Although	  the	  traditional	  t-­‐test	  does	  not	  perform	  optimally	  in	  cases	  with	  
small	  sample	  sizes,	  as	  are	  often	  found	  in	  microarray	  studies,	  variations	  of	  the	  t-­‐test	  
such	  as	  penalized	  t-­‐tests	  and	  moderated	  t-­‐tests	  as	  well	  as	  likelihood	  ratio	  tests	  can	  
be	  more	  suited	  to	  these	  designs	  (Tusher	  et	  al.	  2001;	  Smyth	  2004;	  Zhang	  and	  Cao	  
2009).	  In	  those	  cases	  where	  we	  wish	  to	  find	  genes	  that	  have	  significantly	  different	  
estimated	  average	  expressions	  across	  more	  than	  two	  groups,	  a	  multi-­‐group	  analog	  
of	  the	  t-­‐test,	  analysis	  of	  variance	  (ANOVA),	  can	  be	  used	  that	  asks	  if	  variance	  among	  
groups	  is	  significantly	  large	  compared	  to	  within-­‐group	  variance	  (Kerr	  et	  al.	  2000).	  
By	  using	  a	  statistical	  approach	  to	  determining	  which	  genes	  are	  significantly	  
differentially	  expressed,	  we	  can	  rest	  our	  premise	  on	  p-­‐values	  for	  rejecting	  null	  
hypotheses	  and	  confidence	  intervals	  for	  describing	  modeled	  distributions	  of	  test	  
statistics.	  	  
	   Single	  gene	  expression	  analysis	  techniques	  offer	  a	  very	  limited	  view	  of	  the	  
overall	  gene	  expression	  profile,	  one	  approach	  to	  allow	  us	  to	  characterize	  the	  
expression	  of	  multiple	  genes	  is	  unsupervised	  methods	  for	  generating	  gene	  
signatures	  by	  treatment	  group.	  Unsupervised	  methods	  are	  useful	  as	  they	  do	  not	  
require	  any	  a	  priori	  information	  about	  the	  samples,	  nor	  do	  they	  focus	  on	  any	  subset	  
of	  gene	  pathways	  or	  networks,	  allowing	  the	  user	  to	  generate	  new	  hypotheses	  more	  
freely.	  Simple	  examples	  of	  these	  include	  gene	  ordering	  based	  on	  ranked-­‐
correlations	  or	  expression	  profiles	  based	  on	  clustering	  (van	  't	  Veer	  et	  al.	  2002;	  Chin	  
et	  al.	  2009).	  These	  can	  suggest	  genes	  and	  expression	  patterns	  that	  differentiate	  
treatment	  groups,	  but	  may	  not	  provide	  a	  clear	  way	  to	  classify	  new	  samples	  or	  a	  
quantification	  of	  specificity	  and	  sensitivity.	  Examples	  of	  machine	  learning	  and	  
multivariate	  analysis	  approaches	  that	  are	  unbiased	  include	  support	  vector	  machines	  
(Brown	  et	  al.	  2000),	  neural	  networks	  (Khan	  et	  al.	  2001),	  Baysian	  analysis	  (Chang	  et	  
al.	  2011),	  and	  random	  forests	  (Diaz-­‐Uriarte	  and	  Alvarez	  de	  Andres	  2006).	  	  Properly	  
trained	  and	  tested,	  these	  approaches	  can	  classify	  gene	  expression	  profiles	  with	  great	  
accuracy.	  However,	  extracting	  biological	  relevance	  can	  be	  daunting,	  particularly	  if	  
they	  only	  provide	  sparse	  weightings	  across	  broad	  ranges	  of	  genes,	  as	  can	  often	  be	  
found	  with	  support	  vector	  machines,	  or	  uninterpretable	  models,	  as	  can	  be	  found	  in	  
neural	  networks.	  Even	  from	  significantly	  differentially	  expressed	  sets	  of	  genes	  
obtained	  via	  Bayesian	  analysis	  and	  random	  forests,	  knowledge-­‐driven	  analysis	  is	  
required	  to	  extract	  biological	  meaning.	  Searches	  on	  well-­‐curated	  databases	  for	  gene	  
product	  annotation	  such	  as	  the	  Gene	  Ontology,	  Molecular	  Signatures	  Database,	  and	  
GeneSigDB	  can	  add	  organization	  by	  function	  (Subramanian	  et	  al.	  2005;	  Chang	  and	  
Nevins	  2006;	  Culhane	  et	  al.	  2010).	  Moreover,	  gene	  enrichment	  analysis	  for	  
significantly	  enriched	  annotation	  terms	  can	  be	  performed	  with	  tools	  such	  as	  Gene	  
Set	  Enrichment	  Analysis	  and	  GeneGO	  MetaCore	  tools	  (Subramanian	  et	  al.	  2005;	  
Reuters	  2012).	  
	   Whether	  we	  consider	  differential	  expression	  across	  individual	  genes	  or	  gene	  
sets,	  large	  numbers	  of	  hypotheses	  tests	  are	  commonly	  encountered	  in	  gene	  
expression	  studies.	  This	  creates	  the	  problem	  of	  generating	  false	  discoveries,	  where	  
false	  positives,	  apparently	  significant	  rejections	  of	  the	  null	  hypothesis,	  appear	  with	  
greater	  frequency	  owing	  to	  the	  large	  number	  of	  tests.	  We	  can	  implement	  a	  number	  
of	  methods	  to	  control	  and	  estimate	  the	  rate	  of	  false	  discoveries.	  Most	  methods	  used	  
in	  gene	  expression	  analysis	  fall	  into	  methods	  that	  control	  the	  family-­‐wise	  error	  rate	  
(FWER)	  or	  the	  false	  discovery	  rate	  (FDR).	  FWER	  attempts	  to	  quantify	  and	  adjust	  for	  
the	  rate	  of	  false	  discoveries	  among	  all	  tests	  of	  hypotheses,	  which	  is	  typically	  the	  
most	  stringent	  approach	  for	  multiple	  testing	  correction.	  Examples	  of	  this	  include	  the	  
Bonferroni	  correction	  and	  Hochberg	  method	  (Hochberg	  1988;	  Bland	  and	  Altman	  
1995).	  Particularly	  in	  gene	  expression	  studies	  where	  effect	  sizes	  are	  small	  compared	  
to	  sample	  numbers,	  FWER	  approaches	  can	  result	  in	  high	  false	  negative	  rates,	  
effectively	  reducing	  exploratory	  capacity	  (Weller	  et	  al.	  1998).	  FDR	  methods	  attempt	  
to	  quantify	  and	  adjust	  for	  the	  rate	  of	  false	  discoveries	  among	  the	  significant	  genes	  or	  
gene	  sets	  after	  correction.	  While	  being	  less	  stringent,	  effectively	  letting	  in	  more	  false	  
positives,	  we	  also	  limit	  the	  number	  of	  false	  negatives.	  This	  can	  be	  useful	  in	  
experiments	  designed	  to	  be	  hypothesis	  generating,	  where	  we	  wish	  to	  maximize	  our	  
window	  for	  discovery.	  Examples	  of	  this	  approach	  include	  the	  Benjamini-­‐Hochberg	  
method,	  beta-­‐uniform	  mixture	  models,	  and	  Storey’s	  method	  (Benjamini	  and	  
Hochberg	  1995;	  Allison	  et	  al.	  2002;	  Storey	  2002).	  
	  
1.2	  Ovarian	  cancer	  
Ovarian	  cancer	  is	  the	  eighth	  most	  common	  cancer	  and	  fifth	  most	  common	  cause	  of	  
cancer	  deaths	  among	  women	  in	  the	  USA	  with	  an	  annual	  incidence	  rate	  of	  12.2	  per	  
100,000	  and	  annual	  death	  rate	  of	  8	  per	  100,000	  in	  2007	  (Group	  2012).	  Although	  the	  
overall	  5-­‐year	  relative	  survival	  rate	  is	  43.2%,	  mortality	  is	  high	  because	  70%	  of	  
ovarian	  cancers	  are	  diagnosed	  at	  advanced	  stage,	  with	  extensive	  metastasis	  within	  
the	  peritoneal	  cavity,	  where	  the	  5-­‐year	  relative	  survival	  rate	  is	  30%	  (Cho	  and	  Shih	  Ie	  
2009;	  Howlader	  et	  al.	  2012).	  	  In	  the	  US	  in	  2009,	  an	  estimated	  1	  in	  72	  women	  would	  
develop	  ovarian	  cancer	  in	  their	  lifetime	  (Howlader	  et	  al.	  2012).	  	  Globally,	  ovarian	  
cancer	  is	  the	  sixth	  most	  common	  cancer	  in	  women,	  and	  more	  than	  90%	  of	  primary	  
malignant	  ovarian	  tumors	  are	  epithelial	  in	  origin	  (Sankaranarayanan	  and	  Ferlay	  
2006).	  	  
Unlike	  other	  solid	  tumors	  that	  go	  through	  multiple	  steps	  of	  extravasation	  
before	  metastasizing	  through	  the	  blood	  circulatory	  system,	  ovarian	  cancer	  cells	  
typically	  metastasize	  by	  direct	  contact	  with	  adjacent	  organs	  or	  by	  detaching	  from	  
the	  primary	  tumor	  (Gupta	  and	  Massague	  2006).	  Detached	  tumor	  cells	  can	  then	  
travel	  in	  peritoneal	  fluids	  throughout	  the	  abdominal	  cavity.	  In	  this	  manner,	  
carcinoma	  can	  attach	  to	  reproductive	  organs,	  the	  omentum,	  or	  the	  sigmoid	  colon.	  
Additionally,	  metastasized	  carcinoma	  can	  also	  be	  transported	  via	  the	  lymph	  node	  
system	  (Eisenkop	  and	  Spirtos	  2001).	  	  
The	  epithelial-­‐mesenchymal	  transition	  (EMT)	  of	  ovarian	  surface	  epithelium	  
(OSE)	  is	  thought	  to	  normally	  be	  involved	  in	  postovulatory	  repair,	  where	  the	  
transition	  to	  a	  mesenchymal	  phenotype	  provides	  the	  motility	  and	  proliferation	  
necessary	  for	  extracellular	  matrix	  remodeling	  (Salamanca	  et	  al.	  2004).	  Early	  
evidence	  of	  EMT’s	  potential	  role	  in	  cancer	  was	  suggested	  in	  studies	  of	  kidney	  
fibrosis	  in	  mouse	  models,	  where	  large	  numbers	  of	  fibroblast-­‐specific	  protein-­‐1	  
expressing	  fibroblasts	  arose	  via	  EMT	  in	  response	  to	  injury	  (Iwano	  et	  al.	  2002).	  The	  
presence	  of	  EMT	  in	  fibrosis	  was	  offered	  as	  an	  example	  of	  a	  mechanism	  present	  in	  
both	  tumors	  and	  wound	  healing	  that	  could	  explain	  changes	  in	  cell	  phenotype.	  The	  
transition	  is	  typical	  of	  cellular	  transformations	  crucial	  in	  embryogenesis,	  such	  as	  
mesoderm	  formation,	  neural	  crest	  development,	  and	  secondary	  palate	  formation,	  as	  
well	  as	  in	  organogenesis.	  EMT	  is	  also	  the	  first	  step	  in	  the	  epithelial-­‐mesenchymal-­‐
epithelial	  transitions	  during	  ovarian	  carcinoma	  metastasis,	  beginning	  with	  the	  
disruption	  of	  E-­‐cadherin-­‐mediated	  cell-­‐cell	  interactions	  (Ahmed	  et	  al.	  2007).	  This	  
permits	  epithelial	  cells	  to	  detach	  from	  the	  basement	  membrane	  and	  loosens	  
connections	  between	  carcinoma	  cells.	  Once	  detached	  these	  cells	  can	  now	  enter	  the	  
peritoneal	  fluid,	  and	  be	  passively	  moved	  into	  the	  coelomic	  space.	  The	  cancer	  cells	  
also	  acquire	  a	  mesenchymal	  phenotype	  becoming	  spindle-­‐like,	  and	  more	  motile.	  	  
The	  reverse	  process,	  known	  as	  the	  mesenchymal-­‐epithelial	  transition	  (MET)	  
is	  involved	  in	  reverting	  the	  motile	  mesenchymal-­‐like	  ovarian	  cancer	  cells	  created	  via	  
EMT	  to	  a	  more	  epithelial-­‐like	  phenotype	  at	  the	  secondary	  tumor	  site.	  E-­‐cadherin,	  
known	  to	  induce	  the	  MET	  pathway,	  is	  expressed	  in	  both	  primary	  and	  metastatic	  
ovarian	  carcinomas,	  but	  not	  normal	  ovarian	  surface	  epithelium	  (Veatch	  et	  al.	  1994;	  
Darai	  et	  al.	  1997;	  Maines-­‐Bandiera	  and	  Auersperg	  1997;	  Davies	  et	  al.	  1998).	  E-­‐
cadherin	  expression	  in	  human	  ovarian	  surface	  epithelium	  induces	  the	  localization	  of	  
E-­‐cadherin,	  catenins,	  and	  f-­‐actin	  to	  the	  locations	  of	  cell-­‐cell	  contact,	  gaining	  
epithelial	  characteristics	  associated	  with	  MET	  (Auersperg	  et	  al.	  1999).	  	  Consistent	  
with	  this	  model,	  work	  in	  a	  human	  bladder	  cancer	  model	  has	  shown	  that	  MET	  
contributes	  to	  the	  establishment	  of	  metastatic	  deposits,	  where	  targeted	  abrogation	  
of	  fibroblast	  growth	  factor	  (FGF)	  pathways	  involved	  in	  MET	  both	  reverses	  MET	  and	  
increases	  survival	  in	  TSU-­‐Pr1	  tumor	  cell	  line	  inoculated	  mice	  (Chaffer	  et	  al.	  2005;	  
Chaffer	  et	  al.	  2006).	  MET	  occurs	  naturally	  during	  somitogenesis,	  kidney	  formation,	  
and	  coelomic-­‐cavity	  formation,	  and	  work	  done	  in	  these	  areas	  has	  identified	  
important	  modulators	  likely	  to	  be	  involved	  in	  cancer	  metastasis	  (Saga	  and	  Takeda	  
2001;	  Vainio	  and	  Lin	  2002).	  Given	  the	  plasticity	  of	  the	  native	  ovarian	  surface	  
epithelium,	  MET	  is	  thought	  to	  be	  the	  molecular	  reversal	  of	  EMT	  (Wong	  and	  Leung	  
2007).	  	  
At	  the	  same	  time,	  our	  understanding	  about	  the	  mechanisms	  involved	  in	  EMT	  
and	  MET	  is	  incomplete,	  particularly	  in	  its	  role	  in	  cancer	  progression.	  A	  major	  
advance	  in	  understanding	  this	  dynamic	  was	  the	  identification	  of	  transcription	  
factors	  capable	  of	  inducing	  EMT	  in	  cancer	  cells.	  Blanco	  et	  al	  (2002)	  noted	  the	  
presence	  of	  Snail,	  a	  transcription	  factor	  involved	  in	  EMT	  in	  embryonic	  development,	  
in	  human	  breast	  carcinomas,	  its	  expression	  inversely	  correlated	  with	  the	  grade	  of	  
tumor	  differentiation.	  High	  levels	  of	  expression	  of	  the	  transcription	  factor	  Twist	  was	  
correlated	  with	  invasive	  breast	  lobular	  carcinoma,	  and	  further	  expression	  studies	  
demonstrated	  Twist’s	  ability	  to	  promote	  the	  loss	  of	  cell-­‐cell	  adhesion,	  activated	  
mesenchymal	  markers,	  and	  induce	  cell	  motility	  (Yang	  et	  al.	  2004).	  E-­‐cadherin	  is	  
involved	  in	  signaling	  and	  capable	  of	  inducing	  MET	  in	  human	  ovarian	  surface	  
epithelium	  (Auersperg	  1999).	  Studies	  comparing	  primary	  ovarian	  carcinomas	  to	  
metastases	  demonstrated	  lower	  Snail	  expression	  in	  metastases	  than	  in	  primary	  
carcinomas,	  higher	  expression	  of	  TWIST1	  and	  ZEB1	  in	  metastases,	  and	  the	  
regulation	  of	  Snail	  localization	  by	  Pak1,	  leading	  to	  E-­‐cadherin	  re-­‐expression	  in	  
metastases	  (Elloul	  et	  al.	  2010).	  EMT	  induced	  by	  TGF-­‐β1	  signaling	  through	  a	  Smads-­‐
dependent	  pathway	  in	  rat	  and	  human	  alveolar	  epithelial-­‐like	  cells	  could	  be	  reversed,	  
via	  the	  MAPK/ERK	  kinase	  pathway,	  by	  culturing	  with	  FGF-­‐1	  for	  48	  hours,	  suggesting	  
that	  EMT	  and	  MET	  might	  arise	  from	  induction	  of	  separate	  pathways	  rather	  than	  
reversing	  the	  induction	  of	  a	  single	  pathway	  (Ramos	  et	  al.	  2010).	  These	  experiments	  
outline	  the	  complex	  signaling	  involved	  in	  both	  EMT	  and	  MET	  coordinated	  by	  the	  
actions	  of	  multiple	  transcription	  factors.	  
	   In	  2005,	  Tarin	  suggested	  EMT	  did	  not	  actually	  occur	  in	  cancer	  metastasis,	  
pointing	  out	  the	  most	  glaring	  of	  the	  gaps	  in	  the	  EMT	  model	  in	  cancer	  (Tarin	  et	  al.	  
2005).	  First,	  that	  stable	  epithelial	  mesenchymal	  transition	  had	  not	  been	  extensively	  
documented	  or	  recognized	  by	  surgical	  pathologists	  when	  examining	  tumor	  samples.	  
Moreover,	  that	  EMT	  had	  primarily	  been	  observed	  only	  in	  cell	  culture	  or	  engineered	  
animal	  models,	  and	  that	  phenotypic	  descriptions	  used	  by	  researchers	  focused	  on	  
molecular	  markers	  were	  not	  rigorous	  or	  based	  on	  changes	  in	  single	  molecular	  
markers.	  Finally,	  that	  markers	  described	  as	  being	  indicative	  of	  EMT	  were	  not	  
specific	  for	  mesenchymal	  cells	  and	  were	  unreliable	  due	  to	  the	  genetic	  instability	  of	  
tumors.	  	  
	   Supporters	  of	  the	  EMT	  model	  in	  cancer	  metastasis	  argued	  that	  EMT	  is	  not	  
being	  used	  in	  the	  strict	  irreversible	  sense	  of	  transition	  between	  two	  differentiation	  
states,	  but	  to	  describe	  the	  spectrum	  of	  phenotypic	  changes	  observed	  that	  
inextricably	  link	  both	  molecular	  markers	  and	  biological	  process	  (Cardiff	  2005;	  Yang	  
and	  Weinberg	  2008).	  A	  number	  of	  models	  to	  bridge	  this	  gap	  have	  been	  suggested,	  
including	  incomplete	  EMT,	  epithelial-­‐amoeboid	  transitions,	  and	  EMT-­‐like	  states.	  
EMT-­‐like	  reflects	  a	  dedifferentiation	  rather	  than	  trans-­‐differentiation	  process,	  
where	  transformed	  epithelial	  cells	  may	  simply	  fail	  to	  differentiate	  normally,	  
resulting	  in	  a	  state	  defined	  by	  cell	  cohesiveness,	  intermediate	  filament	  protein	  
expression,	  and	  cell	  polarization	  (Klymkowsky	  and	  Savagner	  2009).	  Incomplete	  
EMT,	  on	  the	  other	  hand,	  suggests	  a	  signal	  cascade	  through	  a	  variety	  of	  mechanisms,	  
ranging	  from	  TGF-­‐B	  initiated	  cascades,	  to	  activation	  of	  downstream	  MAPK	  signaling,	  
to	  activation	  of	  signaling	  by	  virally	  encoded	  oncogenes	  like	  v-­‐Src	  and	  v-­‐Ras	  that	  
triggers	  some	  of	  the	  EMT	  properties	  without	  a	  complete	  transition	  of	  phenotypes	  
(Christiansen	  and	  Rajasekaran	  2006).	  Wolf	  et	  al	  (2003)	  suggest	  a	  third	  model	  of	  
epithelial-­‐amoeboid	  transition	  in	  which	  carcinoma	  cells	  gain	  mobility	  through	  
protease-­‐independent	  migration,	  adopting	  a	  spherical	  morphology	  without	  
degradation	  of	  extracellular	  matrix	  barriers.	  As	  EMT	  continues	  to	  be	  unobserved	  in	  
human	  tumor	  samples,	  while	  the	  molecular	  evidence	  for	  its	  role	  in	  cell	  lines	  and	  
animals	  models	  grows,	  EMT’s	  role	  in	  cancer	  pathogenesis	  remains	  unresolved.	  	  
	   Induction	  of	  this	  transition	  is	  of	  interest	  both	  for	  improving	  our	  
understanding	  of	  this	  complex	  process	  as	  well	  as	  the	  potential	  to	  shift	  cancer	  cells	  
into	  a	  less	  chemotherapeutically-­‐resistant	  state	  (Thomson	  et	  al.	  2005;	  Arumugam	  et	  
al.	  2009;	  Uramoto	  et	  al.	  2010;	  Xie	  et	  al.	  2012).	  	  microRNAs	  (miRNA)	  have	  been	  a	  
potential	  transition	  inducer	  of	  interest	  owing	  to	  their	  regulatory	  impact	  on	  the	  
transcription	  of	  multiple	  targets	  at	  once,	  and	  previous	  studies	  have	  established	  a	  
role	  for	  miR-­‐200	  family	  microRNAs	  in	  the	  induction	  of	  MET	  in	  ovarian	  cancer	  cells	  
in	  single	  time	  point	  gene	  expression	  experiments	  (Chen	  et	  al.	  2011).	  We	  asked	  what	  
the	  impact	  of	  a	  single	  point	  transfection	  of	  miR-­‐429	  from	  the	  miR-­‐200	  family	  
miRNAs	  had	  on	  ovarian	  cancer	  cells	  and	  whether	  or	  not	  this	  effect	  was	  permanent,	  
sampling	  across	  multiple	  time	  points	  at	  0,	  24,	  48,	  and	  144	  hours	  after	  transfection.	  
We	  used	  a	  control-­‐adjusted	  time	  course	  analysis	  to	  show	  that	  by	  24	  and	  48	  hours,	  
those	  cells	  exposed	  to	  miR-­‐429	  had	  gained	  morphologic	  and	  gene	  expression	  
features	  consistent	  with	  a	  more	  epithelial	  state.	  And	  by	  144	  hours	  had	  returned	  to	  a	  
more	  mesenchymal-­‐like	  state	  in	  both	  morphology	  and	  expression,	  suggesting	  a	  
rebound	  or	  plastic	  response	  to	  this	  miRNA.	  
	  
1.3	  Atherosclerosis	  
Atherosclerosis,	  the	  build	  up	  of	  fatty	  deposits,	  inflammation,	  proliferated	  cells,	  and	  
scar	  tissue	  within	  the	  walls	  of	  arteries,	  is	  the	  leading	  cause	  of	  mortality	  and	  
morbidity	  in	  the	  industrialized	  world.	  A	  chronic	  disease,	  its	  complications	  can	  lead	  
to	  stenosis,	  stroke,	  and	  myocardial	  infarction,	  and	  is	  thought	  to	  be	  the	  underlying	  
cause	  of	  most	  clinical	  cardiovascular	  events.	  	  In	  2008,	  approximately	  one	  in	  every	  
six	  deaths	  in	  the	  United	  States	  was	  caused	  by	  coronary	  heart	  disease	  (CHD),	  and,	  in	  
2012,	  an	  estimated	  1,200,000	  Americans	  would	  experience	  myocardial	  infarctions	  
(MI),	  in	  addition	  to	  195,000	  silent	  myocardial	  infarctions	  a	  year	  (Members	  et	  al.	  
2012).	  Strokes	  account	  for	  approximately	  795,000	  of	  cardiovascular	  disease	  
incidents	  per	  year,	  and	  1	  in	  18	  deaths	  in	  the	  United	  States	  in	  2008.	  Risk	  factors	  for	  
atherosclerosis	  include	  high	  LDL	  cholesterol,	  low	  HDL	  cholesterol,	  high	  blood	  
pressure,	  smoking,	  diabetes,	  obesity,	  age,	  family	  history,	  and	  insulin	  resistance	  
(Anderson	  et	  al.	  1991).	  	  
Atherosclerosis	  begins	  with	  a	  site	  of	  chronic	  inflammation	  in	  the	  arterial	  wall,	  
initiated	  by	  endothelial	  dysfunction	  and	  structural	  changes	  followed	  by	  the	  
accumulation	  of	  LDLs	  inside	  the	  vessel	  wall	  (Moore	  and	  Tabas	  2011).	  The	  
accumulation	  of	  oxidized	  lipids	  and	  lipoproteins	  drives	  the	  extravasation	  of	  immune	  
cells	  attracted	  to	  adhesion	  molecules	  and	  chemokines	  expressed	  by	  the	  endothelial	  
cells	  (Libby	  2002).	  The	  continuing	  accumulation	  of	  lipids	  in	  these	  monocytes	  
eventually	  leads	  to	  the	  formation	  of	  “fatty-­‐streak”	  lesions,	  consisting	  of	  T	  cells	  and	  
foam	  cells,	  which	  can	  appear	  as	  early	  as	  childhood.	  	  These	  plaques	  grow	  by	  
accumulating	  lipid,	  and	  form	  a	  fibrous	  plaque	  through	  smooth	  muscle	  cell	  
proliferation	  and	  collagen	  matrix	  growth.	  These	  plaques	  can	  then	  rupture,	  detaching	  
to	  occlude	  elsewhere	  resulting	  in	  thromboembolism	  and	  strokes	  or	  cause	  a	  local	  
thrombotic	  occlusion	  resulting	  in	  infarction.	  Even	  those	  plaques	  that	  are	  stable	  and	  
do	  not	  rupture	  can	  cause	  stenosis	  and	  restrict	  blood	  flow	  to	  downstream	  tissue	  
resulting	  in	  ischemia.	  
	   Coronary	  calcification	  (CAC)	  associated	  with	  atherosclerotic	  plaques	  has	  
emerged	  as	  a	  high	  accuracy	  predictor	  for	  major	  adverse	  coronary	  heart	  disease	  
events	  including	  myocardial	  infarction,	  angina,	  cardiac	  arrest	  and	  CHD	  death	  
(Budoff	  et	  al.	  2009b).	  Histological	  analysis	  and	  ultrasound	  studies	  have	  confirmed	  a	  
direct	  relationship	  between	  plaque	  burden	  and	  coronary	  calcification	  (Baumgart	  et	  
al.	  1997;	  Mintz	  et	  al.	  1997).	  The	  presence	  of	  calcification	  is	  now	  well	  established	  as	  a	  
sign	  of	  atherosclerosis,	  and	  does	  not	  occur	  in	  the	  normal	  artery	  wall	  (Janowitz	  et	  al.	  
1991;	  Wexler	  et	  al.	  1996).	  Absent	  or	  minimal	  calcification	  in	  asymptomatic	  
individuals	  has	  been	  shown	  to	  be	  associated	  with	  a	  very	  low	  risk	  of	  adverse	  
cardiovascular	  events	  when	  followed-­‐up	  at	  a	  median	  of	  4.1	  years	  (Budoff	  et	  al.	  
2009a).	  Although	  previously	  believed	  to	  be	  the	  result	  of	  calcium	  precipitation	  or	  the	  
degeneration	  of	  fibrous	  tissue,	  the	  mechanism	  of	  coronary	  calcification	  has	  been	  
shown	  to	  be	  an	  active	  process	  similar	  to	  that	  of	  normal	  bone	  formation	  (Bostrom	  et	  
al.	  1993;	  Proudfoot	  et	  al.	  1998).	  	  
	   Defined	  as	  the	  distance	  between	  the	  luminal-­‐intimal	  interface	  and	  the	  media-­‐
adventitial	  interface	  of	  the	  common	  carotid	  artery,	  carotid	  intima-­‐media	  thickness	  
(CIMT)	  is	  visualized	  by	  B-­‐mode	  vascular	  ultrasound	  (Pignoli	  et	  al.	  1986).	  Increases	  
in	  this	  distance	  are	  interpreted	  intimal	  thickenings	  from	  the	  early	  stages	  of	  
atherosclerotic	  disease,	  particularly	  because	  carotid	  arteries	  have	  less	  muscular	  
media	  than	  other	  arteries	  (Stary	  et	  al.	  1992).	  Because	  intima-­‐media	  thickness	  (IMT)	  
can	  react	  dynamically	  to	  blood	  pressure	  and	  sheer	  stress,	  lower	  degrees	  of	  IMT	  can	  
represent	  a	  mixture	  of	  response	  to	  these	  transient	  hemodynamics	  as	  well	  as	  
atherosclerotic	  burden	  (Bots	  et	  al.	  1997).	  It	  is	  now	  commonly	  accepted	  that	  
atherosclerosis	  is	  more	  likely	  at	  IMTs	  above	  0.9	  mm	  (Naghavi	  et	  al.	  2006).	  Although	  
total	  intima-­‐media	  thickness	  can	  be	  correlated	  with	  future	  coronary	  heart	  disease	  
risk,	  changes	  in	  CIMT	  have	  been	  found	  to	  be	  poorly	  predictive	  of	  changes	  in	  the	  
potential	  for	  major	  adverse	  coronary	  events	  (Goldberger	  et	  al.	  2010).	  
	   Firefighters,	  compared	  to	  other	  first	  responder	  personnel,	  have	  an	  elevated	  
risk	  for	  major	  adverse	  coronary	  events	  that	  is	  thought	  to	  be	  linked	  to	  heat,	  
dehydration,	  strong	  cardiovascular	  strain,	  smoke	  exposure,	  and	  shift	  work	  (Kales	  et	  
al.	  2003;	  Kales	  et	  al.	  2007).	  Traditionally	  used	  coronary	  artery	  disease	  risk	  
calculators	  like	  the	  ATP	  III	  version	  of	  the	  Framingham	  Risk	  Score	  (FRS)	  that	  are	  
commonly	  used	  by	  clinicians	  may	  underestimate	  the	  risk	  of	  heart	  disease	  and	  
atherosclerotic	  burden	  present	  in	  firefighters.	  By	  comparing	  FRS	  with	  CIMT	  and	  
coronary	  artery	  calcification	  (CAC)	  in	  159	  male	  firefighters	  from	  Gwinnett	  County,	  
Georgia,	  we	  determined	  that	  FRS	  misclassified	  a	  large	  number	  of	  individuals	  with	  
clinically	  significant	  atherosclerosis.	  By	  using	  Receiver-­‐Operator	  Characteristic	  
curves	  to	  set	  new	  FRS	  thresholds,	  we	  were	  able	  to	  improve	  the	  sensitivity	  of	  the	  
scoring	  method.	  
 Percutaneous	  transluminal	  coronary	  angioplasty	  (PTCA)	  has	  revolutionized	  
the	  treatment	  of	  coronary	  artery	  disease	  since	  its	  introduction	  in	  1977	  (Grüntzig	  et	  
al.	  1979).	  However,	  restenosis	  or	  the	  arterial	  healing	  response	  has	  proven	  to	  be	  
problematic	  for	  PTCA	  due	  to	  negative	  remodeling,	  contraction	  formation	  and	  
consequent	  late	  luminal	  loss	  in	  30-­‐60%	  of	  post-­‐angioplasty	  patients	  (Fischman	  et	  al.	  
1994;	  Serruys	  et	  al.	  1994).	  The	  use	  of	  bare	  metal	  stents	  (BMS)	  in	  PTCA	  has	  been	  
effective	  in	  reducing	  restenosis	  by	  acting	  as	  a	  scaffold	  against	  elastic	  recoil	  and	  
negative	  remodeling	  (Sigwart	  et	  al.	  1987;	  Fischman	  et	  al.	  1994;	  Serruys	  et	  al.	  1994).	  
Referred	  to	  generally	  as	  percutaneous	  coronary	  intervention	  (PCI)	  the	  use	  of	  stents	  
in	  PTCA	  has	  resulted	  in	  a	  significant	  reduction	  in	  many	  of	  the	  major	  adverse	  cardiac	  
events	  associated	  with	  PTCA	  and	  is	  currently	  considered	  a	  standard	  procedure	  
worldwide.	  However,	  the	  increased	  use	  of	  BMS	  in	  PTCA	  has	  resulted	  in	  the	  
emergence	  of	  an	  unanticipated	  complication,	  i.e.,	  the	  occurrence	  of	  restenosis	  within	  
the	  stent	  (“in-­‐stent	  restenosis”	  or	  ISR)	  resulting	  in	  	  >	  50%	  late	  lumen	  diameter	  loss	  
in	  treated	  patients.	  
In	  an	  effort	  to	  reduce	  ISR,	  a	  new	  generation	  of	  drug-­‐eluting	  stents	  (DES)	  has	  
been	  designed	  to	  release	  anti-­‐restenotic	  agents	  at	  the	  stent	  site.	  Built	  on	  top	  of	  
stainless	  steel,	  cobalt,	  chrome,	  or	  platinum-­‐chrome	  alloy	  stents	  these	  devices	  
feature	  polymer	  coatings	  that	  deliver	  drug	  payloads	  in	  a	  controlled	  fashion	  and	  
increasingly	  chosen	  for	  their	  biocompatibility	  to	  reduce	  inflammation	  and	  
thrombocity	  (Cheol	  Whan	  et	  al.	  2009;	  Kandzari	  et	  al.	  2011).	  Drug	  eluting	  stents	  that	  
have	  been	  released	  to	  market	  either	  carry	  paclitaxel	  or	  rapamycin-­‐related	  
compounds.	  At	  the	  present	  moment,	  the	  anti-­‐restenotic	  drugs	  used	  in	  drug-­‐eluting	  
stents	  are	  sirolimus	  (Sirolimus	  Eluting	  Stents,	  SES),	  everolimus,	  and	  zotarolimus	  
(Zotarolimus	  Eluting	  Stents,	  ZES).	  All	  three	  drugs	  have	  similar	  antimicrobial	  and	  
immunosuppressive	  properties	  since	  they	  are	  derived	  from	  the	  same	  natural	  
compound,	  rapamycin	  (Pendyala	  et	  al.	  2008).	  Rapamycin	  acts	  by	  binding	  to	  the	  
cytosolic	  receptor	  FKBP12,	  forming	  a	  complex	  that	  inhibits	  the	  activation	  of	  the	  
mammalian	  target	  of	  rapamycin	  (mTOR)	  (Fischman	  et	  al.	  1994).	  mTOR	  inhibition	  
ultimately	  results	  in	  cell	  cycle	  arrest	  in	  the	  late	  G1	  phase,	  arresting	  smooth	  muscle	  
cell	  growth	  (Braun-­‐Dullaeus	  et	  al.	  1998;	  Marx	  and	  Marks	  2001).	  Sirolimus	  is	  bound	  
to	  the	  stent	  with	  a	  poly-­‐ethylene-­‐covinyl/poly-­‐n-­‐butyl	  methacrylate	  copolymer.	  ZES	  
elute	  zotarolimus,	  a	  derivative	  of	  sirolimus	  that	  incorporates	  a	  phosphorylcholine	  
coating	  that	  imparts	  high	  lipophilicity	  (Lewis	  and	  Stratford	  2002).	  It	  has	  been	  
suggested	  that	  ZES	  are	  better	  suited	  for	  stent	  based	  drug	  delivery	  since	  they	  have	  
been	  shown	  to	  reduce	  endothelialisation	  and	  neointimal	  formation	  relative	  to	  SES	  
(Burke	  et	  al.	  2006).	  Although	  the	  impact	  of	  these	  stents	  has	  been	  characterized	  in	  
longitudinal	  studies	  across	  multiple	  treatment	  centers,	  the	  broad	  transcriptomic	  
impact	  of	  rapamycin-­‐derived	  drug-­‐eluting	  stents	  in	  vivo	  has	  not	  been	  studied	  (Cheol	  
Whan	  et	  al.	  2009;	  Park	  et	  al.	  2010;	  Rasmussen	  et	  al.	  2010;	  Kandzari	  et	  al.	  2011).	  In	  
order	  to	  better	  understand	  the	  molecular	  changes	  in	  coronary	  arteries	  at	  the	  site	  of	  
stent	  implantation,	  we	  conducted	  a	  comparative	  microarray	  profiling	  study	  to	  
examine	  differences	  in	  gene	  expression	  and	  pathway	  function	  in	  coronary	  arteries	  
exposed	  to	  ZES,	  SES,	  and	  BMS	  in	  a	  porcine	  animal	  model.	  	  Through	  gene	  ontology	  
analysis	  and	  comparison	  to	  prior	  work	  examining	  arterial	  response	  to	  BMS,	  we	  
were	  able	  to	  characterize	  the	  progression	  of	  restenosis	  in	  arteries	  exposed	  to	  these	  
two	  drug	  eluting	  stents	  and	  hypothesize	  that	  rapamycin-­‐eluting	  stents	  were	  
delaying,	  rather	  than	  permanently	  reducing,	  restenosis.	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CHAPTER	  2	  
IMPROVING	  FRAMINGHAM	  RISK	  SCORE	  ESTIMATION	  OF	  CORONARY	  
CALCIFICATION	  AND	  CAROTID	  INTIMA-­‐MEDIAL	  THICKNESS	  IN	  
FIREFIGHTERS	  
	  
	  
	  
2.1	  Introduction	  
Cardiovascular	  disease	  (CVD)	  is	  the	  largest	  cause	  (45%)	  of	  on-­‐duty	  firefighter	  
fatalities,	  accounting	  for	  a	  larger	  fraction	  of	  deaths	  than	  by	  burns,	  asphyxiation,	  or	  
other	  injuries	  (TriData	  Corporation	  2002;	  Fahy	  2005).	  Most	  of	  these	  CVD	  fatalities	  
were	  caused	  by	  coronary	  heart	  disease	  (CHD),	  of	  which	  32%	  occurred	  during	  fire	  
suppression	  and	  31%	  occurred	  during	  alarm	  response	  or	  return	  (Kales	  et	  al.	  2007).	  
In	  other	  public	  service	  sectors	  such	  as	  police	  work	  and	  emergency	  medical	  services,	  
on-­‐duty	  CHD	  deaths	  only	  account	  for	  22%	  and	  11%	  of	  deaths,	  respectively	  (Kales	  et	  
al.	  2003;	  Fahy	  2005).	  In	  addition	  to	  the	  standard	  risk	  factors	  for	  CHD,	  firefighters	  
are	  also	  subject	  to	  less	  common	  cardiovascular	  stressors	  such	  as	  shift	  work,	  smoke	  
exposure,	  acute	  and	  irregular	  cardiovascular	  strain,	  heat,	  dehydration,	  and	  excess	  
physical	  workload	  (Soteriades	  et	  al.	  2011).	  	  The	  impact	  of	  CHD	  on	  firefighting	  
readiness	  and	  emergency	  resources	  can	  be	  appreciated	  when	  we	  add	  the	  estimated	  
17	  non-­‐fatal,	  line-­‐of-­‐duty	  CHD	  events	  that	  also	  occur	  for	  each	  CHD	  death	  (Karter	  and	  
Molis	  2006).	  Monitoring	  and	  management	  of	  firefighter	  cardiac	  health	  is	  important	  
for	  both	  individual	  health	  and	  public	  safety.	  
A	  number	  of	  mathematical	  functions	  using	  traditional	  risk	  factors	  as	  
variables	  have	  been	  written	  to	  predict	  coronary	  heart	  disease	  risk	  (Beswick	  and	  
Brindle	  2006).	  From	  both	  a	  personal	  health	  and	  public	  policy	  point	  of	  view,	  we	  are	  
interested	  in	  the	  degree	  to	  which	  such	  functions	  correspond	  and	  predict	  coronary	  
heart	  disease	  risk	  in	  firefighters.	  One	  of	  the	  most	  commonly	  used	  risk	  scoring	  
methods	  is	  based	  on	  the	  data	  from	  the	  Framingham	  Heart	  Study	  cohort,	  based	  on	  an	  
original	  cohort	  of	  5,209	  adults	  from	  Framingham,	  Massachusetts	  as	  well	  as	  their	  
children,	  spouses,	  and	  grandchildren,	  known	  as	  the	  Framingham	  Risk	  Score	  (FRS)	  
(Anderson	  et	  al.	  1991a;	  Anderson	  et	  al.	  1991b;	  Wilson	  et	  al.	  1998).	  The	  updated	  FRS,	  
endorsed	  by	  the	  National	  Cholesterol	  Education	  Program	  Adult	  Treatment	  Panel	  III	  
and	  used	  by	  clinicians,	  takes	  into	  account	  age,	  total	  cholesterol,	  smoking	  status,	  high	  
density	  lipoprotein	  fraction,	  and	  systolic	  blood	  pressure	  to	  estimate	  10	  year	  “hard”	  
CHD	  (myocardial	  infarction	  or	  coronary	  heart	  disease	  death)	  risk	  (National	  
Cholesterol	  Education	  Program	  Expert	  Panel	  2002).	  Some	  of	  the	  limitations	  of	  the	  
FRS	  include	  its	  emphasis	  on	  older	  patients,	  an	  influence	  from	  its	  original	  cohort	  
make-­‐up;	  its	  homogeneous	  white	  middle-­‐class	  demography;	  and	  10-­‐year	  risk	  
quantification	  that	  fails	  to	  account	  for	  lifetime	  risk,	  particularly	  in	  younger	  patients	  
(Akosah	  et	  al.	  2003;	  Hemann	  et	  al.	  2007).	  Younger	  individuals	  (men	  <55	  and	  women	  
<65	  years	  of	  age)	  with	  low-­‐	  or	  medium-­‐risk	  FRS	  scores,	  but	  early	  onset	  CHD	  are	  
often	  misclassified	  as	  not	  meeting	  the	  criteria	  for	  pharmacotherapy	  (Akosah	  et	  al.	  
2003).	  	  
As	  a	  result,	  there	  is	  an	  interest	  in	  non-­‐invasive	  diagnostic	  tools	  that	  can	  
improve	  risk	  assessment	  using	  well-­‐quantified	  measures	  of	  CHD.	  Coronary	  artery	  
calcification	  (CAC)	  is	  a	  marker	  of	  atherosclerosis	  that	  can	  be	  quantified	  using	  
electron	  beam	  computed	  tomography	  and	  multi-­‐detector	  computed	  tomography,	  
and	  may	  help	  to	  assess	  the	  extent	  of	  subclinical	  atherosclerosis	  (Greenland	  et	  al.	  
2007).	  Tissue	  and	  ultrasound	  studies	  have	  confirmed	  a	  direct	  relationship	  between	  
atherosclerotic	  plaque	  burden	  and	  the	  quantity	  of	  CAC	  (Baumgart	  et	  al.	  1997;	  Mintz	  
et	  al.	  1997).	  Also	  in	  prospective	  studies	  where	  follow-­‐up	  was	  performed,	  the	  
amount	  of	  CAC	  has	  been	  shown	  in	  a	  number	  of	  studies	  to	  predict	  cardiac	  events	  in	  
asymptomatic	  individuals	  3-­‐5	  years	  later	  (Wayhs	  et	  al.	  2002;	  Raggi	  et	  al.	  2003;	  Shaw	  
et	  al.	  2003).	  Carotid	  intima-­‐media	  thickness	  (CIMT),	  measured	  by	  B-­‐mode	  
ultrasound,	  has	  also	  been	  used	  as	  an	  assessment	  for	  the	  presence	  of	  coronary	  
atherosclerosis	  and	  an	  independent	  predictor	  of	  future	  cardiovascular	  events	  
(Naghavi	  et	  al.	  2006).	  Again	  in	  prospective	  studies	  asymptomatic	  individuals	  with	  
abnormal	  CIMT	  were	  shown	  to	  have	  increased	  risk	  of	  myocardial	  infarctions	  and	  
stroke	  4	  to	  7	  years	  later,	  with	  a	  direct	  correspondence	  between	  degree	  of	  thickness	  
and	  risk	  of	  coronary	  event	  (Chambless	  et	  al.	  1997;	  Hodis	  et	  al.	  1998;	  O'Leary	  et	  al.	  
1999b).	  	  
In	  our	  study,	  we	  were	  interested	  in	  assessing	  the	  utility	  of	  the	  Framingham	  
Risk	  Score	  in	  evaluating	  the	  atherosclerotic	  risk	  in	  asymptomatic	  firefighters.	  To	  
this	  end	  we	  determined	  FRS	  for	  159	  male	  firefighters	  from	  Gwinnett	  County,	  
Georgia,	  and	  compared	  their	  risk	  categorization	  against	  their	  known	  atherosclerotic	  
burden	  as	  determined	  by	  CIMT	  and	  CAC.	  While	  the	  20%	  FRS	  threshold,	  
corresponding	  to	  medium	  risk,	  had	  a	  high	  specificity	  for	  both	  CAC	  and	  CIMT,	  it	  also	  
had	  a	  low	  sensitivity	  (17%	  and	  40%,	  respectively),	  indicating	  that	  a	  large	  
percentage	  of	  individuals	  with	  clinically	  significant	  atherosclerosis	  are	  being	  
misclassified.	  By	  adjusting	  the	  FRS	  threshold	  downward,	  we	  were	  able	  to	  raise	  the	  
sensitivity	  greatly	  with	  only	  a	  modest	  loss	  of	  specificity.	  We	  also	  proposed	  the	  use	  of	  
a	  smoking	  adjustment	  as	  a	  proxy	  for	  firefighter	  exposure	  to	  combustion	  products.	  
	  
2.2	  Methods	  
The	  Firefighter	  Heart	  Disease	  Prevention	  (FHDP)	  study	  was	  designed	  as	  a	  cross-­‐
sectional	  investigation	  of	  subclinical	  atherosclerosis	  as	  defined	  by	  noninvasive	  
imaging,	  and	  multiple	  phenotypes	  and	  genotypes	  previously	  established	  to	  be	  
associated	  with	  increased	  cardiovascular	  risk.	  Following	  recruitment	  and	  informed	  
consent,	  firefighters	  completed	  a	  series	  of	  questionnaires	  that	  address	  standard	  
demographic,	  nutrition,	  exercise,	  lifestyle,	  and	  family	  history	  variables.	  Standard	  
physiologic	  measurements	  were	  obtained	  including,	  resting	  12-­‐lead	  
electrocardiogram	  (ECG),	  blood	  pressure,	  ankle-­‐brachial	  index	  (ABI),	  height/weight,	  
and	  waist-­‐to-­‐hip	  measurements.	  	  
One	  hundred	  and	  fifty-­‐nine	  active	  duty	  firefighters	  older	  than	  40	  years	  were	  
recruited	  from	  the	  Gwinnett	  County	  Fire	  Department	  that	  serves	  a	  population	  of	  
approximately	  800,000	  individuals.	  The	  study	  was	  approved	  by	  the	  Institutional	  
Review	  Boards	  of	  Saint	  Joseph's	  Hospital	  and	  Georgia	  Institute	  of	  Technology.	  	  
	  
2.2.1	  Blood	  pressure	  measurement	  
Following	  five	  minutes	  of	  rest	  in	  the	  sitting	  position,	  blood	  pressure	  was	  determined	  
in	  the	  right	  arm	  following	  American	  Heart	  Association	  criteria	  (Pickering	  et	  al.	  
2005).	  Three	  measurements	  were	  made	  one	  minute	  apart.	  Heart	  rate	  and	  blood	  
pressure	  were	  obtained	  prior	  to	  blood	  draw.	  
	  
2.2.2	  Coronary	  artery	  calcium	  scoring	  
Calcium	  scoring	  computed	  tomographic	  images	  were	  performed	  on	  a	  64-­‐slice	  multi-­‐
detector	  computed-­‐tomography	  scanner	  (MDCT)	  (Somatom	  Sensation	  64,	  Siemens,	  
Forchhcim,	  Germany).	  The	  scan	  parameters	  were	  tube	  voltage	  110	  kY,	  tube	  current	  
250	  mAs	  effective,	  collimation	  64	  x	  0.6	  mm,	  and	  rotation	  time	  330	  ms.	  Image	  
acquisition	  was	  triggered	  to	  60%	  to	  80%	  timing	  interval	  after	  the	  Q,	  R,	  and	  S	  wave	  
(QRS)	  complex	  during	  diastole	  throughout	  a	  breath	  hold	  by	  the	  patient	  (Taylor	  et	  al.	  
2004).	  A	  standard	  calcium-­‐scoring	  kernel	  (B35f)	  was	  used	  for	  reconstruction	  of	  the	  
MDCT-­‐data.	  An	  experienced	  reader	  scored	  the	  images.	  Images	  were	  retrospectively	  
reconstructed	  with	  a	  slice	  thickness	  of	  3.0	  mm	  and	  scoring	  of	  the	  common	  carotid,	  
carotid	  bulb,	  and	  internal	  carotid	  artery	  vessels	  was	  performed.	  The	  total	  number	  of	  
calcified	  lesions	  in	  the	  coronary	  anatomy	  was	  documented	  and	  the	  total	  Agatston	  
score	  was	  calculated	  for	  all	  calcified	  lesions.	  Percentile	  rank	  score	  was	  based	  on	  the	  
age	  and	  sex	  of	  the	  patient	  as	  described	  previously	  (Agatston	  et	  al.	  1990).	  	  
	  
2.2.3	  Carotid	  Arterial	  Wall	  Imaging	  
Carotid	  intima	  media	  thickness	  measurements	  were	  performed	  on	  an	  ultrasound	  
machine	  equipped	  with	  software	  that	  has	  been	  demonstrated	  to	  accurately	  measure	  
carotid	  plaque	  thickness	  (Toshiba	  Xario	  Ultrasound,	  Tokyo,	  Japan)	  (O'Leary	  et	  al.	  
1999a;	  Tanaka	  et	  al.	  2001).	  The	  machine	  was	  equipped	  with	  a	  high	  resolution	  7.5	  
MHz	  linear	  array	  transducer.	  Scanning	  was	  performed	  of	  the	  common	  carotid,	  
carotid	  bulb,	  and	  internal	  carotid	  arteries.	  Five	  measurements	  of	  the	  carotid-­‐intimal	  
medial	  thickness	  were	  recorded	  of	  each	  vessel	  utilizing	  a	  method	  for	  the	  
determination	  of	  the	  intimal-­‐medial	  thickness	  that	  has	  been	  previously	  described	  
(Pignoli	  et	  al.	  1986).	  The	  measurements	  in	  each	  vessel	  were	  performed	  as	  follows:	  
two	  within	  the	  common	  carotid	  artery,	  two	  within	  the	  internal	  carotid	  artery,	  and	  
one	  within	  the	  carotid	  bulb.	  One	  measurement	  in	  each	  common	  and	  internal	  carotid	  
artery	  was	  recorded	  within	  the	  relatively	  straight	  portion	  of	  each	  vessel	  at	  the	  area	  
of	  greatest	  intimal-­‐medial	  thickness.	  One	  measurement	  within	  each	  common	  and	  
internal	  carotid	  artery	  was	  recorded	  at	  1-­‐cm	  interval	  from	  the	  carotid	  bulb.	  All	  
recordings	  were	  performed	  in	  the	  far	  wall	  of	  the	  vessel	  using	  the	  same	  depth	  for	  
each	  measurement.	  	  
	  
2.2.4	  Laboratory	  Tests	  
Blood	  samples	  were	  obtained	  following	  a	  16-­‐hour	  fast.	  Plasma	  was	  prepared	  from	  
blood	  within	  30	  minutes	  and	  blood	  and	  plasma	  were	  all	  kept	  at	  4°C.	  Plasma	  lipid	  
and	  lipoprotein	  cholesterol	  concentrations	  were	  determined	  by	  the	  methods	  of	  the	  
Lipid	  Research	  Clinics	  (Office	  USGP	  1982).	  Triglyceride,	  total	  cholesterol,	  and	  
lipoprotein	  cholesterol	  values	  were	  measured	  by	  enzymatic	  procedures.	  High-­‐
density	  lipoprotein	  (HDL)	  cholesterol	  was	  determined	  by	  the	  dextran	  sulfate-­‐
magnesium	  precipitation	  procedure	  (Thompson	  and	  Roy	  1981).	  Low-­‐density	  
lipoprotein	  cholesterol	  was	  calculated	  from	  the	  following	  equation:	  Low	  density	  
lipoprotein	  (LDL)	  cholesterol	  =	  total	  cholesterol	  -­‐	  [HDL	  cholesterol	  +	  
(triglycerides/5)]	  (Wagner	  et	  al.	  2000).	  
	  
2.2.5	  Coronary	  calcium	  and	  carotid	  intima-­‐media	  thickness	  thresholds	  	  
Based	  on	  prior	  studies,	  the	  American	  College	  of	  Cardiology	  Foundation	  (ACCF)	  has	  
classified	  patients	  without	  detectable	  coronary	  calcification	  (CAC	  score	  =	  0)	  as	  low	  
risk,	  having	  a	  very	  low	  rate	  of	  CHD	  death	  or	  MI	  three	  to	  five	  years	  later	  (Greenland	  
et	  al.	  2007).	  Those	  patients	  with	  any	  measurable	  calcium	  were	  determined	  to	  have	  a	  
relative	  risk	  ratio	  of	  4.3	  (95%	  confidence	  interval	  =	  3.5	  to	  5.2)	  compared	  to	  the	  zero	  
calcium	  patient	  group,	  from	  the	  ACCF	  meta-­‐analysis.	  The	  Screening	  for	  Heart	  Attack	  
Prevention	  and	  Education	  Task	  Force	  classifies	  individuals	  with	  CIMT	  greater	  than	  
or	  equal	  to	  1	  mm	  as	  high	  risk	  and	  having	  a	  positive	  result	  for	  subclinical	  
atherosclerosis	  (Naghavi	  et	  al.	  2006).	  We	  follow	  these	  conclusions	  when	  classifying	  
risks	  based	  on	  calcium	  scores	  and	  carotid	  intima	  media	  thickness.	  
	  
2.2.6	  Framingham	  Risk	  Score	  standards	  
The	  Third	  Report	  of	  the	  National	  Cholesterol	  Education	  Program	  Expert	  Panel	  on	  
Detection,	  Evaluation,	  and	  Treatment	  of	  High	  Blood	  Cholesterol	  in	  Adults	  (National	  
Cholesterol	  Education	  Program	  Expert	  Panel	  2002)	  recommends	  the	  use	  of	  the	  
Framingham	  Risk	  scoring	  to	  assess	  10	  year	  risk	  for	  coronary	  heart	  disease	  in	  
individuals	  who	  otherwise	  do	  not	  have	  coronary	  artery	  disease	  (CHD)	  or	  other	  
clinical	  atherosclerotic	  diseases.	  Age,	  total	  cholesterol,	  HDL	  cholesterol,	  systolic	  
blood	  pressure,	  treatment	  for	  hypertension,	  and	  cigarette	  smoking	  are	  included	  in	  
the	  Framingham	  calculation	  of	  10-­‐year	  risk.	  The	  primary	  endpoint	  in	  the	  10-­‐year	  
risk	  assessment	  is	  myocardial	  infarction	  or	  coronary	  heart	  disease	  death.	  Although	  
the	  Framingham	  risk	  assessment	  also	  has	  been	  used	  to	  estimate	  total	  CHD	  at	  the	  
rate	  of	  about	  two-­‐thirds	  to	  three-­‐fourths	  of	  hard	  CHD,	  ATP	  III	  does	  not	  recommend	  
this	  use.	  The	  risk	  probabilities	  are	  divided	  into	  three	  categories.	  Low	  risk	  is	  
described	  as	  less	  than	  10%	  risk	  by	  Framingham	  scoring	  (FRS).	  Medium	  risk	  is	  10	  to	  
20%,	  while	  high	  risk	  (CHD	  risk	  equivalent)	  is	  greater	  than	  20%	  by	  FRS.	  
	  
2.3	  Results	  
2.3.1	  Baseline	  characteristics	  
Our	  study	  sample	  consisted	  of	  159	  male	  firefighters	  (mean	  age	  46.5	  years)	  (Table	  
2.1)	  not	  on	  any	  medications	  and	  without	  known	  coronary	  artery	  disease	  (CAD).	  
Each	  participant	  underwent	  clinical	  and	  serological	  risk	  factor	  screening,	  MDCT,	  and	  
CIMT.	  One	  of	  our	  primary	  interests	  is	  how	  well	  coronary	  artery	  calcium	  scoring	  
(CAC)	  by	  MDCT	  and	  carotid-­‐intimal	  media	  thickness	  by	  ultrasound	  imaging	  aligns	  
with	  traditional	  CAD	  risk	  factors.	  We	  asked	  if	  average	  risk	  factor	  values	  were	  
significantly	  different	  between	  groups	  as	  defined	  by	  well-­‐accepted	  thresholds	  for	  
CAC	  and	  CIMT	  determined	  by	  Student’s	  t-­‐test.	  When	  comparing	  individuals	  with	  no	  
detectable	  coronary	  calcification	  (CAC=0)	  with	  individuals	  with	  measurable	  
calcification	  (CAC	  >0),	  there	  were	  significant	  differences	  in	  ages,	  diastolic	  blood	  
pressure,	  and	  systolic	  blood	  pressure	  (p-­‐value	  =	  0.0028	  0.0084,	  0.0045,	  
respectively)	  (Table	  2.2).	  Total	  cholesterol,	  high-­‐density	  lipoprotein,	  and	  low-­‐
Table	  2.1.	  Characteristics	  (means)	  of	  the	  sampled	  firefighter	  population	  (n=159)	  
Age (years) 46.55  ± 5.08 
Systolic blood pressure (mm Hg) 124.13 ± 11.1 
Diastolic blood pressure (mm Hg) 78.18 ± 8 
Total cholesterol (mg/dL) 203.68 ± 34.82 
HDL cholesterol  (mg/dL) 48.38 ± 13.78 
LDL cholesterol (mg/dL) 134.27 ± 31.79 
Framingham Risk Score (10 yr):   
     Low    128 
     Med     22 
     High      9 
	  
	  
Table	  2.2.	  Comparison	  of	  common	  characteristics	  between	  firefighters	  at	  different	  
risk	  levels	  as	  determined	  by	  CAC	  
 CAC   
 Positive (CAC>0) Negative (CAC = 0) 
T-test p-
value 
N 37 122  
Age (yrs) 48.7 +/- 5.6 45.9 +/- 4.7 0.0027 
Diastolic BP avg (mm 
Hg) 81.2 +/- 8.9 77.27 +/- 7.5 0.0084 
Systolic BP avg (mm Hg)  128.6 +/- 13.6 122/7 +/- 9.9 0.0045 
Total cholesterol (mg/dL) 209.4 +/- 40.7 201.9 +/- 32.9 0.2545 
High-density lipoprotein 
cholesterol (mg/dL) 49.8 +/- 16.8 47.9 +/- 12.8 0.4836 
Low-density lipoprotein 
cholesterol (mg/dL) 139.9 +/- 39.0 132.6 +/- 29.2 0.2211 
	  
	  
Table	  2.3.	  Comparison	  of	  common	  characteristics	  between	  firefighters	  at	  different	  
risk	  levels	  as	  determined	  by	  CIMT	  
	  
 CIMT   
 Positive  Negative T-test 
 (CIMT >0.9mm) (CIMT < 0.9 mm) p-Value 
N 15 144  
Age (yrs) 53.21 +/- 5.59 45.91 +/- 4.58 1.013E-07 
Diastolic BP avg (mm 
Hg) 82.71 +/- 8.21 77.74 +/- 7.9 0.0267 
Systolic BP avg (mm 
Hg)  133.47 +/- 14.36 123.22 +/- 10.40 0.00087 
Total cholesterol 
(mg/dL) 213.57 +/- 31.15 202.73 +/- 35.22 0.2688 
High-density lipoprotein 
cholesterol (mg/dL) 46.78 +/- 12.82 48.53 +/- 13.95 0.6521 
Low-density lipoprotein 
cholesterol (mg/dL) 148 +/- 32.14 132.95 +/- 31.55 0.0908 
density	  lipoproteins	  levels	  did	  not	  differ	  significantly	  between	  these	  two	  groups.	  
The	  same	  pattern	  was	  also	  true	  when	  comparing	  individuals	  with	  carotid	  intima-­‐
media	  thicknesses	  (CIMT)	  greater	  than	  0.9	  mm	  and	  those	  whose	  CIMTs	  were	  less	  
than	  0.9	  mm,	  where	  there	  were	  significant	  differences	  in	  ages,	  diastolic	  blood	  
pressure,	  and	  systolic	  blood	  pressure	  (p-­‐value	  =	  1x10-­‐7,	  0.026,	  0.00087,	  
respectively)	  (Table	  2.3).	  In	  order	  to	  set	  a	  new	  FRS	  threshold	  and	  then	  test	  its	  utility,	  
we	  randomly	  split	  our	  159-­‐person	  population	  into	  a	  training	  group	  of	  106	  
individuals	  and	  a	  testing	  group	  of	  53	  individuals	  that	  will	  be	  used	  for	  threshold	  
validation.	  Given	  our	  sample	  size	  larger	  than	  100,	  a	  1/3rds	  to	  2/3rds	  split	  has	  been	  
previously	  determined	  to	  retain	  both	  high	  classification	  and	  testing	  accuracy	  in	  high	  
dimensional	  data	  sets	  (Dobbin	  and	  Simon	  2011).	  	  
	  
2.3.2	  Standard	  FRS	  thresholds	  fail	  to	  recognize	  existing	  atherosclerosis	  
To	  first	  analyze	  the	  utility	  of	  the	  Framingham	  Risk	  Score	  we	  asked	  if	  its	  risk	  
categories	  were	  well	  correlated	  with	  our	  measures	  of	  actual	  atherosclerotic	  burden	  
using	  CAC	  and	  CIMT.	  For	  the	  training	  group,	  we	  calculated	  Framingham	  Risk	  Scores	  
(FRS),	  using	  their	  risk	  factor	  and	  medical	  history	  data.	  We	  then	  split	  these	  scores	  by	  
Framingham	  risk	  categories:	  high	  (>	  20%	  risk	  of	  a	  major	  adverse	  coronary	  event	  
within	  10	  years),	  medium	  (10-­‐20%	  risk),	  and	  low	  (<10%	  risk).	  Out	  of	  106	  
individuals,	  85	  have	  FRS	  below	  10%,	  17	  have	  FRS	  between	  10%	  and	  20%,	  and	  4	  
have	  FRS	  above	  20%.	  	  Out	   	  of	  the	  85	  with	  FRS	  below	  10%,	  16	  were	  positive	  for	  
coronary	  calcification	  and	  two	  were	  positive	  by	  CIMT	  (as	  well	  as	  CAC)	  (Figures	  2.1	  
and	  2.2).	  Out	  of	  the	  17	  with	  FRS	  between	  10	  and	  20%,	  three	  were	  positive	  for	  
	  
	  
	  
	  
Figure	  2.1.	  Coronary	  artery	  calcification	  vs	  Framingham	  Risk	  Score	  
Coronary	  artery	  calcification	  scores	  (CAC)	  above	  zero	  are	  classified	  as	  clinically	  
significant	  for	  atherosclerosis.	  The	  majority	  of	  atherosclerosis	  positive	  individuals	  
as	  determined	  by	  CAC,	  particularly	  those	  with	  high	  scores,	  are	  also	  classified	  as	  
having	  low	  or	  moderate	  risk	  by	  Framingham	  Risk	  Score.	  The	  Pearson	  correlation	  
between	  the	  two	  measures	  is	  relatively	  weak	  (r=0.3184629,	  p-­‐value=0.000878).	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Figure	  2.2.	  Carotid	  intima-­media	  thickness	  vs	  Framingham	  Risk	  Score	  	  
Carotid	  intima-­‐media	  thicknesses	  (CIMT)	  above	  0.9	  mm	  are	  classified	  as	  clinically	  
significant	  for	  atherosclerosis.	  Again,	  the	  majority	  of	  atherosclerosis	  positive	  
individuals	  as	  determined	  by	  CIMT	  are	  also	  classified	  as	  having	  low	  or	  moderate	  
risk	  by	  Framingham	  Risk	  Score.	  The	  Pearson	  correlation	  between	  the	  two	  measures	  
is	  relatively	  weak	  (r=0.3395805,	  p-­‐value	  =	  0.0003692).	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coronary	  calcification	  and	  one	  was	  positive	  by	  CIMT	  (but	  not	  by	  CAC).	  	  Of	  the	  four	  
individuals	  in	  the	  high	  risk	  FRS	  group,	  all	  were	  positive	  for	  coronary	  calcification	  
and	  two	  were	  positive	  by	  CIMT.	  
Nineteen	  out	  of	  23	  of	  the	  sampled	  individuals	  with	  clinically	  significant	  
coronary	  calcification	  that	  indicates	  the	  presence	  of	  atherosclerosis	  are	  classified	  as	  
low	  or	  medium	  risk	  by	  FRS.	  At	  the	  20%	  FRS	  threshold,	  FRS	  has	  100%	  specificity	  for	  
significant	  coronary	  calcium,	  but	  only	  17%	  sensitivity	  (Table	  2.4).	  Likewise	  for	  
significant	  carotid	  intima-­‐media	  thickness	  at	  the	  20%	  FRS	  threshold,	  FRS	  has	  98%	  
specificity,	  and	  only	  40%	  sensitivity	  (Table	  2.5).	  Even	  at	  a	  more	  conservative	  10%	  
FRS	  threshold,	  FRS	  has	  83%	  specificity	  for	  significant	  coronary	  calcium,	  and	  30%	  
sensitivity.	  And	  a	  10%	  FRS	  threshold	  has	  82%	  specificity	  for	  significant	  carotid	  
intima-­‐media	  thickness,	  and	  60%	  sensitivity.	  This	  low	  sensitivity	  represents	  a	  large	  
number	  of	  affected	  individuals	  who	  would	  appear	  as	  low	  risk	  by	  Framingham	  Risk	  
Score.	  	  
	  
2.3.3	  Optimizing	  FRS	  thresholds	  for	  specificity	  and	  sensitivity	  	  
Because	  of	  the	  high	  cost	  of	  misclassifying	  affected	  individuals	  as	  low	  risk,	  we	  sought	  
to	  find	  a	  new	  optimal	  FRS	  threshold	  that	  provided	  a	  better	  balance	  between	  
specificity	  and	  sensitivity.	  Using	  a	  receiver-­‐operator	  characteristic	  (ROC)	  curve,	  we	  
determined	  new	  FRS	  thresholds	  for	  capturing	  significant	  coronary	  calcification	  
(Figure	  2.3)	  or	  carotid	  intima-­‐media	  thickness	  (Figure	  2.4).	  The	  ROC	  curve	  provides	  
an	  intuitive	  path	  for	  optimizing	  specificity	  and	  sensitivity.	  	  For	  coronary	  
calcification,	  this	  optimized	  FRS	  threshold	  is	  6%	  risk,	  while	  for	  CIMT	  the	  optimized	  
	  
Table	  2.4.	  Low	  sensitivity	  for	  CAC	  at	  traditional	  FRS	  thresholds	  
 FRS 
CAC Positive (high) 
Negative (low-
med) 
Positive (>0) 4 19 
Negative (=0) 0 83 
   
 Specificity 1.00 
 Sensitivity 0.17 
	  
	  
	  
Table	  2.5.	  Low	  sensitivity	  for	  CIMT	  at	  traditional	  FRS	  thresholds	  
 FRS 
CIMT Positive (high) 
Negative (low-
med) 
Positive (>0.9mm) 2 3 
Negative (<0.9mm) 2 99 
   
 Specificity 0.98 
 Sensitivity 0.40 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  2.3.	  Receiver-­operator	  characteristic	  curve	  for	  Framingham	  Risk	  Score	  in	  
predicting	  coronary	  artery	  calcification	  status	  
The	  receiver-­‐operator	  characteristic	  curve	  (ROC)	  plots	  specificities	  and	  sensitivities	  
of	  all	  possible	  threshold	  percentage	  values	  of	  the	  Framingham	  Risk	  Scores	  (FRS)	  
when	  calling	  coronary	  calcification	  status.	  Here	  positive	  calcification	  status	  is	  
defined	  as	  any	  score	  above	  zero.	  The	  numbered	  points	  represent	  FRS	  thresholds	  
above	  which	  significant	  risk	  of	  major	  adverse	  coronary	  events	  would	  be	  predicted.	  
	  
	  
	  
Figure	  2.4.	  Receiver-­operator	  characteristic	  curve	  for	  Framingham	  Risk	  Score	  in	  
predicting	  carotid	  intima-­media	  thickness	  status	  
The	  receiver-­‐operator	  characteristic	  curve	  (ROC)	  plots	  specificities	  and	  sensitivities	  
of	  all	  possible	  threshold	  values	  of	  the	  Framingham	  Risk	  Scores	  (FRS)	  when	  calling	  
carotid	  intima-­‐medial	  thickness	  status.	  Here	  a	  CIMT	  status	  associated	  with	  clinically	  
significant	  atheroslerosis	  is	  defined	  as	  any	  score	  above	  0.9	  mm.	  The	  numbered	  
points	  represent	  FRS	  thresholds	  above	  which	  significant	  risk	  of	  major	  adverse	  
coronary	  events	  would	  be	  predicted.	  	  
	  
	  
	  
	  
	  
	  
	  
threshold	  is	  8%	  risk.	  Both	  are	  lower	  than	  the	  current	  ATP	  III	  10%	  threshold	  for	  
designating	  low	  risk.	  	  
	  
2.3.4	  Testing	  optimized	  FRS	  thresholds	  reveals	  improved	  sensitivity	  
To	  test	  the	  performance	  of	  these	  new	  thresholds,	  we	  applied	  them	  to	  a	  test	  
population	  of	  53	  firefighters	  with	  similar	  characteristics	  and	  known	  CAC	  and	  CIMT	  
status	  and	  calculate	  specificity	  and	  sensitivity	  measures	  for	  each.	  At	  the	  6%	  FRS	  
threshold	  for	  coronary	  calcium,	  specificity	  decreases	  to	  74%,	  while	  sensitivity	  
increases	  to	  50%	  (Table	  2.6).	  Using	  the	  8%	  FRS	  threshold	  for	  CIMT,	  specificity	  
decreases	  to	  91%,	  while	  sensitivity	  increases	  to	  67%	  (Table	  2.7).	  These	  new	  
lowered	  thresholds	  improve	  the	  sensitivity	  of	  the	  FRS	  calculation	  at	  a	  modest	  cost	  to	  
specificity.	  
	  
2.3.5	  Treating	  firefighters	  as	  smokers	  
The	  ATP	  III	  guidelines	  recently	  quantified	  additional	  CHD	  risk	  from	  smoking	  as	  a	  
sliding	  scale	  by	  subject	  age	  (Table	  2.8),	  where	  points	  are	  added	  based	  on	  the	  
subject’s	  age	  group.	  Fewer	  points	  are	  added	  at	  increased	  ages	  to	  account	  for	  
exposure	  over	  time.	  To	  account	  for	  chronic	  firefighter	  exposure	  to	  toxins	  and	  
particles	  generated	  by	  ignition	  at	  firefighting	  incidents,	  we	  examined	  the	  effects	  of	  
treating	  all	  firefighters	  as	  smokers	  for	  the	  purposes	  of	  the	  FRS	  calculation,	  
regardless	  of	  their	  actual	  smoking	  status.	  Following	  this	  recalculation,	  we	  
determined	  the	  specificity	  and	  sensitivity	  of	  the	  traditional	  20%	  FRS	  thresholds	  for	  
CAC	  and	  CIMT	  using	  our	  training	  group.	  For	  CAC,	  the	  FRS	  threshold	  had	  a	  specificity	  
	  
	  
	  
Table	  2.6.	  Improved	  FRS	  correspondence	  to	  CAC	  at	  6%	  risk	  threshold	  
 FRS 
CAC Positive (>6%) 
Negative 
(<=6%) 
Positive (>0) 7 7 
Negative (=0) 10 29 
   
 Specificity 0.74 
 Sensitivity 0.50 
	  
	  
	  
Table	  2.7.	  Improved	  FRS	  correspondence	  to	  CIMT	  at	  8%	  risk	  threshold	  
 FRS 
CIMT Positive (>8%) 
Negative 
(<=8%) 
Positive (>0.9mm) 6 3 
Negative 
(<0.9mm) 4 40 
   
 Specificity 0.91 
 Sensitivity 0.67 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Table	  2.8.	  	  FRS	  smoking	  adjustment	  
	  
	  
	  
	  
Table	  2.9.	  Changes	  in	  traditional	  FRS	  threshold	  correspondence	  with	  CAC	  with	  
smoking	  adjustment	  
 FRS with smoking adjustment 
CAC 
Positive 
(high) Negative (low-med) 
Positive (>0) 6 17 
Negative (=0) 6 77 
   
 Specificity 0.93 
 Sensitivity 0.26 
	  
	  
	  
Table	  2.10.	  Changes	  in	  traditional	  FRS	  threshold	  correspondence	  with	  CIMT	  with	  
smoking	  adjustment	  
 FRS with smoking adjustment 
CIMT Positive (high) 
Negative (low-
med) 
Positive (>0.9mm) 5 0 
Negative (<0.9mm) 7 94 
   
 Specificity 0.93 
 Sensitivity 1.00 
	  
	  
	  
	  
	  
	  
	  
	  
of	  93%,	  and	  a	  sensitivity	  of	  26%	  (Table	  2.9).	  While	  for	  CIMT,	  the	  FRS	  threshold	  had	  
a	  specificity	  of	  93%	  and	  a	  sensitivity	  of	  100%	  (Table	  2.10).	  
We	  also	  generated	  ROC	  curves	  for	  FRS	  thresholds	  for	  coronary	  calcification	  
and	  CIMT	  including	  this	  smoking	  adjustment	  (Figures	  2.5	  and	  2.6).	  These	  ROC	  
curves	  yielded	  an	  optimized	  FRS	  threshold	  for	  significant	  coronary	  calcium	  of	  12%	  
and	  an	  optimized	  FRS	  threshold	  of	  20%	  for	  CIMT.	  We	  again	  tested	  the	  performance	  
of	  these	  new	  thresholds	  by	  applying	  them	  to	  our	  test	  population	  of	  53	  firefighters.	  
The	  new	  FRS	  threshold	  for	  significant	  coronary	  calcium	  of	  12%	  yielded	  a	  specificity	  
of	  51%	  and	  sensitivity	  of	  43%	  (Table	  2.11).	  For	  CIMT,	  the	  FRS	  threshold	  of	  20%	  
yielded	  a	  specificity	  of	  88%	  and	  sensitivity	  of	  75%	  (Table	  2.12).	  
	  
2.4	  Discussion	  
The	  standard	  threshold	  (positive	  FRS	  >	  20%)	  assigns	  a	  large	  proportion	  of	  
firefighters	  with	  existing	  atherosclerosis	  into	  low	  and	  medium	  risk	  categories	  
(Table	  2.1	  –	  2.3).	  Although	  the	  Framingham	  Risk	  assessment	  was	  designed	  to	  
measure	  the	  probability	  of	  future	  myocardial	  infarction	  and	  death	  from	  coronary	  
artery	  disease,	  the	  presence	  of	  current	  significant	  coronary	  calcification	  or	  carotid	  
intima-­‐media	  thickening	  would	  suggest	  that	  these	  individuals	  are	  in	  fact	  already	  at	  
high	  risk	  for	  coronary	  artery	  disease.	  Indeed,	  coronary	  calcification	  is	  an	  indicator	  of	  
subclinical	  atherosclerosis	  and	  when	  combined	  with	  risk	  factors	  can	  be	  considered	  a	  
CHD	  risk	  equivalent	  (National	  Cholesterol	  Education	  Program	  Expert	  Panel	  2002).	  
CIMT	  also	  is	  a	  predictor	  of	  future	  cardiovascular	  events	  and	  has	  been	  used	  in	  many	  
	  
Figure	  2.5.	  Receiver-­operator	  characteristic	  curve	  for	  Framingham	  Risk	  Score	  
prediction	  of	  coronary	  calcification	  with	  smoking	  adjustment.	  
The	  receiver-­‐operator	  characteristic	  curve	  (ROC)	  plots	  specificities	  and	  sensitivities	  
of	  all	  possible	  threshold	  values	  of	  the	  Framingham	  Risk	  Scores	  (FRS)	  when	  calling	  
coronary	  calcification	  status.	  Here	  positive	  calcification	  status	  is	  defined	  as	  any	  
score	  above	  zero.	  The	  numbered	  points	  represent	  FRS	  thresholds	  above	  which	  
significant	  risk	  of	  major	  adverse	  coronary	  events	  would	  be	  predicted	  when	  the	  
smoking	  adjustment	  is	  applied	  to	  this	  score	  regardless	  of	  the	  individual	  firefighter’s	  
actual	  smoking	  status.	  	  
	  
	  
	  
Figure	  2.6.	  Receiver-­operator	  characteristic	  curve	  for	  Framingham	  Risk	  Score	  
prediction	  of	  carotid	  intima-­medial	  thickness	  with	  smoking	  adjustment	  
The	  receiver-­‐operator	  characteristic	  curve	  (ROC)	  plots	  specificities	  and	  sensitivities	  
of	  all	  possible	  threshold	  values	  of	  the	  Framingham	  Risk	  Scores	  (FRS)	  when	  calling	  
carotid	  intima-­‐medial	  thickness	  status.	  Here	  a	  CIMT	  status	  associated	  with	  clinically	  
significant	  atheroslerosis	  is	  defined	  as	  any	  score	  above	  0.9	  mm.	  The	  numbered	  
points	  represent	  FRS	  thresholds	  above	  which	  significant	  risk	  of	  major	  adverse	  
coronary	  events	  would	  be	  predicted.	  when	  the	  smoking	  adjustment	  is	  applied	  to	  this	  
score	  regardless	  of	  the	  individual	  firefighter’s	  actual	  smoking	  status.	  	  
	  
	  
	  
Table	  2.11.	  Changes	  in	  FRS	  correspondence	  with	  CAC	  with	  smoking	  adjustment	  at	  
12%	  threshold	  
 FRS with smoking adjustment 
CAC 
Positive 
(>12%) 
Negative 
(<=12%) 
Positive (>0) 6 8 
Negative (=0) 19 20 
   
 Specificity 0.51 
 Sensitivity 0.43 
	  
	  
	  
Table	  2.12.	  Changes	  in	  FRS	  correspondence	  with	  CIMT	  with	  smoking	  adjustment	  at	  
20%	  threshold	  
 FRS with smoking adjustment 
CIMT 
Positive 
(>20%) 
Negative 
(<=20%) 
Positive (>0.9mm) 3 1 
Negative 
(<0.9mm) 6 43 
   
 Specificity 0.88 
 Sensitivity 0.75 
	  
other	  studies	  as	  a	  surrogate	  end	  point	  (Salonen	  and	  Salonen	  1993;	  Belcaro	  et	  al.	  
1996;	  Bots	  et	  al.	  1997;	  Chambless	  et	  al.	  1997;	  O'Leary	  et	  al.	  1999a).	  	   	  
	   In	  order	  to	  correct	  the	  shortcomings	  of	  applying	  the	  standard	  FRS	  thresholds	  
to	  firefighters,	  we	  used	  receiver-­‐operator	  characteristic	  curves	  to	  determine	  new	  
thresholds	  that	  would	  improve	  the	  sensitivity	  while	  maintaining	  the	  high	  degree	  of	  
specificity	  held	  by	  the	  existing	  threshold.	  This	  resulted	  in	  lower	  thresholds,	  6%	  for	  
CAC	  and	  8%	  for	  CIMT,	  for	  predicting	  CAD.	  We	  were	  able	  to	  generate	  substantial	  
gains	  in	  sensitivity	  (17%	  improved	  to	  50%	  for	  CAC,	  and	  40%	  improved	  to	  67%	  for	  
CIMT)	  with	  a	  modest	  loss	  of	  specificity	  (100%	  to	  74%	  for	  CAC,	  and	  98%	  to	  91%	  for	  
CIMT).	  We	  argue	  that	  misdiagnosing	  affected	  individuals	  as	  healthy	  is	  far	  costlier	  
than	  misdiagnosing	  healthy	  individuals	  as	  affected.	  The	  Multi-­‐Ethnic	  Study	  of	  
Atherosclerosis	  and	  the	  Prospective	  Army	  Coronary	  Calcium	  Project	  also	  found	  that	  
individuals	  with	  low	  FRS	  (5.1-­‐20%)	  also	  had	  clinically	  significant	  atherosclerosis	  as	  
determined	  by	  CAC,	  indicating	  that	  this	  pattern	  is	  not	  exclusive	  to	  firefighters	  
(Taylor	  et	  al.	  2010;	  Okwuosa	  et	  al.	  2011).	  	  
	   Despite	  the	  widespread	  use	  of	  self-­‐contained	  breathing	  apparatuses	  by	  
firefighters	  during	  fire	  suppression	  activities,	  this	  respiratory	  protection	  is	  often	  
removed	  during	  the	  salvage	  and	  overhaul	  duties	  immediately	  following	  (Rosenstock	  
and	  Olsen	  2007).	  Significant	  exposure	  to	  the	  products	  of	  combustion,	  including	  toxic	  
chemicals,	  such	  as	  carbon	  monoxide,	  benzene,	  sulphur	  dioxide,	  hydrogen	  cyanide,	  
acrolein,	  and	  fine	  particulate	  matter	  occurs	  during	  the	  overhaul	  process	  (Gold	  et	  al.	  
1978;	  Burgess	  et	  al.	  2001).	  Exposure	  to	  both	  toxic	  chemicals	  and	  fine	  particulate	  
matter	  has	  been	  implicated	  in	  the	  progression	  of	  coronary	  heart	  disease	  (Brandt-­‐
Rauf	  et	  al.	  1988;	  Baxter	  et	  al.	  2010).	  Specifically,	  long-­‐term	  exposure	  to	  particulate	  
matter	  may	  increase	  the	  risk	  of	  subclinical	  atherosclerosis	  through	  an	  oxidative	  
stress	  mechanism	  due	  to	  the	  high	  content	  of	  redox-­‐cycling	  chemicals	  in	  ultrafine	  
particles	  (<0.18	  µm	  in	  diameter)	  found	  abundantly	  in	  post-­‐suppression	  air	  (Araujo	  
and	  Nel	  2009).	  To	  account	  for	  this	  exposure	  over	  time,	  we	  altered	  the	  Framingham	  
Risk	  Score	  calculation	  to	  include	  all	  firefighters	  as	  smokers.	  Following	  the	  
application	  of	  ROC	  curves,	  we	  set	  new	  thresholds	  of	  12%	  FRS	  for	  CAC	  and	  20%	  FRS	  
for	  CIMT.	  Application	  of	  these	  thresholds	  to	  our	  test	  group	  revealed	  gains	  in	  
sensitivity	  for	  the	  predictive	  power	  of	  smoking-­‐adjusted	  FRS	  for	  clinically	  significant	  
CIMT,	  but	  a	  loss	  in	  both	  specificity	  and	  sensitivity	  when	  it	  came	  to	  CAC.	  	  
	   Our	  attempts	  to	  adjust	  the	  thresholds	  by	  ROC	  and	  smoking	  correction	  
demonstrate	  that	  substantial	  changes	  can	  be	  made	  in	  the	  sensitivity	  of	  traditional	  
testing,	  though	  our	  smoking	  adjustment	  improved	  the	  correspondence	  of	  FRS	  to	  
CIMT	  and	  not	  CAC.	  The	  presence	  of	  clinically	  significant	  CAC	  and	  CIMT	  at	  low	  FRS	  
combined	  with	  increased	  risk	  of	  CAD	  in	  firefighters	  even	  when	  compared	  to	  other	  
first	  responders	  suggests	  that	  all	  firefighters	  should	  be	  screened	  for	  CAD	  regardless	  
of	  their	  classification	  by	  traditional	  means	  such	  as	  FRS.	  	  In	  this	  setting,	  non-­‐invasive	  
tests	  like	  CAC	  and	  CIMT	  could	  compliment	  FRS	  in	  determining	  the	  aggressiveness	  of	  
treatment.	  	  
Given	  our	  experimental	  design,	  it	  is	  difficult	  to	  accurately	  contrast	  coronary	  
health	  markers	  in	  firefighters	  against	  those	  observed	  in	  the	  general	  population,	  
though	  it	  appears	  that	  other	  large	  scale	  studies	  have	  found	  clinically	  significant	  CAC	  
and	  CIMT	  in	  low-­‐risk	  FRS	  categorized	  individuals	  as	  well	  (Folsom	  et	  al.	  2008;	  Lester	  
et	  al.	  2009;	  Khalil	  et	  al.	  2010;	  Polak	  et	  al.	  2011).	  We	  suggest	  follow-­‐up	  studies	  that	  
examine	  firefighter	  and	  non-­‐firefighter	  populations	  in	  parallel.	  Moreover,	  long-­‐term	  
studies	  that	  encompass	  5	  and	  10	  year	  follow	  on	  surveying	  for	  major	  adverse	  
coronary	  events	  would	  help	  to	  affirm	  our	  predictions	  of	  early	  signs	  of	  risk.	  Finally	  
long-­‐term	  studies	  of	  toxin	  and	  particulate	  exposure	  impact	  on	  firefighter	  coronary	  
health	  are	  also	  warranted.	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CHAPTER	  3	  
INFLAMMATION	  AND	  EXTRACELULAR	  MATRIX	  GENES	  
DIFFERENTIALLY	  EXPRESSED	  IN	  CORONARY	  ARTERIES	  FOLLOWING	  
ZOTAROLIMUS-­‐	  AND	  SIROLIMUS-­‐ELUTING	  STENT	  IMPLANTATION	  
	  
	  
	  
3.1.	  INTRODUCTION	  
Percutaneous	   transluminal	   coronary	   angioplasty	   (PTCA)	   has	   revolutionized	   the	  
treatment	  of	  coronary	  artery	  disease	  since	  its	  introduction	  in	  1977	  (Grüntzig	  et	  al.	  
1979).	   However,	   restenosis	   or	   the	   arterial	   healing	   response	   has	   proven	   to	   be	  
problematic	   for	   PTCA	   due	   to	   negative	   remodeling,	   contraction	   formation	   and	  
consequent	  late	  luminal	  loss	  in	  30-­‐60%	  of	  post-­‐angioplasty	  patients	  (Fischman	  et	  al.	  
1994;	   Serruys	   et	   al.	   1994).	   The	  use	   of	   bare	  metal	   stents	   (BMS)	   in	   PTCA	  has	   been	  
effective	   in	   reducing	   restenosis	   by	   acting	   as	   a	   scaffold	   against	   elastic	   recoil	   and	  
negative	  remodeling	  (Sigwart	  et	  al.	  1987;	  Fischman	  et	  al.	  1994;	  Serruys	  et	  al.	  1994).	  
Referred	  to	  generally	  as	  percutaneous	  coronary	  intervention	  (PCI)	  the	  use	  of	  stents	  
in	  PTCA	  has	  resulted	  in	  a	  significant	  reduction	  in	  many	  of	  the	  major	  adverse	  cardiac	  
events	   associated	   with	   PTCA	   and	   is	   currently	   considered	   a	   standard	   procedure	  
worldwide.	   However,	   the	   increased	   use	   of	   BMS	   in	   PTCA	   has	   resulted	   in	   the	  
emergence	  of	  an	  unanticipated	  complication,	  i.e.,	  the	  occurrence	  of	  restenosis	  within	  
the	  stent	  (“in-­‐stent	  restenosis”	  or	  ISR)	  resulting	  in	  	  >	  50%	  late	  lumen	  diameter	  loss	  
in	  treated	  patients.	  
In	  an	  effort	   to	  reduce	   ISR,	  a	  new	  generation	  of	  drug-­‐eluting	  stents	  (DES)	  has	  been	  
designed	  to	  release	  anti-­‐restenotic	  agents	  at	   the	  stent	  site.	  The	   two	  most	  common	  
anti-­‐restenotic	   drugs	   used	   in	   drug-­‐eluting	   stents,	   are	   sirolimus	   (Sirolimus	   Eluting	  
Stents,	   SES)	   and	   zotarolimus	   (Zotarolimus	   Eluting	   Stents,	   ZES).	   Both	   drugs	   have	  
similar	   antimicrobial	   and	   immunosuppressive	   properties	   since	   they	   are	   derived	  
from	  the	  same	  natural	  compound,	  rapamycin	  (Pendyala	  et	  al.	  2008).	  Rapamycin	  acts	  
by	   binding	   to	   the	   cytosolic	   receptor	   FKBP12,	   forming	   a	   complex	   that	   inhibits	   the	  
activation	   of	   the	  mammalian	   target	   of	   rapamycin	   (mTOR)	   (Fischman	   et	   al.	   1994).	  
mTOR	  inhibition	  ultimately	  results	  in	  cell	  cycle	  arrest	  in	  the	  late	  G1	  phase,	  arresting	  
smooth	   muscle	   cell	   growth	   (Braun-­‐Dullaeus	   et	   al.	   1998;	   Marx	   and	   Marks	   2001).	  
Sirolimus	   is	   bound	   to	   the	   stent	   with	   a	   poly-­‐ethylene-­‐covinyl/poly-­‐n-­‐butyl	  
methacrylate	   copolymer.	   ZES	   elute	   zotarolimus,	   a	   derivative	   of	   sirolimus	   that	  
incorporates	  a	  phosphorylcholine	  coating	  that	  imparts	  high	  lipophilicity	  (Lewis	  and	  
Stratford	   2002).	   It	   has	   been	   suggested	   that	   ZES	   are	   better	   suited	   for	   stent	   based	  
drug	   delivery	   since	   they	   have	   been	   shown	   to	   reduce	   endothelialisation	   and	  
neointimal	  formation	  relative	  to	  SES	  (Burke	  et	  al.	  2006).	  	  
Despite	  the	  apparent	  design	  advantage	  of	  ZES,	  recent	  clinical	  studies	  show	  that	  both	  
short-­‐term	  (1	  month)	  and	  long	  term	  (1	  year)	  use	  of	  ZES	  results	  in	  an	  elevated	  rate	  of	  
ISR,	  stent	  thrombosis,	  lesion	  revascularization,	  and	  vessel	  revascularization	  relative	  
to	   SES	   (Cheol	   Whan	   et	   al.	   2009;	   Rasmussen	   et	   al.	   2010).	   While	   these	   and	   other	  
comparative	   studies	   have	   revealed	   significant	   differences	   between	   BMS,	   SES	   and	  
ZES	   at	   both	   the	   clinical	   and	   histological	   levels,	   the	   molecular	   basis	   of	   these	  
differences	  remains	  poorly	  understood.	  	  
In	   an	   effort	   to	   better	   understand	   the	  molecular	   basis	   of	   the	   variable	   response	   of	  
coronary	   arteries	   to	   the	   different	   classes	   of	   stents,	   we	   conducted	   a	   comparative	  
microarray	  profiling	  study	  to	  examine	  differences	  in	  gene	  expression	  and	  pathway	  
function	   in	   coronary	   arteries	   exposed	   to	   ZES,	   SES,	   and	   BMS	   in	   a	   porcine	   animal	  
model.	  
	  
3.2.	  MATERIAL	  AND	  METHODS	  
3.2.1	  Stent	  characteristics	  
SES	   (Cypher®,	   13	   mm	   in	   length,	   Johnson	   &	   Johnson,	   Bridgewater,	   New	   Jersey)	  
contain	   sirolimus	   combined	   with	   non-­‐erodable	   polymers	   (polyethylene-­‐co-­‐vinyl	  
acetate	  [PEVA]	  and	  poly-­‐n-­‐butyl	  methacrylate	  [PBMA]).	  The	  thickness	  of	  the	  coating	  
is	   about	   12.6-­‐µm.	   The	   dose	   of	   the	   drug	   on	   the	   SES	   surface	   is	   10	   μg/mm	   of	   stent	  
length.	  Both	  SES	  and	  bare	  metal	  stents	  (BMS,	  12	  mm	  in	  length,	  Driver®,	  Medtronic	  
Cardiovascular,	   Minneapolis,	   MN)	   were	   purchased	   as	   commercially	   available	  
products.	   ZES	   (Endeavor®,	   12	   mm	   in	   length,	   Medtronic	   Cardiovascular)	   were	  
provided	   by	   Medtronic	   formulated	   with	   zotarolimus,	   a	   chemical	   analogue	   of	  
sirolimus,	   and	  were	   coated	  with	  phosphorylcholine	   (PC).	  The	  dose	  of	   the	  drug	  on	  
the	  ZES	  surface	  is	  10	  μg/mm	  of	  stent	  length	  with	  a	  coating	  thickness	  of	  4.8-­‐µm.	  ZES	  
has	  a	  relatively	  rapid	  drug	  elution	  profile	  as	  90%	  of	  the	  drug	  is	  released	  during	  the	  
first	   10-­‐14	   days	   as	   compared	  with	   the	   SES,	   in	  which	   80%	   elution	   occurs	   over	   30	  
days.	  All	  of	  the	  devices	  were	  FDA	  approved	  and	  currently	  in	  clinical	  use.	  
3.2.2	  Animals	  and	  experimental	  protocol	  
Animal	  handling	  and	  care	  followed	  the	  recommendations	  of	  the	  National	  Institutes	  
of	   Health	   (NIH)	   guide	   for	   The	   Care	   and	   Use	   of	   Laboratory	   Animals,	   and	   were	  
consistent	  with	   guidelines	  of	   the	  American	  Heart	  Association	   (AHA).	  All	   protocols	  
were	  approved	  by	   the	  Saint	   Joseph’s	  Translational	  Research	   Institute	  Animal	  Care	  
and	   Use	   Committee	   in	   accordance	   with	   the	   Association	   for	   Assessment	   and	  
Accreditation	   of	   Laboratory	   Animal	   Care	   guidelines.	   Juvenile	   Yorkshire	   farm	  
animals	  (n	  =	  6),	  females	  or	  castrated	  males,	  approximately	  40-­‐50	  kg	  and	  4-­‐5	  months	  
of	  age	  were	  enrolled	  into	  three	  different	  randomized	  groups:	  1)	  BMS	  (n	  =	  2);	  2)	  SES	  
(n	  =	  2);	  and	  3)	  ZES	  (n	  =	  2).	  Two	  coronary	  arteries	   in	  each	  animal	  were	   implanted	  
with	   two	   overlapping	   stents,	   for	   a	   total	   of	   four	   stents	   of	   the	   same	   type	   in	   each	  
animal.	  
All	   animals	   received	   a	   combination	   of	   81	   mg	   aspirin	   and	   75	   mg	   clopidogrel	   by	  
mouth	  daily	  for	  3	  days	  prior	  to	  stent	  implantation.	  	  The	  drug	  regimen	  was	  continued	  
until	   termination	   of	   the	   experiment.	   For	   stent	   implantation,	   the	   animals	   were	  
sedated	   by	   intramuscular	   injection	   of	   ketamine	   20	  mg/kg,	   xylazine	   2	  mg/kg,	   and	  
atropine	   0.05	   mg/kg.	   After	   intubation,	   general	   anesthesia	   was	   induced	   and	  
maintained	   with	   isofluorane	   (2.5%).	   Cardiac	   cycle	   and	   blood	   pressure	   were	  
continuously	  monitored.	  	  
Cardiac	  catheterization	  was	  performed	  with	  full	  heparinization	  (200	  units/kg),	  and	  
the	  stents	  were	  implanted	  using	  quantitative	  coronary	  angiography	  (QCA)	  guidance	  
to	  obtain	  a	  stent-­‐to-­‐arterial	  diameter	  ratio	  (S/A	  ratio)	  =	  1.1:1	  with	  an	  overlapping	  
segment	  of	  one-­‐third	  to	  one-­‐half	  of	  single	  stent	  length.	  Activated	  clotting	  time	  (ACT)	  
measurements	  were	  performed	  approximately	  every	  30	  min,	  and	  additional	  heparin	  
was	  administered	  when	  ACT	  was	  below	  5	  min.	  	  
At	  one	  month,	  baseline	  angiography	  was	  performed	  by	  a	  single	  angiographer	  using	  
consistent	  contrast	  injection	  volumes.	  	  
3.2.3	  RNA	  extraction	  and	  microarray	  	  
After	   28	   days,	   tissue	   samples	   were	   collected	   from	   the	   stented	   segment	   of	   both	  
arteries	   from	   each	   animal	   (Table	   3.1).	   Tissue	   was	   manually	   dissected	   from	   each	  
stent	   and	   10-­‐20	   mg	   was	   ground	   with	   a	   Polytron	   homogenizer	   (Kinematica	   AG,	  
Lucerne,	  Switzerland)	  in	  RNeasy	  lysis	  buffer	  (Qiagen	  Inc.,	  Valencia,	  California).	  RNA	  
was	   isolated	  according	  to	  the	  manufacturer’s	   instructions.	   	  Quantity	  and	  quality	  of	  
RNA	  was	  determined	  with	  a	  NanoDrop	  spectrophotometer	  (Thermo	  Scientific	   Inc.,	  
Wilmington,	   Delaware)	   and	   BioAnalyser	   total	   RNA	   PicoChip	   assay	   (Agilent	  
Technologies	  Inc.,	  Santa	  Clara,	  California).	  50	  ng	  of	  the	  total	  RNA	  was	  converted	  into	  
cDNA	   and	   amplified	  with	   the	  Applause	   3'-­‐Amp	   System	   (NuGEN	  Technologies	   Inc.,	  
San	   Carlos,	   California).	   3	   μg	   of	   amplified	   cDNA	  was	   fragmented	   and	   labeled	  with	  
Encore™	   Biotin	   Module	   (NuGEN	   Technologies	   Inc.).	   The	   resulting	   cDNA	   was	  
hybridized	   to	   the	   GeneChip	   Porcine	   Genome	   array	   (Affymetrix	   Inc.,	   Santa	   Clara,	  
	  
	  
Table	  3.1.	  Analyzed	  stents	  and	  their	   implant	  positions.	  We	  generated	  12	   individual	  
gene	   expression	   profiles	   (Affymetrix	   Porcine	  Genome	  Array)	   from	   artery	   samples	  
taken	   from	   two	  SES	   implanted	  animals,	   two	  ZES	   implanted	  animals,	   and	   two	  BMS	  
implanted	  animals.	  Two	  coronary	  arteries	  in	  each	  animal	  were	  implanted	  with	  two	  
overlapping	   stents,	   for	   a	   total	   of	   four	   stents	   of	   the	   same	   type	   in	   each	   animal.	   For	  
each	   artery	   the	   tissues	   surrounding	   overlapping	   stents	   were	   processed	   together,	  
generating	   two	   gene	   expression	   profiles	   per	   animal,	   one	   for	   each	   artery.	   Stents,	  
animals,	  and	  stented	  coronary	  arteries	  are	  listed	  here.	  
Stent	   Animal	  #	   Artery	  
Bare	  metal	   4746	   Right	  coronary	  
	   	  
Left	  anterior	  
descending	  
	   	   	   	  
	   4747	   Right	  coronary	  
	   	  
Left	  anterior	  
descending	  
	   	   	   	  
Sirolimus	  eluting	   4745	   Left	  circumflex	  
	   	   Right	  coronary	  
	   	   	   	  
	   4750	   Right	  coronary	  
	   	  
Left	  anterior	  
descending	  
	   	   	   	  
Zotarolimus	  
eluting	   4757	   Right	  coronary	  
	   	  
Left	  anterior	  
descending	  
	   	   	   	  
	   4751	   Right	  coronary	  
	   	  
Left	  anterior	  
descending	  
	  
	  
	  
	  
	  
	  
	  
	  
California)	  for	  16	  hours	  at	  45˚C.	  The	  arrays	  then	  were	  washed,	  stained	  and	  scanned	  
according	  to	  the	  Affymetrix	  Technical	  Manual.	  
3.2.4	  Microarray	  data	  analysis	  
Affymetrix	   .CEL	  files	  were	  processed	  using	  the	  Affymetrix	  Expression	  Console	  (EC)	  
Software	   Version	   5.0.	   Files	   were	   processed	   using	   the	   default	  MAS5	   3'	   expression	  
workflow.	   All	   reported	  microarray	   data	   are	   described	   in	   accordance	  with	  MIAME	  
guidelines	   and	   deposited	   in	   the	   National	   Center	   for	   Biotechnology	   Information’s	  
Gene	   Expression	   Omnibus	   database	   with	   the	   accession	   numbers	   GSM712656,	  
GSM712657,	   GSM712658,	   GSM712659,	   GSM712660,	   GSM712661,	   GSM712662,	  
GSM712663,	   GSM712664,	   GSM712665,	   GSM712666,	   and	   GSM712667.	   Probe	   sets	  
that	  were	   called	   absent	   by	   default	  MAS5	   criteria	   in	   all	   24	   samples	  were	   removed	  
before	   further	  processing.	   Probe	   set	   results	  were	   further	   evaluated	  using	   Spotfire	  
DecisionSite	   software.	   Using	   a	   beta-­‐uniform	  model	   to	   control	   the	   false	   discovery	  
rate	  to	  less	  than	  0.25	  for	  our	  pooled	  pair-­‐wise	  stent	  comparisons,	  we	  determined	  a	  
new	  multiple	   testing-­‐adjusted	  p-­‐value	   threshold	  of	  0.016	  (Coombes	  2010).	  Probes	  
were	  considered	  differentially	  expressed	  if	  they	  had	  a	  fold	  change	  value	  of	  ≥	  2	  or	  <=	  
-­‐2	  and	  a	  p-­‐value	  <	  .016	  (Student's	  t-­‐test).	  	  
3.3.	  RESULTS	  
Relative	  to	  BMS-­‐exposed	  arteries,	  955	  and	  508	  genes	  were	  differentially	  expressed	  
in	  SES-­‐exposed	  and	  ZES-­‐exposed	  arteries,	  respectively	  (Table	  3.2).	  More	  genes	  were	  
down	   regulated	   than	   up	   regulated	   in	   both	   of	   the	   drug-­‐eluting	   stent-­‐	   exposed	  
samples	   relative	   to	   the	   BMS-­‐exposed	   samples.	   For	   the	   SES-­‐exposed	   samples	   470	  
	  
	  
	  
Table	  3.2.	  Significantly	  differentially	  expressed	  genes.	  Numerous	  and	  characteristic	  
genes	  distinguish	  expression	  patterns	  in	  arterial	  tissue	  exposed	  to	  sirolimus-­‐eluting	  
compared	  to	  bare	  metal	  (SES-­‐BMS),	  zotarolimus-­‐eluting	  compared	  to	  bare	  metal	  
(ZES-­‐BMS),	  and	  zotarolimus-­‐eluting	  compared	  to	  sirolimus-­‐eluting	  stents	  (ZES-­‐SES).	  
This	  table	  lists	  those	  genes	  with	  fold	  change	  greater	  than	  two	  between	  groups	  and	  t-­‐
test	  p-­‐value	  <	  0.05	  for	  significant	  differences	  in	  average	  expression	  levels	  between	  
groups.	  Displayed	  are	  those	  genes	  with	  the	  10	  largest	  fold	  changes	  up	  or	  down	  for	  
each	  comparison.	  
Gene	  Title	   Gene	  Symbol	   Fold	  
change	  
t-­‐test	  p-­‐
value	  
	   	   	   	  
SES-­BMS	  comparison	   	   	   	  
arginase	  liver	   ARG1	   118.37	   0.00274	  
interleukin	  1	  beta	   IL1B	   71.60	   0.00910	  
similar	  to	  dual	  specificity	  
phosphatase	  5	  
LOC100157144	   39.48	   0.00053	  
nucleoside	  phosphorylase	   NP	   38.77	   0.00258	  
interleukin	  8	   IL8	   35.00	   0.02333	  
muscle	  specific	  intermediate	  
filament	  desmin	  
LOC396725	   -­‐28.56	   0.02247	  
similar	  to	  potassium	  channel	  
subfamily	  K	  member	  10	  
LOC100155276	   -­‐19.34	   0.00720	  
vitronectin	   VTN	   -­‐19.03	   0.00712	  
similar	  to	  Interferon	  induced	  
protein	  with	  tetratricopeptide	  
repeats	  2	  
LOC100155467	   -­‐18.72	   0.01335	  
Aquaporin	  8	   LOC100127152	   -­‐18.51	   0.00486	  
	   	   	   	  
ZES-­BMS	  comparison	   	   	   	  
arginase	  liver	   ARG1	   64.17	   0.00570	  
amelogenin	   AMELX	   41.98	   0.00223	  
Serum	  amyloid	  A2	   LOC733603	   22.69	   0.01469	  
Similar	  to	  orphan	  G-­‐protein	  
coupled	  receptor	  bRGR1	  
LOC100153615	   20.87	   0.04727	  
similar	  to	  Carbonic	  anhydrase	  2	   LOC100154873	   19.76	   0.00293	  
casein	  kappa	   CSN3	   -­‐30.04	   0.00187	  
Neurotrophin	  3	   NTF3	   -­‐22.71	   0.00224	  
transforming	  growth	  factor	  beta	  2	   TGFB2	   -­‐20.77	   0.03254	  
sialoadhesin	   SIGLEC-­‐1	   -­‐20.43	   0.00316	  
similar	  to	  uncharacterized	  protein	  
C22orf13	  
LOC100154708	   -­‐20.09	   0.00035	  
	   	   	   	  
	   	   	   	  
Table	  3.2	  (continued)	   	   	   	  
ZES-­SES	  comparison	   	   	   	  
Aquaporin	  8	   LOC100127152	   16.89	   0.00230	  
anti	  Mullerian	  hormone	   AMH	   15.52	   0.00014	  
Ras	  homolog	  gene	  family	  member	  
F	  
RHOF	   14.57	   0.00075	  
transcription	  factor	  AP	  2	  gamma	   CH242-­‐
255C19.1	  
12.39	   0.00059	  
similar	  to	  Polymerase	  (RNA)	  I	  
polypeptide	  D	  
LOC100152160	   11.63	   0.02974	  
stefin	  A8	   LOC396867	   -­‐30.30	   0.01232	  
Similar	  to	  coagulation	  factor	  XIII	  
A1	  subunit	  
LOC100153504	   -­‐19.08	   0.00279	  
metallothionein	   MT1A	   -­‐17.16	   0.01625	  
haptocorrin	   LOC396873	   -­‐14.58	   0.03641	  
similar	  to	  Apolipoprotein	  B	  mRNA	  
editing	  enzyme	  catalytic	  
polypeptide	  like	  2	  
LOC100156477	   -­‐13.90	   0.00256	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
were	  up	  regulated	  and	  485	  down	  regulated	  while	  for	  the	  ZES-­‐exposed	  samples,	  188	  
were	  up	   regulated	   and	  320	  down	   regulated	   relative	   to	   the	  BMS-­‐exposed	   samples.	  
Comparing	   ZES-­‐exposed	   samples	   with	   SES-­‐exposed	   samples,	   206	   genes	   are	   up	  
regulated	  in	  ZES	  compared	  to	  SES	  and	  208	  genes	  are	  down	  regulated.	  
Some	  of	  the	  differentially	  expressed	  genes	  observed	  in	  the	  SES-­‐BMS	  comparison	  and	  
differentially	   expressed	   genes	   observed	   in	   the	   ZES-­‐BMS	   comparison	   overlap.	   This	  
overlap	   consists	   of	   158	   genes	   identified	   as	   being	   significantly	   differentially	  
expressed	   in	   the	   SES-­‐exposed	   and	   ZES-­‐exposed	   arteries.	   All	   of	   these	   overlapping	  
genes	  were	   differentially	   expressed	   co-­‐directionally.	   That	   is,	   93	   of	   the	   158	   genes	  
were	   up	   regulated	   in	   both	   the	   SES-­‐BMS	   and	   ZES-­‐BMS	   comparisons.	   And	   the	  
remaining	   65	   genes	   were	   down	   regulated	   in	   both	   the	   SES-­‐BMS	   and	   ZES-­‐BMS	  
comparisons.	  This	  strong	  co-­‐directionality	  is	  consistent	  with	  the	  rapamycin-­‐derived	  
origin	  of	  both	  zotarolimus	  and	  sirolimus.	  
A	   supervised	   (ANOVA	   p-­‐value	   <	   0.05)	   differential	   expression	   analysis	   and	  
hierarchical	   clustering	   between	   BMS-­‐,	   SES-­‐	   and	   ZES-­‐exposed	   artery	   samples	  
resulted	  in	  a	  distinct	  separation	  between	  all	  three	  groups	  (Figure	  3.1).	  Not	  only	  do	  
the	   artery	   samples	   from	   each	   stent	   type	   group	   together,	   the	   samples	   from	   each	  
individual	  group	  together,	  indicating	  a	  similar	  expression	  profile.	  	  
3.3.1	  Genes	  differentially	  expressed	  in	  SES	  
Gene	   Set	   Enrichment	   Analysis	   (GSEA)	   demonstrated	   that	   in	   SES-­‐exposed	   arteries	  
compared	   to	   BMS-­‐exposed	   arteries	   there	   was	   up	   regulation	   in	   gene	   sets	   for	  
	  
	  
Figure	   3.1.	   Hierarchical	   clustering	   of	   3008	   genes	   differentially	   expressed	   among	  
arterial	  tissue	  exposed	  to	  bare	  metal,	  sirolimus-­eluting,	  and	  zotarolimus-­eluting	  stents.	  
This	   heat	  map	  was	   generated	   by	   Z-­‐score	   normalization	   of	   log2	   expression	   values	  
from	   Affymetrix	   GeneChip	   Porcine	   Genome	   arrays.	   Displayed	   are	   the	   relative	  
expression	   levels	   of	   genes	   (rows)	   differentially	   expressed	   (red	   =	   relatively	   over-­‐
expressed	   compared	   to	   BMS-­‐exposed	   tissues;	   green	   =	   relatively	   under-­‐expressed	  
compared	   to	   BMS-­‐exposed	   tissues)	   in	   4	   arteries	   exposed	   to	   bare	   metal	   stents,	   4	  
arteries	  exposed	  to	  sirolimus-­‐eluting	  stents,	  and	  4	  arteries	  exposed	  to	  zotarolimus-­‐
eluting	  stents.	  	  
	  
	  
chemokine	   activity	   and	   inflammatory	   response	   and	   down	   regulation	   in	   gene	   sets	  
having	   to	   do	   with	   potassium	   transport	   and	   channels,	   as	   well	   as	   muscle	   activity	  
(Mootha	  et	  al.	  2003;	  Subramanian	  et	  al.	  2005).	  
3.3.1.1	  Extracellular	  matrix	  activity	  associated	  with	  SES	  
In	   the	   integrated	   model	   of	   in-­‐stent	   restenosis,	   vascular	   smooth	   muscle	   cell	  
migration	  from	  the	  tunica	  media	  to	  the	  tunica	  intima	  occurs	  concurrently	  with	  the	  
infiltration	  of	  leukocytes	  (Welt	  and	  Rogers	  2002).	  Thus	  in	  order	  to	  migrate,	  vascular	  
smooth	   muscle	   cells	   (VSMC)	   must	   degrade	   and	   breach	   the	   extracellular	   matrix	  
(ECM)	   layers	   of	   the	   media,	   in	   a	   three	   step	   process	   of	   phenotypic	   change	   from	  
contractile	  state	   into	  synthetic	  state,	  proteolytic	  dissolution	  of	  ECM,	  and	  migration	  
through	  the	  digested	  matrix	  (Kuzuya	  and	  Iguchi	  2003).	  
Matrix	   metalloproteinases	   are	   involved	   in	   the	   turnover	   of	   ECM	   in	   the	   normal	  
physiological	   life	   of	   connective	   tissue,	   morphogenesis,	   and	   wound	   healing	   by	  
cleaving	   collagens	   (Kuzuya	   and	   Iguchi	   2003).	   In	   our	   samples	   (Table	   3.3),	   matrix	  
metalloproteinases	  1,3,	  and	  9	  (MMP1,	  MMP3,	  MMP9)	  are	  all	  over-­‐expressed	  in	  SES-­‐
exposed	   arteries	   relative	   to	   arteries	   exposed	   to	   BMS	   (p-­‐value	   =	   0.005,	   log2	   fold	  
change	  =	  3.69	   ;	  p-­‐value	  =	  0.002,	   log2	  fold	  change	  =	  3.13;	  p-­‐value	  =	  0.002	  log2	  fold	  
change	   =	   2.46,	   respectively).	   MMP-­‐1	   is	   a	   collagenase,	   able	   to	   cleave	   interstitial	  
collagens	  I,	   II,	  and	  III	  at	  a	  specific	  site,	  as	  well	  as	  digesting	  other	  ECM	  components	  
(Will	   et	   al.	   1996).	  MMP3,	   also	   known	   as	   stromelysin	   1,	   digests	   ECM	   components,	  
including	  basement	  membrane,	   and	   also	   cleaves	  proMMP1	   to	   form	   fully	   activated	  
MMP1	   (Suzuki	   et	   al.	   1990).	   MMP1-­‐mediated	   cleavage	   is	   also	   associated	   with	   cell	  
Table	  3.3.	  Extracellular	  matrix	  process	  genes.	  	  
Significant	  up	  regulation	  of	  metalloproteinase	  genes	   involved	   in	   the	  breakdown	  of	  
ECM	  when	   comparing	   arterial	   tissue	   exposed	   to	   sirolimus-­‐eluting	   stents	   and	  bare	  
metal	   stents.	   This	   breakdown	   is	   essential	   to	   the	   migration	   of	   vascular	   smooth	  
muscle	   cells	   during	   the	   middle	   stages	   of	   restenosis.	   This	   table	   lists	   the	   log2	   fold	  
change	  difference	  comparing	  sirolimus-­‐eluting,	  and	  bare	  metal	  stents,	  as	  well	  as	  t-­‐
test	  p-­‐values	  for	  tests	  of	  differences	  in	  average	  expression	  levels	  between	  the	  two.	  
Displayed	  are	  fold	  change	  differences	  and	  p-­‐values	  for	  all	  genes	  grouped	  under	  the	  
gene	  ontology	  listing	  for	  extracellular	  matrix	  part,	  basement	  matrix,	  proteinaceous	  
extracellular	   matrix,	   and	   extracellular	   matrix.	   Genes	   with	   a	   p-­‐value	   less	   than	   the	  
multiple	  testing	  adjusted	  value	  of	  0.046	  are	  bolded.	  
Gene	  
Symbol	  
SES-­‐BMS	  log2	  
fold	  change	  
SES-­‐BMS	  t-­‐test	  
p-­‐value	   Gene	  title	  
AEBP1	   -­‐3.67	   ±	  1.71	   0.006573346	   AE	  binding	  protein	  
ANXA2	   0.5	   ±	  0.08	   0.001576484	   annexin	  A2	  
APP	   -­‐0.99	   ±	  0.55	   0.012302513	   amyloid	  beta	  (A4)	  precursor	  protein	  
ATP7A	   -­‐3.51	   ±	  1.44	   0.00684966	   ATPase	  Cu++	  transporting	  alpha	  polypeptide	  
BGLAP	   -­‐2.62	   ±	  1.32	   0.021518431	   bone	  gamma	  carboxyglutamate	  (gla)	  protein	  
BGN	   -­‐1.18	   ±	  0.88	   0.039634364	   biglycan	  
CLU	   1.37	   ±	  0.39	   0.000948126	   clusterin	  
COL1A1	   -­‐2.82	   ±	  0.84	   0.015206919	   collagen	  type	  I	  alpha	  1	  
COL2A1	   -­‐2.02	   ±	  0.89	   0.010637478	   collagen	  type	  II	  alpha	  1	  
COL3A1	   -­‐0.69	   ±	  0.34	   0.023999384	   collagen	  type	  III	  alpha	  1	  
COL5A3	   2.07	   ±	  0.13	   0.004183389	   Collagen	  type	  V	  alpha	  3	  
CST3	   -­‐1.37	   ±	  0.45	   0.020747497	   Cystatin	  C	  
CTSD	   -­‐1.54	   ±	  1.01	   0.028342424	   cathepsin	  D	  
DPP4	   2.54	   ±	  0.38	   0.000318554	   dipeptidyl	  peptidase	  4	  
FN1	   1.86	   ±	  0.24	   0.000292543	   fibronectin	  
IGFBP7	   -­‐1.5	   ±	  0.84	   0.033975975	   insulin	  like	  growth	  factor	  binding	  protein	  7	  
LAMB1	   -­‐1.42	   ±	  0.79	   0.02463023	   laminin	  beta	  1	  
LGALS1	   -­‐1.54	   ±	  0.48	   0.001043365	   lectin	  galactoside	  binding	  soluble	  1	  
LMCD1	   -­‐1.6	   ±	  1	   0.037627101	   LIM	  and	  cysteine	  rich	  domains	  1	  
LPL	   1.65	   ±	  0.5	   0.014813832	   lipoprotein	  lipase	  
MGP	   -­‐1.11	   ±	  0.46	   0.011740611	   matrix	  Gla	  protein	  
MMP1	   3.69	   ±	  0.98	   0.005682639	   matrix	  metallopeptidase	  1	  (interstitial	  collagenase)	  
MMP3	   3.13	   ±	  0.48	   0.002120225	   matrix	  metallopeptidase	  3	  (stromelysin	  1	  progelatinase)	  
MMP9	   2.46	   ±	  0.71	   0.001878166	   Matrix	  metallopeptidase	  9	  (gelatinase	  B	  92kDa	  gelatinase	  92kDa	  type	  IV	  collagenase)	  
	  
Table	  3.3	  (continued)	  
MMP13	   -­‐6.69	   ±	  0.38	   0.030576684	   Matrix	  metallopeptidase	  13	  
PLAT	   2.3	   ±	  0.43	   0.00237602	   plasminogen	  activator	  tissue	  
RPSA	   -­‐0.5	   ±	  0.22	   0.036423376	   ribosomal	  protein	  SA	  
SOD1	   -­‐0.36	   ±	  0.22	   0.029389833	   superoxide	  dismutase	  1	  soluble	  
SPARC	   -­‐2.18	   ±	  0.5	   0.000145088	   Secreted	  protein	  acidic	  cysteine	  rich	  (osteonectin)	  
SPARC	   -­‐0.88	   ±	  0.31	   0.0364355	   Secreted	  protein	  acidic	  cysteine	  rich	  (osteonectin)	  
SPARCL1	   -­‐3.26	   ±	  1.8	   0.01767792	   SPARC	  like	  1	  (hevin)	  
TIMP1	   1.37	   ±	  0.28	   0.000589379	   TIMP	  metallopeptidase	  inhibitor	  1	  
TNC	   -­‐3.25	   ±	  2.1	   0.035336136	   tenascin	  C	  
VCAN	   -­‐3.09	   ±	  2.23	   0.041221801	   Versican	  
VEGFA	   2.55	   ±	  0.47	   0.000532369	   vascular	  endothelial	  growth	  factor	  A	  
VTN	   -­‐4.25	   ±	  2.03	   0.007115448	   vitronectin	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
migration,	   platelet	   aggregation,	   and	   inflammation.	   MMP3-­‐mediated	   cleavage	   is	  
associated	   with	   cell	   migration,	   angiostatin-­‐like	   fragment	   generation,	   enhanced	  
collagen	   affinity,	   and	   inflammation	   (Visse	   and	   Nagase	   2003).	   MMP9	   digests	   the	  
denatured	  collagens,	  known	  as	  gelatins.	  	  Elevated	  serum	  levels	  of	  MMP9	  have	  been	  
noted	   in	   humans	   post-­‐stent	   implantation	   in	   association	  with	   restenosis	   (Ge	   et	   al.	  
2006;	  Katsaros	  et	  al.	  2010).	  
Tissue	  inhibitors	  of	  metalloproteinases	  (TIMP)	  are	  endogenous	  inhibitors	  of	  MMPs	  
that	  bind	  one	  to	  one.	  TIMPs	  inhibit	  all	  MMPs,	  although	  TIMP1	  does	  not	  inhibit	  MT1-­‐
MMP	  (Visse	  and	  Nagase	  2003).	  TIMP1	   is	  up	   regulated	   in	  SES-­‐exposed	  arteries	   (p-­‐
value	  =	  0.00058,	  log2	  fold	  change	  =	  1.37).	  TIMP1	  expression	  is	  known	  to	  be	  largely	  
constitutive	  (Dollery	  et	  al.	  1995).	  
In	   our	   experiments,	   extracellular	   matrix	   gene	   expression	   is	   significantly	  
differentially	  expressed	  in	  SES-­‐exposed	  arteries	  compared	  to	  BMS-­‐exposed	  arteries.	  
We	   do	   not	   observe	   this	   differential	   expression	   in	   ZES-­‐exposed	   arteries	   (data	   not	  
shown).	   	   The	  ECM	  genes	   that	   are	   differentially	   expressed	   in	   SES-­‐exposed	   arteries	  
are	   largely	   involved	   in	   collagen	   cleavage	   mediated	   by	   matrix	   metalloproteinase	  
(MMP1,	  MMP3,	  MMP9,	  MMP13)	  and	  the	  regulation	  of	  collagen	  cleavage	  (TIMP1	  and	  
TIMP2).	  This	  is	  consistent	  with	  previous	  experimental	  evidence	  showing	  that	  matrix	  
metalloproteinases	  are	  correlated	  with	  smooth	  muscle	  cell	  migration	  into	  the	  intima	  
(Wu	  et	  al.	  2008).	  
Up-­‐regulation	   of	   MMP1	   (collagenase)	   has	   been	   observed	   in	   in	   vivo	   studies	  
immediately	   following	   stent	   implantation	   (Wu	  et	   al.	   2008),	   and	   its	   expression	  has	  
also	  been	  induced	  by	  mechanical	  injury	  in	  cultured	  vascular	  smooth	  muscle	  cells	  as	  
well	   as	   by	   rapamycin	   in	   fibroblasts	   (James	   et	   al.	   1993).	   Up-­‐regulation	   of	  MMP3	  
(stromelysin	  1)	  and	  MMP9	  (collagenase)	  has	  been	  detected	  in	  the	  plasma	  of	  in-­‐stent	  
restenosis	  cases	  (compared	  to	  restenosis-­‐free	  individuals)	  at	  the	  1-­‐year	  mark	  post-­‐
bare	  metal	  stent	   implantation	  (Jones	  et	  al.	  2009).	  Up-­‐regulation	  of	  MMP9	   in	  artery	  
tissue	  has	  been	  observed	   in	   in	  vivo	   studies	   immediately	   following	  angioplasty	  and	  
vessel	  damage	  (Godin	  et	  al.	  2000;	  Feldman	  et	  al.	  2001).	  Moreover,	  MMP3	  expression	  
in	   arteries	   is	   a	   known	   activator	   of	   MMP9-­‐mediated	   vascular	   smooth	   muscle	   cell	  
migration	  and	  neointimal	  formation	  (Johnson	  et	  al.	  2011).	  
Our	   results	   show	   that	   SES-­‐exposed	   arteries	   have	   elevated	   levels	   of	  MMP1,	  MMP3,	  
and	  MMP9	  expression	  (Table	  3.3),	  even	  prior	  to	  measurable	  luminal	  narrowing.	  This	  
suggests	   that	   the	   collagen	   remodeling	   associated	   with	   middle-­‐stage	   restenosis	   is	  
occurring	   in	   individuals	   implanted	   with	   the	   SES.	   Expression	   levels	   for	   genes	  
associated	  with	  the	  extracellular	  matrix	  appeared	  elevated	  in	  ZES-­‐exposed	  arteries	  
compared	   to	   BMS-­‐exposed	   arteries,	   but	   were	   not	   significantly	   differentially	  
expressed.	   	   Because	   ECM	   gene	   expression	   in	   ZES-­‐exposed	   arteries	   generally	   lies	  
between	   that	   observed	   in	   SES-­‐exposed	   arteries	   and	   BMS-­‐exposed	   arteries,	   most	  
ECM	   genes	   are	   not	   significantly	   differentially	   expressed	   when	   comparing	   ZES-­‐
exposed	  and	  SES-­‐exposed	  arteries	  (see	  also	  Section	  3.2.1).	  
3.3.1.2	  Ion	  channel	  activity	  associated	  with	  SES	  
When	  comparing	  SES-­‐exposed	  arteries	  to	  BMS-­‐exposed	  arteries,	  gene	  sets	  related	  to	  
ion	  channels	  and	  muscle	  components	  are	  down	  regulated.	  The	  ion	  channel	  gene	  sets	  
include	  those	   involved	  in	  potassium	  channel	  activity,	  potassium	  ion	  transport,	  and	  
ion	  channel	  activity	  (Table	  3.4).	  Among	  the	  genes	  that	  contribute	  to	  these	  gene	  sets	  
are	   L-­‐type	   voltage-­‐dependent	   calcium	   channel	   alpha	   1C	   subunits	   (CACNA1C,	   also	  
known	   as	   CaV1.2),	   and	   alpha	   1S	   subunits	   (CACNA1S,	   also	   known	   as	   CaV1.1),	   both	  
primary	   components	   of	   different	   L-­‐type	   calcium	   channels.	   Also	   contributing	   is	  
calcium-­‐activated	   large	   potassium	   channel	   sub-­‐family	   M	   beta	   member	   1	   subunit	  
(KCNMB1,	   also	   known	   as	   KCa1.1),	   a	   modulatory	   component	   of	   large	   calcium-­‐
activated	   potassium	   channels.	   Contractile	   vascular	   smooth	   muscle	   cells	   (VSMC)	  
strongly	   express	   KCa1.1,	   which	   provides	   negative	   feedback	   against	   depolarization	  
(Beech	  2007).	  These	  potassium	  channels	  thus	  limit	  Ca2+	  flow	  through	  CaV1.2.	  When	  
VSMC	   switch	   to	   the	   proliferating	   phenotype	   there	   is	   a	   noted	   down-­‐regulation	   of	  
CaV1.2	   observed	   in	   cultured	   rat	   VSMC,	   as	   well	   as	   following	   balloon	   injury	   in	   rat	  
arteries	   (Richard	   et	   al.	   1992;	   Quignard	   et	   al.	   2001;	   Ihara	   et	   al.	   2002).	   Normal	  
contractile	   VSMC	   also	   predominantly	   express	   KCa1.1,	   and	   studies	   in	   cultured	   rat	  
aortic	   cells	   show	   that	   in	   response	   to	   injury	   their	   expression	   is	   down	   regulated	  
(Neylon	   et	   al.	   1999;	   Si	   et	   al.	   2006).	   	   The	   down-­‐regulation	   of	   both	   of	   these	   ion	  
channels	   is	   indicative	   of	   the	   phenotypic	   changes	   that	   accompany	   a	   shift	   from	  
contractile	  to	  proliferative	  function	  in	  VSMCs.	  	  
3.3.2	  Genes	  differentially	  expressed	  in	  ZES	  
3.3.2.1	   Extracellular	   matrix,	   basement	   membrane,	   and	   proteinaceous	   extracellular	  
matrix	  genes	  up-­regulated	  in	  ZES	  compared	  to	  SES	  
Table	  3.4.	  Potassium	  ion	  channel	  activity	  and	  ion	  channel	  activity	  genes	  differentially	  
expressed	  in	  SES	  compared	  to	  BMS	  
Significant	  down	  regulation	  of	   ion	  channel	  activity	  genes	  characteristic	  of	  vascular	  
smooth	  muscle	   cells	   (VSMCs)	   switching	   from	   a	   sessile	   to	   proliferative	   phenotype.	  
This	   switch	   occurs	   during	   the	   migration	   of	   VSMCs	   from	   the	   tunica	   media	   to	   the	  
tunica	  intima	  as	  a	  part	  of	  the	  middle	  stages	  of	  in-­‐stent	  restenosis.	  This	  table	  lists	  the	  
log2	   fold	   change	  difference	  comparing	  sirolimus-­‐eluting,	   and	  bare	  metal	   stents,	   as	  
well	  as	  t-­‐test	  p-­‐values	  for	  tests	  of	  differences	  in	  average	  expression	  levels	  between	  
the	   two.	  Displayed	  are	   fold	   change	  differences	   and	  p-­‐values	   for	   all	   genes	   grouped	  
under	  the	  gene	  ontology	  listing	  for	  potassium	  ion	  channel	  activity	  and	  ion	  channel	  
activity.	  Genes	  with	  a	  p-­‐value	  less	  than	  the	  multiple	  testing	  adjusted	  value	  of	  0.046	  
are	  bolded.	  	  
Gene	  
symbol	   Gene	  title	  
SES-­‐BMS	  log2	  
fold	  change	  
SES-­‐BMS	  
t-­‐test	  p-­‐
value	  
CACNA1B	   calcium	  channel,	  voltage-­‐dependent,	  beta	  1	  subunit	   -­‐1.83	   ±	   1.89	   0.1053	  
CACNA1C	  
calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  alpha	  
1C	  subunit	   -­‐5.47	   ±	   6.8	   0.0597	  
CACNA1E	  
calcium	  channel,	  voltage-­‐dependent,	  alpha	  1E	  
subunit	   -­‐1.5	   ±	   1.56	   0.2509	  
CACNA1S	  
calcium	  channel,	  voltage-­‐dependent,	  L	  type,	  alpha	  
1S	  subunit	   -­‐2.42	   ±	   3.5	   0.2806	  
CACNB2	   calcium	  channel,	  voltage-­‐dependent,	  beta	  2	  subunit	   -­‐3.85	   ±	   5	   0.0632	  
CACNB3	   calcium	  channel,	  voltage-­‐dependent,	  beta	  3	  subunit	   -­‐1.42	   ±	   0.37	   0.1859	  
CLCN2	   chloride	  channel	  2	   -­‐1.92	   ±	   3.51	   0.3828	  
CLCN2	   chloride	  channel	  2	   -­‐2.39	   ±	   0.26	   0.0048	  
CLCN4	   chloride	  channel	  4	   -­‐2.9	   ±	   3.95	   0.2391	  
KCNH2	  
potassium	  voltage-­‐gated	  channel,	  subfamily	  H	  (eag-­‐
related),	  member	  2	   -­‐3.03	   ±	   4.38	   0.226	  
KCNH3	  
potassium	  voltage-­‐gated	  channel,	  subfamily	  H	  (eag-­‐
related),	  member	  3	   -­‐3.35	   ±	   16.96	   0.1927	  
KCNH4	  
potassium	  voltage-­‐gated	  channel,	  subfamily	  H	  (eag-­‐
related),	  member	  4	   -­‐2.22	   ±	   2.02	   0.1232	  
KCNMB1	  
potassium	  large	  conductance	  calcium-­‐activated	  
channel,	  subfamily	  M,	  beta	  member	  1	   -­‐7.73	   ±	   9.38	   0.0202	  
KCNMB1	  
potassium	  large	  conductance	  calcium-­‐activated	  
channel,	  subfamily	  M,	  beta	  member	  1	   -­‐2.99	   ±	   2.3	   0.2285	  
NMUR2	   neuromedin	  U	  receptor	  2	   -­‐1.88	   ±	   2.31	   0.2096	  
RYR3	   ryanodine	  receptor	  3	   -­‐1.74	   ±	   8.81	   0.6811	  
RYR3	   ryanodine	  receptor	  3	   -­‐6.47	   ±	   5.94	   0.062	  
SCN1B	   sodium	  channel,	  voltage-­‐gated,	  type	  I,	  beta	   -­‐2.17	   ±	   0.78	   0.2813	  
TRPC1	  
transient	  receptor	  potential	  cation	  channel,	  
subfamily	  C,	  member	  4	   -­‐2.3	   ±	   1.17	   0.1525	  
TRPV6	  
transient	  receptor	  potential	  cation	  channel,	  
subfamily	  V,	  member	  6	   -­‐2.8	   ±	   8.55	   0.3805	  
	  
	  
We	   used	   GSEA	   to	   find	   those	   gene	   sets	   whose	   member	   genes	   do	   not	   individually	  
show	   large	   fold-­‐changes,	   but	   may	   be	   acting	   in	   concert	   to	   generate	   a	   biologically	  
significant	   effect.	   The	   gene	   sets	   significantly	   up-­‐regulated	   in	   ZES-­‐exposed	   arteries	  
compared	  to	  SES-­‐exposed	  arteries	  as	  determined	  by	  GSEA	  can	  be	  grouped	  into	  two	  
categories;	  extracellular	  matrix	  genes	  and	  muscle	  component	  genes.	  	  	  
Of	   the	   extracellular	   matrix	   gene	   sets,	   the	   terms	   basement	   membrane	   and	  
extracellular	  matrix	  have	  FDR	  q-­‐values	  of	  0.18	  and	  0.24,	  respectively.	  The	  genes	  that	  
contribute	   to	   the	   up	   regulation	   of	   the	   entire	   process	   are	   related	   to	   collagen	  
synthesis	   and	  non-­‐collagen	   components	   associated	  with	   the	  basement	  membrane.	  	  
The	  collagen	  elements	  include	  collagen	  type	  IV	  alpha	  2,	  collagen	  type	  IV	  alpha	  5,	  and	  
collagen	   type	   VII	   alpha	   1	   (Table	   3.5).	   The	   type	   IV	   collagens	   found	   in	   basement	  
membranes	   are	   known	   to	   be	   genetically	   distinct	   from	   the	   Type	   I	   –	   III	   fibrillar	  
collagens	  found	  in	  neointimal	  growth.	  Collagen	  type	  VII	  alpha	  1	  is	  specifically	  found	  
in	   basement	   membranes,	   anchoring	   the	   external	   endothelia	   to	   the	   underlying	  
stroma.	  The	  non-­‐collagen	  elements	  include	  laminin	  alpha	  2,	  laminin	  alpha	  3,	  laminin	  
alpha	   4,	   laminin	   beta	   1,	   laminin	   beta	   2,	   laminin	   gamma	   1,	   as	  well	   as	   sarcoglycan	  
delta,	   sarcoglycan	   epsilon	   syntrophin	   gamma	  1,	   and	   sarcospan.	   	   Laminins	   are	   the	  
principle	  multiadhesive	  matrix	  protein	  found	  in	  basement	  membranes	  and	  the	  most	  
abundant	  non-­‐collagenous	  protein	  in	  basement	  membranes.	  	  	  
Denudation	   of	   the	   endothelial	   layer	   and	   damage	   to	   the	   supporting	   basement	  
membrane	   occur	   during	   angioplasty	   (Welt	   and	   Rogers	   2002).	   At	   30	   days,	   the	  
luminal	  surfaces	  of	  stented	  porcine	  arteries	  have	  fully	  re-­‐endothelialized,	  and	  are	  in	  
Table	   3.5.	  Extracellular	  matrix	   genes	   and	   basement	  membrane	   genes	   differentially	  
expressed	  in	  ZES	  compared	  to	  SES	  
Significant	   up	   regulation	   of	   extracellular	   matrix	   genes	   consistent	   with	   newly	  
replaced	   endothelial	   cells	   synthesizing	   and	   depositing	   new	   basement	   membrane	  
following	   denudation	   of	   the	   endothelial	   layer.	   Re-­‐deposit	   of	   this	   basement	  
membrane	   layer	   follows	   re-­‐endotheialization	   at	   30	   days	   post-­‐stent	   implantation.	  
This	   table	   lists	   the	   log2	   fold	   change	   difference	   comparing	   sirolimus-­‐eluting,	   and	  
zotarolimus-­‐eluting	   stents,	   as	   well	   as	   t-­‐test	   p-­‐values	   for	   tests	   of	   differences	   in	  
average	   expression	   levels	   between	   the	   two.	  Displayed	   are	   fold	   change	  differences	  
and	  p-­‐values	  for	  all	  genes	  grouped	  under	  the	  gene	  ontology	  listing	  for	  extracellular	  
matrix	   genes	   and	   basement	  membrane	   genes.	   Genes	  with	   a	   p-­‐value	   less	   than	   the	  
multiple	  testing	  adjusted	  value	  of	  0.046	  are	  bolded.	  	  
Gene	  Symbol	   Gene	  Title	  
ZES-­‐SES	  log2	  
fold-­‐change	  
ZES-­‐SES	  t-­‐
test	  p-­‐
value	  
LAMA3	   laminin,	  alpha	  3	   4.44	   ±	   2.37	   0.028	  
LAMB2	   laminin,	  beta	  2	  (laminin	  S)	   4.91	   ±	   1.28	   0.008	  
SGCD	  
sarcoglycan,	  delta	  (35kDa	  
dystrophin-­‐associated	  
glycoprotein)	   3.02	   ±	   1.61	   0.053	  
COL9A2	   collagen,	  type	  IX,	  alpha	  2	   2.67	   ±	   1.37	   0.265	  
COL18A1	   collagen,	  type	  XVIII,	  alpha	  1	   2.89	   ±	   1.29	   0.120	  
SNTG1	   syntrophin,	  gamma	  1	   3.54	   ±	   6.59	   0.299	  
COL4A2	   collagen,	  type	  IV,	  alpha	  2	   5.11	   ±	   2.53	   0.004	  
COL7A1	  
collagen,	  type	  VII,	  alpha	  1	  
(epidermolysis	  bullosa,	  
dystrophic,	  dominant	  and	  
recessive)	   2.51	   ±	   5.00	   0.197	  
COL4A5	  
collagen,	  type	  IV,	  alpha	  5	  
(Alport	  syndrome)	   2.81	   ±	   0.86	   0.012	  
EFEMP2	  
EGF-­‐containing	  fibulin-­‐like	  
extracellular	  matrix	  protein	  2	   2.15	   ±	   0.27	   0.051	  
LAMC1	  
laminin,	  gamma	  1	  (formerly	  
LAMB2)	   2.48	   ±	   1.51	   0.057	  
COL16A1	   collagen,	  type	  XVI,	  alpha	  1	   1.99	   ±	   2.44	   0.134	  
SGCE	   sarcoglycan,	  epsilon	   1.84	   ±	   0.80	   0.141	  
APLP1	  
amyloid	  beta	  (A4)	  precursor-­‐
like	  protein	  1	   1.63	   ±	   0.52	   0.142	  
LAMB1	   laminin,	  beta	  1	   1.94	   ±	   0.78	   0.100	  
LAMA4	   laminin,	  alpha	  4	   1.55	   ±	   0.13	   0.013	  
NID2	   nidogen	  2	  (osteonidogen)	   1.16	   ±	   1.76	   0.605	  
COL8A1	   collagen,	  type	  VIII,	  alpha	  1	   1.62	   ±	   0.74	   0.263	  
SSPN	  
sarcospan	  (Kras	  oncogene-­‐
associated	  gene)	   1.64	   ±	   0.37	   0.063	  
LAMA2	  
laminin,	  alpha	  2	  (merosin,	  
congenital	  muscular	  
dystrophy)	   1.68	   ±	   0.47	   0.011	  
	  	   	  	   	  	   	  	   	  	   	  	  
the	   process	   of	   re-­‐depositing	   the	   basement	  membrane	  matrix	   (Virmani	   et	   al.).	   Our	  
observed	  up-­‐regulation	  of	  key	  basement	  membrane	  component	  genes	  in	  our	  GSEA	  
analysis	   is	   consistent	   with	   the	   newly	   replaced	   endothelial	   cells	   synthesizing	   and	  
depositing	   a	  new	  basement	  membrane.	  That	  we	  observe	  no	   significant	   regulatory	  
differences	   in	   basement	   membrane	   or	   extracellular	   matrix	   gene	   sets	   when	  
comparing	   ZES-­‐exposed	   arteries	   to	   BMS-­‐exposed	   arteries	   is	   consistent	   with	   ZES	  
having	   already	   exhausted	   its	   drug-­‐elution	   and	   leaving	   the	   arteries	   in	   the	   early	  
phases	  of	  neointima	  formation.	  	  
Of	   the	   muscle	   component	   gene	   sets,	   the	   terms	   contractile	   fiber,	   contractile	   fiber	  
part,	  myofibril,	  and	  structural	  constituent	  of	  muscle	  have	  FDR	  q-­‐values	  of	  0.21,	  0.22,	  
and	  0.22,	   respectively.	  The	  genes	   that	  contribute	   to	   the	  myofibril,	   contractile	   fiber	  
and	   contractile	   fiber	   part	   term	   include	   supervillin,	   desmin,	   troponin	   I	   type	   3,	  
nebuline,	   titin,	  myomesin	   1,	   and	  myosin	   light	   chain	   9	   (Table	   3.6).	   The	   genes	   that	  
contribute	   to	   the	   structural	   constituent	   of	   muscle	   term	   are	   nebulin,	   titin,	  
smoothelin,	  myomesin	  1,	  myosin	  heavy	  chain	  11,	  actinin	  alpha	  2,	  actin	  alpha,	  sorbin,	  
myomesin	  2,	  myosin	   light	  chain	  2,	   telethonin,	   tropomyosin,	  nebulette,	  and	  myosin	  
binding	  protein	  H.	  	  	  
Smoothelin	   (SMTN)	   and	   desmin	   (DES)	   are	   well-­‐established	   VSMC	   differentiation	  
markers	  in	  porcine	  coronary	  arteries	  after	  stent	  implantation	  (Christen	  et	  al.	  1999).	  
In	  our	  samples	  smoothelin	  was	  up-­‐expressed	  at	  a	  log2	  fold	  change	  of	  2.74±0.69	  (t-­‐
test	   p-­‐value	   0.0227),	   while	   desmin	   was	   up-­‐expressed	   at	   a	   log2	   fold	   change	   of	  
1.44±0.66	  (t-­‐test	  p-­‐value	  of	  0.041).	  	  Smoothelin	  is	  a	  cytoskeletal	  protein	  specifically	  
	  
	  
	  
Table	  3.6.	  Muscle	  component	  gene	  set	  genes	  differentially	  expressed	  in	  ZES	  compared	  
to	  SES	  
Gene	  
symbol	   Gene	  title	  
ZES-­‐SES	  log2	  fold-­‐
change	  
ZES-­‐
SES	  t-­‐
test	  p-­‐
value	  
SVIL	   supervillin	   3.70	   ±	   3.05	   0.094	  
DES	   desmin	   6.73	   ±	   4.02	   0.023	  
TNNI3	   troponin	  I	  type	  3	  (cardiac)	   5.21	   ±	   2.03	   0.216	  
NEB	   nebulin	   2.58	   ±	   1.15	   0.017	  
TTN	   titin	   -­‐6.54	   ±	   6.11	   0.048	  
MYOM1	   myomesin	  1	  (skelemin)	  185kDa	   4.67	   ±	   3.98	   0.198	  
MYL9	   myosin,	  light	  chain	  9,	  regulatory	   3.91	   ±	   2.65	   0.093	  
	  	   	  	   	  	   	  	   	  	   	  	  
	  
	  
	  
Table	   3.7.	   Inflammatory	   process	   genes	   differentially	   expressed	   in	   SES	   compared	   to	  
BMS	  and	  ZES	  compared	  to	  BMS	  	  
	  
	  
Gene	  
Symbol	  
SES-­‐BMS	  log2	  
fold-­‐change	  
ZES-­‐BMS	  log2	  
fold-­‐change	  
SES-­‐BMS	  
t-­‐test	  p-­‐
value	  
ZES-­‐
BMS	  t-­‐
test	  p-­‐
value	   Gene	  Title	  
CCL2	   4.18	   ±	   0.03	   1.57	   ±	   0.05	   0.0012	   0.1864	  
chemokine	  (C-­‐C	  motif)	  
ligand	  2	  
CCL5	   10.26	   ±	   0.09	   1.85	   ±	   0.09	   0.0007	   0.1575	  
chemokine	  (C-­‐C	  motif)	  
ligand	  5	  
ICAM-­‐2	   -­‐1.02	   ±	   0.11	   2.56	   ±	   0.06	   0.9617	   0.0091	  
intercellular	  adhesion	  
molecule	  2	  
ICAM-­‐1	   7.29	   ±	   0.07	   4.20	   ±	   0.11	   0.0001	   0.0048	  
intercellular	  adhesion	  
molecule	  1	  
IL1B	   71.60	   ±	   0.44	   10.39	   ±	   0.41	   0.0091	   0.0793	   interleukin	  1	  beta	  
IL1A	   10.46	   ±	   0.20	   4.77	   ±	   0.16	   0.0145	   0.0557	   interleukin-­‐1-­‐alpha	  
SELE	   1.48	   ±	   0.74	   1.83	   ±	   0.55	   0.6866	   0.4753	   selectin-­‐E	  
SYK	   3.11	   ±	   0.05	   1.83	   ±	   0.06	   0.0443	   0.2262	   spleen-­‐tyrosine-­‐kinase	  
expressed	   in	   differentiated	   contractile	   smooth	   muscle	   cells	   and	   appears	   later	   in	  
VSMC	  development	  than	  other	  differentiation	  markers	  like	  desmin	  (van	  der	  Loop	  et	  
al.	  1996).	   	  Desmin	  is	  an	  intermediate	  filament	  protein	  of	  both	  smooth	  and	  striated	  
muscles	  known	  to	  be	  a	  VSMC	  differentiation	  marker.	  Both	  smoothelin	  and	  desmin	  
have	   been	   found	   to	   be	   up-­‐expressed	   in	   neointima	   induced	   by	   bare	   metal	   stent	  
implantation	   in	   porcine	   arteries	   at	   7,	   15,	   and	  30	   days	   (Christen	   et	   al.	   2001).	   This	  
supports	  our	  extracellular	  matrix	  expression	  results	  suggesting	  that	  restenosis	  has	  
progressed	  to	  neointima	  formation	  by	  VSMC	  proliferation	  in	  our	  ZES-­‐exposed	  artery	  
samples.	  	  
3.3.3	  Inflammation	  in	  both	  ZES	  and	  SES	  exposed	  arteries	  
When	   comparing	   ZES-­‐exposed	   to	   BMS-­‐exposed	   arteries	   expression	   of	   gene	   sets	  
related	  to	  the	  inflammatory	  response	  are	  up	  regulated	  (FDR	  q-­‐value	  =	  0.18).	  We	  also	  
see	   up-­‐regulation	   in	   this	   gene	   set	   when	   comparing	   SES-­‐exposed	   to	   BMS-­‐exposed	  
arteries	   (FDR	   q-­‐value	   =	   0.050).	   A	   number	   of	   components	   of	   the	   inflammatory	  
response	  gene	  set	  are	  known	  to	  be	  involved	  in	  the	  restenotic	  process	  (Table	  3.7).	  	  
3.3.3.1	  Intercellular	  adhesion	  molecule	  1	  (ICAM-­1)	  
Intercellular	   adhesion	   molecule	   1	   is	   an	   Ig-­‐like	   adhesion	   molecule	   expressed	   by	  
endothelial	  cells	  and	  leukocytes	  both,	  mediating	  the	  binding	  of	  integrins	  that	  result	  
in	  adhesion	  between	  leukocytes	  and	  endothelial	  cells.	  This	  reversible	  adhesion	  with	  
leukocytes,	  slows	  their	  progress	  and	  causes	  them	  to	  roll	  on	  the	  endothelial	  surface.	  
This	  is	  the	  first	  step	  in	  recruiting	  neutrophils	  to	  adhere	  to	  the	  blood	  vessel	  wall	  and	  
enter	   the	   inflammatory	   site.	   In	   our	   samples,	   ICAM-­‐1	   is	   significantly	   up-­‐regulated	  
both	  in	  SES-­‐exposed	  arteries	  compared	  to	  BMS-­‐exposed	  arteries,	  as	  well	  was	  in	  ZES-­‐
exposed	  arteries	  compared	  to	  BMS-­‐exposed	  arteries.	  
3.3.3.2	  Chemokine	  (C-­C	  motif)	  ligand	  5	  (CCL5)	  	  
The	   chemokine	   CCL5	   activate	   leukocyte	   integrins	   to	   more	   strongly	   bind	   to	  
intracellular	   adhesion	  molecules	   (ICAM),	   leading	   to	   tighter	   adhesion	  between	   free	  
blood-­‐borne	  leukocytes	  and	  endothelial	  cells	  prior	  to	  extravasation.	  This	  chemokine	  
gradient	   directs	   the	  migration	   of	   leukocytes	   into	   the	   subendothelial	   space,	  where	  
the	   leukocytes	   can	   then	   release	   growth	   factors	   that	   drive	   the	   proliferation	   and	  
migration	   of	   smooth	   muscle	   cells	   in	   the	   neointima	   (Gomes	   et	   al.	   2005).	   The	  
formation	   of	   neointima	   then	   causes	   restenosis.	   In	   our	   samples,	   CCL5	   was	  
significantly	  up-­‐regulated	  in	  SES-­‐exposed	  artery	  samples	  as	  compared	  to	  bare	  metal	  
stent	  exposed	  arteries	  (fold	  change	  =	  10.26,	  p-­‐value	  =	  0.0007)	  
3.3.3.3	  Interleukin	  1A	  	  
IL-­‐1A	   (IL1A)	   is	   a	   pro-­‐inflammatory	   cytokine.	   It	   is	   an	   important	   mediator	   of	   the	  
inflammatory	  response,	  and	   is	   involved	   in	  a	  variety	  of	   cellular	  activities,	   including	  
cell	   proliferation,	   differentiation,	   and	   apoptosis.	   IL-­‐1A	   is	   significantly	   elevated	   in	  
SES-­‐exposed	  arteries	   compared	   to	  bare	  metal	   stented	   arteries,	  while	  ZES-­‐exposed	  
arteries	  are	  up	  regulated,	  but	  not	  significantly	  so	  relative	  to	  BMS-­‐exposed	  arteries.	  	  
3.4.	  DISCUSSION	  
While	   a	   number	   of	   gene	   expression-­‐profiling	   studies	   have	   been	   conducted	   to	  
characterize	  post-­‐angioplasty	  and	  stented	  arteries,	  none	  to	  date	  have	  focused	  on	  the	  
molecular	  response	  of	  arteries	  to	  drug-­‐eluting	  stents	  (Zohlnhofer	  et	  al.	  2001;	  Li	  et	  al.	  
2007;	  Muldowney	  et	  al.	  2007).	   	  We	  conducted	  gene	  expression	  analyses	  of	  porcine	  
arteries	  exposed	  to	  BMS,	  SES	  and	  ZES	  at	  28	  days	  post-­‐implantation.	  In	  general,	  our	  
results	   indicate	   that	   the	   rapamycin	   family	   eluting	   stents,	   SES	   and	   ZES,	   delay	   the	  
inflammatory	  response	  and	  proliferative	  processes	  associated	  with	  restenosis	  for	  as	  
long	  as	  the	  stents	  elute	  the	  drug.	  	  
At	  28	  days,	  BMS-­‐exposed	  arteries	  have	  been	  shown	  to	  transition	  from	  proliferative	  
smooth	  muscle	   cell-­‐based	  neointimal	  growth	   to	  mature	  extracellular	  matrix-­‐based	  
neointimal	  growth	  (Finn	  et	  al.	  2002).	  Since	  80%	  of	   the	  sirolimus	   is	  reported	  to	  be	  
eluted	  from	  SES	  within	  30	  days	  (Acharya	  and	  Park	  2006)	  following	  implantation,	  at	  
28	   days,	   SES-­‐exposed	   arteries	   might	   be	   expected	   to	   be	   just	   entering	   restenosis	  
where	  the	  process	  of	   leukocyte	  recruitment	  and	  smooth	  muscle	  cell	  migration	  and	  
proliferation	  begins	  (Virmani	  et	  al.).	  	  Consistent	  with	  this	  expectation,	  SES-­‐exposed	  
arteries	  displayed	  a	  gene	  expression	  pattern	  indicative	  of	  leukocyte	  infiltration	  and	  
SMC	  migration	  characteristic	  of	  early	  stages	  of	  in-­‐stent	  restenosis-­‐a	  process	  that	  is	  
typically	   observed	   after	   BMS-­‐stent	   implantation	   after	   only	   1-­‐3	   days	   (Costa	   and	  
Simon	   2005).	   	   In	   contrast,	   ZES	   have	   been	   reported	   to	   release	   90%	   of	   their	   drug	  
payload	  within	  14	  days	  of	  implantation	  (Kandzari	  and	  Leon	  2006).	  Thus	  at	  28	  days	  
post-­‐implantation,	  ZES	  exposed	  arteries	  might	  be	  expected	  to	  be	  at	  the	  same	  stage	  
of	   restenotic	   progression	   as	   a	   14	   day	   old	   BMS-­‐exposed	   artery,	   where	   neointimal	  
formation	   transitions	   from	   SMC	   migration	   to	   a	   more	   mature	   SMC	   proliferation-­‐
driven	   state	   (Welt	   and	   Rogers	   2002).	   Consistent	   with	   this	   expectation,	   we	   found	  
that	  at	  28	  days	  post-­‐implantation,	  ZES-­‐exposed	  arteries	  displayed	  gene	  expression	  
patterns	   indicative	   of	   extracellular	   matrix	   formation,	   muscle	   cell	   growth	   and	  
basement	  membrane	  formation,	  all	  emblematic	  of	  a	  transition	  from	  migratory	  VSMC	  
to	  proliferative	  SMC	  and	  a	   restored	  endothelial	   layer.	  Thus,	   the	  molecular	  profiles	  
are	   consistent	   with	   a	   model	   of	   delayed	   restenosis	   due	   to	   the	   drug-­‐induced	  
suppression	  of	  inflammatory	  responses	  and	  proliferative	  processes	  associated	  with	  
drug	  eluting	  stents.	  	  
3.5.	  CONCLUSION	  
Our	   results	   suggest	   that	   the	   reported	   differences	   between	   SES	   and	   ZES	   stents	   in	  
delaying	  restenosis	  is	  mostly	  due	  to	  a	  differential	  delay	  in	  the	  onset	  of	  the	  response	  
due	  to	  differences	  in	  the	  drug	  elution	  rates	  associated	  with	  the	  two	  stents	  and	  less	  
to	  a	  qualitative	  difference	   in	   the	   responses	  of	  arteries	   to	   the	  stents.	   In	  addition	   to	  
providing	   insight	   into	   the	   detailed	   molecular	   responses	   of	   arterial	   tissues	   to	   the	  
implantation	  of	  SES	  and	  ZES,	  our	  results	  indicate	  that	  biomarkers	  of	  restenosis	  are	  
clearly	   apparent	  on	   the	  molecular	   level	  well	   before	   the	  process	  manifests	   itself	   at	  
the	  macroscopic	   level.	  Thus,	  molecular	  profiling	  may	  be	  useful	   in	   evaluating	  early	  
arterial	   responses	   to	   implants	  and	  may	  serve	  as	  an	  asset	   in	   the	   future	  design	  and	  
evaluation	  of	  drug	  eluting	  stents.	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4.1.	  Introduction	  
Ovarian	  cancer	  is	  the	  eighth	  most	  common	  cancer	  and	  fifth	  most	  common	  cause	  of	  
cancer	  deaths	  among	  women	  in	  the	  USA	  with	  an	  annual	  incidence	  rate	  of	  12.2	  per	  
100,000	  and	  annual	  death	  rate	  of	  8	  per	  100,000	  in	  2007	  (Group	  2012).	  Although	  the	  
overall	  5-­‐year	  relative	  survival	  rate	  is	  43.2%,	  mortality	  is	  high	  because	  70%	  of	  
ovarian	  cancers	  are	  diagnosed	  after	  metastatic	  spread	  of	  the	  tumor	  (Cho	  and	  Shih	  Ie	  
2009;	  Howlader	  et	  al.	  2012).	  	  In	  the	  US	  in	  2009,	  an	  estimated	  1	  in	  72	  women	  would	  
develop	  ovarian	  cancer	  in	  their	  lifetime	  (Howlader	  et	  al.	  2012).	  	  Globally,	  ovarian	  
cancer	  is	  the	  sixth	  most	  common	  cancer	  in	  women,	  and	  more	  than	  90%	  of	  primary	  
malignant	  ovarian	  tumors	  are	  epithelial	  in	  origin	  (Sankaranarayanan	  and	  Ferlay	  
2006).	  	  
Unlike	  other	  solid	  tumors	  that	  go	  through	  multiple	  steps	  of	  extravasation	  
before	  metastasizing	  through	  the	  blood	  circulatory	  system,	  ovarian	  cancer	  cells	  
typically	  metastasize	  by	  direct	  contact	  with	  adjacent	  organs	  or	  by	  detaching	  from	  
the	  primary	  tumor	  (Gupta	  and	  Massague	  2006).	  Detached	  tumor	  cells	  can	  then	  
travel	  in	  peritoneal	  fluids	  throughout	  the	  abdominal	  cavity.	  In	  this	  manner,	  
carcinoma	  can	  attach	  to	  reproductive	  organs,	  the	  omentum,	  or	  the	  sigmoid	  colon.	  
Additionally,	  metastasized	  carcinoma	  can	  also	  be	  transported	  via	  the	  lymph	  node	  
system	  (Eisenkop	  and	  Spirtos	  2001).	  	  
The	  epithelial-­‐mesenchymal	  transition	  (EMT)	  of	  ovarian	  surface	  epithelium	  
(OSE)	  is	  thought	  to	  normally	  be	  involved	  in	  postovulatory	  repair,	  where	  the	  
transition	  to	  a	  mesenchymal	  phenotype	  provides	  the	  motility	  and	  proliferation	  
necessary	  for	  extracellular	  matrix	  remodeling	  (Salamanca	  et	  al.	  2004).	  	  The	  
transition	  is	  typical	  of	  cellular	  transformations	  crucial	  in	  embryogenesis,	  such	  as	  
mesoderm	  formation,	  neural	  crest	  development,	  and	  secondary	  palate	  formation,	  as	  
well	  as	  in	  organogenesis.	  EMT	  is	  also	  the	  first	  step	  in	  the	  epithelial-­‐mesenchymal-­‐
epithelial	  transitions	  during	  ovarian	  carcinoma	  metastasis,	  beginning	  with	  the	  
disruption	  of	  E-­‐cadherin-­‐mediated	  cell-­‐cell	  interactions	  (Ahmed	  et	  al.	  2007).	  This	  
permits	  epithelial	  cells	  to	  detach	  from	  the	  basement	  membrane	  and	  loosens	  
connections	  between	  carcinoma	  cells.	  Once	  detached	  these	  cells	  can	  now	  enter	  the	  
peritoneal	  fluid,	  and	  be	  passively	  moved	  into	  the	  coelomic	  space.	  The	  cancer	  cells	  
also	  acquire	  a	  mesenchymal	  phenotype	  becoming	  spindle-­‐like,	  and	  more	  motile.	  	  
The	  reverse	  process,	  known	  as	  the	  mesenchymal-­‐epithelial	  transition	  (MET)	  
is	  involved	  in	  reverting	  the	  motile	  mesenchymal-­‐like	  ovarian	  cancer	  cells	  created	  via	  
EMT	  to	  a	  more	  epithelial-­‐like	  phenotype	  at	  the	  secondary	  tumor	  site.	  E-­‐cadherin,	  
known	  to	  induce	  the	  MET	  pathway,	  is	  expressed	  in	  both	  primary	  and	  metastatic	  
ovarian	  carcinomas,	  but	  not	  normal	  ovarian	  surface	  epithelium	  (Veatch	  et	  al.	  1994;	  
Darai	  et	  al.	  1997;	  Maines-­‐Bandiera	  and	  Auersperg	  1997;	  Davies	  et	  al.	  1998).	  E-­‐
cadherin	  expression	  in	  human	  ovarian	  surface	  epithelium	  induces	  the	  localization	  of	  
E-­‐cadherin,	  catenins,	  and	  f-­‐actin	  to	  the	  locations	  of	  cell-­‐cell	  contact,	  gaining	  
epithelial	  characteristics	  associated	  with	  MET	  (Auersperg	  et	  al.	  1999).	  	  Consistent	  
with	  this,	  work	  in	  a	  human	  bladder	  cancer	  model	  has	  shown	  that	  MET	  contributes	  to	  
the	  establishment	  of	  metastatic	  deposits,	  where	  targeted	  abrogation	  of	  FGF	  
pathways	  involved	  in	  MET	  both	  reverses	  MET	  and	  increases	  survival	  in	  TSU-­‐Pr1	  
tumor	  cell	  line	  inoculated	  mice	  (Chaffer	  et	  al.	  2005;	  Chaffer	  et	  al.	  2006).	  MET	  occurs	  
naturally	  during	  somitogenesis,	  kidney	  formation,	  and	  coelomic-­‐cavity	  formation,	  
and	  work	  done	  in	  these	  areas	  has	  identified	  important	  modulators	  likely	  to	  be	  
involved	  in	  cancer	  metastasis	  (Saga	  and	  Takeda	  2001;	  Vainio	  and	  Lin	  2002).	  Given	  
the	  plasticity	  of	  the	  native	  ovarian	  surface	  epithelium,	  MET	  is	  thought	  to	  be	  the	  
molecular	  reversal	  of	  EMT	  (Wong	  and	  Leung	  2007).	  	  
At	  the	  same	  time,	  our	  understanding	  about	  the	  mechanisms	  involved	  in	  MET	  
is	  incomplete,	  particularly	  in	  its	  role	  in	  cancer	  progression.	  E-­‐cadherin	  is	  involved	  in	  
signaling	  capable	  of	  inducing	  MET	  in	  human	  ovarian	  surface	  epithelium	  (Auersperg	  
1999).	  Studies	  comparing	  primary	  ovarian	  carcinomas	  to	  metastases	  demonstrated	  
lower	  Snail	  expression	  in	  metastases	  than	  in	  primary	  carcinomas,	  higher	  expression	  
of	  Twist1	  and	  Zeb1	  in	  metastases,	  and	  the	  regulation	  of	  Snail	  localization	  by	  Pak1,	  
leading	  to	  E-­‐cadherin	  re-­‐expression	  in	  metastases	  (Elloul	  et	  al.	  2010).	  EMT	  induced	  
by	  TGF-­‐β1	  signaling	  through	  a	  Smads-­‐dependent	  pathway	  in	  rat	  and	  human	  alveolar	  
epithelial-­‐like	  cells	  could	  be	  reversed,	  via	  the	  MAPK/ERK	  kinase	  pathway,	  by	  
culturing	  with	  FGF-­‐1	  for	  48	  hours,	  suggesting	  that	  EMT	  and	  MET	  might	  arise	  from	  
induction	  of	  separate	  pathways	  rather	  than	  reversing	  the	  induction	  of	  a	  single	  
pathway	  (Ramos	  et	  al.	  2010).	  These	  experiments	  outline	  the	  complex	  signaling	  
involved	  in	  both	  EMT	  and	  MET	  coordinated	  by	  the	  actions	  of	  multiple	  gene	  
products.	  
microRNA	  (miRNA)	  are	  an	  extensive	  class	  of	  small	  (18-­‐24	  nt)	  endogenous	  
regulatory	  non-­‐coding	  RNAs	  	  that	  post-­‐transcriptionally	  regulate	  gene	  expression	  in	  
plants	  and	  animals	  (Bartel	  2004).	  They	  were	  originally	  discovered	  as	  a	  small	  RNA,	  
encoded	  by	  the	  lin-­‐4	  gene,	  capable	  of	  binding	  the	  3’	  untranslated	  region	  of	  lin-­‐14	  
mRNA	  and	  inhibiting	  its	  translation	  in	  Caenorhabditis	  elegans	  (Wightman	  et	  al.	  
1993).	  	  A	  miRNA	  begins	  as	  a	  hairpin	  structure	  that	  forms	  from	  a	  larger	  transcript,	  
called	  a	  pri-­‐miRNA	  (Lee	  et	  al.	  2004b).	  This	  stem-­‐loop	  structure	  is	  then	  recognized	  
and	  cut	  by	  Drosha/DGCR8,	  leaving	  a	  60-­‐nucleotide	  pre-­‐miRNA	  (Han	  et	  al.	  2004).	  
Dicer,	  a	  RNAse	  III	  enzyme,	  further	  processes	  the	  pre-­‐miRNA	  into	  a	  21-­‐23	  nt	  double-­‐
stranded	  RNA	  duplex,	  of	  which	  one	  strand	  is	  incorporated	  into	  the	  RNA-­‐induced	  
silencing	  complex	  (RISC),	  comprised	  of	  dicer,	  TAR	  (HIV-­‐1)	  RNA	  binding	  protein	  
(TRBP),	  and	  argonaute	  (Lin	  et	  al.	  2005).	  miRNAs	  block	  the	  translation	  of	  target	  
mRNAs	  by	  imperfectly	  base	  pairing	  with	  specific	  sequences	  in	  the	  3’	  untranslated	  
regions	  of	  their	  target	  mRNA	  and	  inhibiting	  translation	  or	  promoting	  degradation	  
via	  the	  RNA-­‐induced	  silencing	  complex.	  miRNAs	  are	  particularly	  attractive	  for	  use	  as	  
cancer	  therapies	  because	  individual	  miRNAs	  can	  post-­‐transcriptionally	  regulate	  
tens	  to	  hundreds	  of	  genes	  at	  once	  (Brennecke	  et	  al.	  2005;	  Wu	  and	  Belasco	  2008).	  
A	  regulatory	  role	  for	  microRNAs	  in	  metastasis-­‐related	  EMT	  and	  MET	  has	  
been	  elucidated	  from	  studies	  examining	  miRNA	  abundance	  in	  metastatic	  cancer	  
tissue	  (Pigati	  et	  al.	  2010;	  Guttilla	  et	  al.	  2012;	  Moes	  et	  al.	  2012;	  Ru	  et	  al.	  2012).	  They	  
suggest	  potential	  therapies	  where	  individual	  miRNAs	  or	  suites	  of	  miRNAs	  may	  be	  
used	  to	  control	  the	  metastatic	  process.	  Multiple	  in	  vitro	  studies	  examining	  miRNA	  
transfections	  of	  cancer	  cell	  lines	  highlight	  a	  role	  for	  miRNAs	  in	  the	  inhibition	  of	  EMT	  
in	  different	  cancer	  cell	  lines	  via	  a	  diverse	  set	  of	  targets	  and	  potential	  pathways.	  
Forced	  miR-­‐7	  expression	  in	  breast	  cancer	  cells	  up-­‐regulated	  E-­‐cadherin	  and	  down-­‐
regulated	  vimentin	  and	  fibronectin	  expression,	  while	  at	  the	  same	  time	  suppressing	  
tumor	  cell	  proliferation,	  anchorage	  independent	  growth,	  migration,	  and	  invasion	  in	  
aggressive	  breast	  cancer	  cell	  lines	  (Kong	  et	  al.	  2012).	  The	  invasive	  fronts	  of	  primary	  
colorectal	  cancers	  showed	  lower	  expression	  of	  miR-­‐200c	  and	  miR-­‐141	  than	  their	  
matched	  liver	  metastatic	  tissue	  (Hur	  et	  al.	  2012).	  Transfection	  of	  the	  primary	  
colorectal	  cancers	  suppressed	  invasion	  and	  migration,	  but	  also	  led	  to	  cell	  
proliferation,	  as	  well	  as	  increased	  E-­‐cadherin	  and	  decreased	  vimentin	  expression.	  
Over-­‐expression	  of	  miR-­‐429	  in	  HEY	  cells,	  mesenchymal-­‐like	  cells	  derived	  from	  
papillary	  cystadenocarcinoma	  of	  the	  ovary,	  resulted	  in	  decreased	  migration,	  
suppression	  of	  anchorage-­‐independent	  growth,	  as	  well	  as	  a	  change	  in	  morphology	  
from	  an	  elongated,	  spindle	  shaped,	  mesenchymal	  phenotype	  to	  a	  rounded,	  
epithelial-­‐like	  phenotype	  (Chen	  et	  al.	  2011).	  This	  was	  accompanied	  by	  decreases	  in	  
ZEB1	  and	  ZEB2,	  known	  activators	  of	  EMT	  and	  targets	  of	  miR-­‐429,	  and	  increases	  in	  
E-­‐cadherin	  expression.	  miR-­‐429	  belongs	  to	  the	  miRNA-­‐200	  family	  of	  microRNAs,	  
identified	  as	  important	  regulators	  in	  EMT-­‐associated	  cancer	  metastasis	  (Gregory	  et	  
al.	  2008a;	  Korpal	  and	  Kang	  2008;	  Paterson	  et	  al.	  2008;	  Chen	  et	  al.	  2011;	  Shahab	  et	  
al.	  2011).	  
Our	  study	  represents	  the	  first	  time	  course	  analysis	  of	  miR-­‐429-­‐induced	  MET	  
in	  ovarian	  cancer	  cells.	  We	  transfected	  Hey	  cells	  with	  miR-­‐429	  and	  assayed	  gene	  
expression	  over	  the	  course	  of	  144	  hours	  at	  regular	  intervals.	  The	  cell	  morphology	  
and	  gene	  expression	  of	  our	  transfected	  cells	  changed	  to	  become	  more	  epithelial-­‐like	  
at	  24	  and	  48	  hours	  and	  then	  became	  more	  mesenchymal-­‐like	  by	  144	  hours.	  	  By	  144	  
hours	  the	  average	  gene	  expression	  levels	  for	  98.6%	  of	  our	  genes	  were	  not	  
significantly	  different	  from	  the	  levels	  they	  started	  from	  at	  0	  hours	  when	  we	  adjusted	  
for	  baseline	  expression	  changes	  observed	  in	  our	  negative	  control	  treated	  cells.	  We	  
also	  examine	  the	  pathways	  and	  genes	  that	  are	  differentially	  expressed	  in	  the	  0-­‐48	  
hour	  and	  48-­‐144	  hour	  time	  spans.	  	  
	  
4.2.	  Methods	  
4.2.1	  Cell	  lines	  and	  transfection	  
The	  HEY	  cell	  line	  was	  derived	  from	  a	  patient	  with	  moderately	  differentiated	  
papillary	  cystadenocarcinoma	  of	  the	  ovary	  (Buick	  et	  al.	  1985).	  The	  HEY	  cell	  line	  was	  
kindly	  provided	  by	  Gordon	  Mills,	  Department	  of	  Molecular	  Therapeutics,	  University	  
of	  Texas,	  MD	  Anderson	  Cancer	  Center.	  HEY	  cells	  were	  cultured	  in	  R10	  medium:	  
RPMI	  1640	  medium	  supplemented	  with	  10%	  fetal	  bovine	  serum	  (FBS,	  Atlanta	  
Biologicals,	  Lawrenceville,	  GA)	  and	  1%	  antibiotic-­‐antimycotic	  solution	  (Mediatech-­‐
Cellgro,	  Manassas,	  VA)	  
	  
Cells	  were	  harvested	  after	  Trypsin/EDTA	  treatment,	  the	  cell	  pellet	  was	  suspended	  
in	  growth	  medium,	  then	  counted	  to	  determine	  density	  before	  being	  diluted	  to	  5x104	  
cells/mL.	  105	  cells	  per	  well	  were	  seeded	  into	  four	  6-­‐well	  plates	  and	  allowed	  to	  grow	  
for	  24	  hours.	  After	  24	  hours,	  cells	  were	  harvested	  from	  one	  plate	  as	  0	  hour	  samples.	  
On	  the	  remaining	  three	  plates,	  cells	  in	  three	  wells	  were	  transfected	  with	  30	  nM	  of	  
miR-­‐429	  miRNA	  oligonucleotides	  (Life	  Technologies,	  Grand	  Island,	  NY)	  and	  cells	  in	  
the	  remaining	  three	  wells	  were	  transfected	  with	  Pre-­‐miR™	  miRNA	  Precursor	  
Negative	  Control	  #1	  (Life	  Technologies,	  Grand	  Island,	  NY),	  using	  Lipofectamine	  
2000	  reagent	  (Life	  technologies,	  Grand	  Island,	  NY).	  These	  transfected	  plates	  were	  
incubated	  at	  37°C	  and	  5%	  CO2	  for	  four	  hours,	  whereupon	  the	  medium	  was	  changed	  
to	  R10	  medium.	  	  At	  24	  hours	  following	  transfection,	  cells	  were	  harvested	  from	  one	  
plate	  for	  the	  24-­‐hour	  timepoint.	  Then	  at	  48	  hours	  following	  transfection,	  cells	  were	  
harvested	  from	  another	  plate	  for	  the	  48-­‐hour	  timepoint.	  At	  72	  hours	  following	  
transfection,	  cells	  were	  split	  from	  the	  remaining	  plate	  and	  allowed	  to	  continue	  to	  
grow.	  Finally	  at	  144	  hours	  following	  transfection,	  cells	  in	  the	  remaining	  plate	  were	  
harvested	  for	  the	  144-­‐hour	  time	  point.	  	  	  
	  
	  
4.2.2	  RNA	  Quantification,	  microarray	  assays	  
Total	  RNA	  was	  isolated	  from	  harvested	  cells	  using	  the	  RNeasy	  Mini	  RNA	  isolation	  kit	  
(QIAGEN,	  Valencia,	  CA).	  The	  integrity	  of	  the	  RNA	  was	  verified	  using	  an	  Agilent	  2100	  
Bioanalyzer	  (1.8-­‐2.0;	  Agilent	  Technologies,	  Palo	  Alto,	  CA).	  mRNAs	  were	  converted	  to	  
double	  stranded	  (ds)-­‐cDNA	  and	  amplified	  using	  Applause	  3’-­‐Amp	  System	  (NuGen,	  
San	  Carlos,	  CA).	  This	  cDNA	  was	  fragmented	  and	  biotin	  labeled	  using	  the	  Encode	  
Biotin	  Module	  (NuGen),	  hybridized	  to	  Affymetrix	  HG-­‐U133	  Plus	  2.0	  oligonucleotide	  
arrays	  and	  analyzed	  with	  a	  GeneChip	  Scanner	  3000	  (Affymetrix,	  Santa	  Clara,	  CA).	  
	  
4.2.3	  Statistical	  analysis	  
Robust	  Microarray	  Averaging	  (RMA)	  was	  used	  for	  normalization	  of	  microarray	  
signal	  and	  summarization	  using	  the	  Affymetrix	  Microarray	  Suite	  (Affymetrix	  Inc.	  
Santa	  Clara,	  CA)	  (Irizarry	  et	  al.	  2003).	  Statistical	  analysis	  of	  the	  expression	  data	  was	  
carried	  out	  using	  the	  R	  statistical	  programming	  environment	  (R	  Development	  Core	  
Team	  2010).	  Genes	  with	  significant	  differential	  expression	  over	  the	  entire	  time	  
course	  from	  0	  to	  144	  hours	  were	  identified	  using	  a	  two	  regression	  step	  approach	  in	  
the	  maSigPro	  R	  package	  where	  individual	  gene	  expression	  across	  time	  (0	  to	  144	  
hours)	  is	  modeled	  with	  a	  global	  regression	  model	  and	  then	  genes	  with	  significantly	  
different	  expression	  models	  in	  the	  miR-­‐429	  treated	  cells	  compared	  to	  the	  negative	  
control	  treated	  cells	  are	  identified	  using	  a	  comparison	  of	  model	  coefficients	  (Conesa	  
et	  al.	  2006).	  This	  allows	  us	  to	  ask	  for	  each	  gene	  if	  its	  expression	  profile	  in	  miR-­‐429-­‐
treated	  cells	  is	  significantly	  different	  from	  its	  expression	  profile	  in	  negative-­‐control	  
treated	  cells	  across	  the	  entire	  time	  period	  (0,	  24,	  48,	  and	  144	  hours).	  	  We	  used	  a	  
significance	  level	  of	  0.05	  for	  the	  global	  regression	  model,	  and	  false-­‐discovery	  rate	  
controlled	  significance	  level	  of	  0.05	  and	  r-­‐squared	  cut-­‐off	  of	  0.6	  for	  the	  step-­‐wise	  
regression	  used	  in	  the	  variable	  selection.	  For	  the	  comparisons	  of	  only	  two	  time	  
points,	  we	  used	  a	  linear	  modeling	  method	  in	  the	  Limma	  R	  package	  where	  
differential	  expression	  changes	  were	  tested	  for	  significance	  using	  a	  moderated	  F-­‐
test	  (Smyth	  2004).	  Results	  from	  both	  selection	  methods	  were	  further	  analyzed	  using	  
GeneGO	  to	  perform	  gene	  enrichment	  to	  determine	  those	  pathways	  that	  showed	  
larger	  numbers	  of	  differentially	  expressed	  constituents	  than	  would	  otherwise	  be	  
expected	  by	  chance	  (GeneGO	  Inc.,	  Carlsbad,	  CA).	  Significantly	  enriched	  GeneGO	  
pathways	  were	  chosen	  for	  a	  false	  discovery	  rate	  of	  0.05.	  
	  
4.3.	  Results	  
To	  characterize	  the	  transcriptomic	  effects	  of	  miR-­‐429	  transfection	  in	  HEY	  cells,	  we	  
conducted	  a	  high-­‐density	  expression	  microarray	  profiling	  analysis	  (Affymetrix	  HG-­‐
U133	  Plus	  2.0)	  comparing	  HEY	  cells	  treated	  with	  miR-­‐429	  with	  negative	  controls	  
treated	  with	  a	  non-­‐targeted	  miRNA.	  We	  sampled	  our	  treatment	  and	  control	  cells	  at	  0	  
(pre-­‐transfection),	  24,	  48,	  and	  144	  hours	  post-­‐transfection	  to	  examine	  the	  
expression	  changes	  in	  these	  cells	  over	  time.	  	  
4.3.1	  Time	  course	  analysis	  (0-­‐144	  hours)	  
Of	  particular	  interest	  are	  genes	  that	  both	  change	  significantly	  over	  the	  time	  course	  
and	  show	  a	  course	  of	  expression	  that	  is	  significantly	  different	  from	  that	  of	  the	  
negative	  control.	  To	  achieve	  this,	  we	  used	  a	  two-­‐step	  linear	  regression	  algorithm	  
that	  identifies	  genes	  with	  statistically	  significant	  changes	  through	  time	  and	  between	  
different	  cell	  treatments	  (Conesa	  et	  al.	  2006).	  Our	  time	  course	  analysis	  results	  show	  
that	  3635	  genes	  were	  significantly	  differentially	  up	  or	  down	  regulated	  compared	  
with	  the	  negative	  control	  over	  the	  time	  course	  (false	  discovery	  rate	  <	  0.05).	  
Mesenchymal	  markers	  like	  FN1	  (fibronectin)	  were	  significantly	  down-­‐regulated,	  
while	  epithelial	  markers	  like	  CAV2	  (caveolin	  2),	  CTNND1	  (cadherin-­‐associated	  
protein,	  delta	  1),	  KRT8	  (keratin,	  type	  II	  cytoskeletal	  8)	  and	  DSP	  (desmoplakin)	  were	  
significantly	  up-­‐regulated	  (Turley	  et	  al.	  2008)	  (Table	  4.1).	  	  Transcription	  factors	  
associated	  with	  metastasis	  like	  ZEB1	  (zinc	  finger	  E-­‐box-­‐binding	  homeobox	  1),	  and	  
ZEB2	  (zinc	  finger	  E-­‐box-­‐binding	  homeobox	  2)	  are	  down-­‐regulated	  (Davidson	  et	  al.	  
2012).	  Signaling	  molecules	  involved	  in	  MET,	  like	  FGF1	  (fibroblast	  growth	  factor	  1	  
Table	  4.1.	  Multiple	  genes	  associated	  with	  EMT	  or	  MET	  are	  differentially	  expressed	  across	  the	  
144	  hour	  time	  course	  
These	  selected	  genes	  are	  those	  that	  are	  known	  to	  be	  involved	  in	  EMT	  or	  MET	  processes	  and	  
are	  differentially	  expressed	  across	  the	  time	  course	  (0-­‐144	  hours)	  by	  maSigPro	  (FDR	  =	  0.05).	  
The	  fold	  change	  values	  compare	  the	  miR-­‐429-­‐treated	  cells’	  average	  expression	  to	  the	  
negative	  control-­‐treated	  cells’	  average	  expression	  at	  each	  time	  point	  (24,	  48,	  and	  144	  
hours).	  	  
  
Fold change 
in miR-429 
treated cells Time course 
Probe ID Symbol 24 hours 
48 
hours 
144 
hours p-value 
220016_at AHNAK -0.63 -0.35 0.95 7.05E-10 
203323_at CAV2 2.21 2.21 0.67 9.20E-07 
203324_s_at CAV2 0.69 0.95 0.35 2.88E-09 
213426_s_at CAV2 0.96 1.13 0.28 1.46E-06 
203440_at CDH2 0.27 0.05 -0.14 0.000233764 
1556499_s_at COL1A1 -0.56 -0.80 -0.42 5.60E-09 
202310_s_at COL1A1 -0.04 -0.39 -0.32 2.99E-09 
208407_s_at CTNND1 0.41 0.40 0.08 5.32E-08 
200606_at DSP 1.20 1.49 0.86 3.76E-10 
1552721_a_at FGF1 0.81 0.96 -0.41 2.33E-10 
204421_s_at FGF2 1.29 0.53 0.01 1.92E-08 
204422_s_at FGF2 1.62 1.71 -0.04 6.91E-12 
205014_at FGFBP1 1.94 1.60 2.79 3.36E-07 
210495_x_at FN1 -1.65 -2.70 -0.13 2.53E-06 
211719_x_at FN1 -1.70 -2.66 -0.12 1.31E-06 
212464_s_at FN1 -1.68 -2.76 -0.05 4.03E-06 
214702_at FN1 -0.67 -1.66 -0.33 7.10E-05 
216442_x_at FN1 -1.58 -2.63 -0.11 4.54E-06 
204115_at GNG11 -0.78 -0.49 0.09 0.000205213 
1561633_at HMGA2 -0.92 -0.14 0.00 1.64E-05 
208025_s_at HMGA2 0.17 -0.36 -0.20 8.88E-16 
201508_at IGFBP4 -0.38 -0.15 0.16 0.000128644 
209008_x_at KRT8 0.29 0.90 0.68 9.49E-06 
226066_at MITF 0.19 0.54 -0.33 8.80E-10 
200600_at MSN -0.66 -0.51 0.28 2.03E-05 
205455_at MST1R 0.49 0.60 0.48 1.44E-05 
207924_x_at PAX8 -0.04 0.09 0.44 8.90E-06 
221990_at PAX8 -0.81 -0.46 0.06 2.06E-07 
202627_s_at SERPINE1 -0.78 0.11 0.99 3.25E-06 
203076_s_at SMAD2 -0.49 -0.59 0.07 3.55E-09 
226563_at SMAD2 -0.28 -0.52 -0.23 0.000342423 
204790_at SMAD7 0.82 -0.14 -0.82 1.61E-07 
209875_s_at SPP1 -0.10 -1.03 -0.38 6.05E-13 
205542_at STEAP1 -0.31 -0.11 0.09 4.29E-05 
212385_at TCF4 0.05 -0.82 -0.73 6.28E-05 
213891_s_at TCF4 -0.48 -0.74 -0.26 1.63E-07 
Table 4.1 (continued) 
202011_at TJP1 1.04 0.89 0.04 0.00108346 
218834_s_at TMEM132A -1.12 -1.06 0.15 7.68E-05 
217979_at TSPAN13 0.21 0.27 0.33 2.24E-06 
204619_s_at VCAN 0.89 0.92 0.22 4.28E-05 
204620_s_at VCAN 0.95 0.95 0.14 8.69E-05 
215646_s_at VCAN 1.04 0.99 -0.37 0.001017159 
221731_x_at VCAN 0.65 0.97 0.18 5.41E-05 
212764_at ZEB1 -1.29 -1.72 -0.14 1.33E-07 
239952_at ZEB1 -1.17 -1.36 -0.20 1.33E-05 
203603_s_at ZEB2 -0.43 -1.12 -0.33 2.14E-05 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
(acidic)),	  and	  in	  EMT,	  like	  FGF2	  (fibroblast	  growth	  factor	  2	  (basic)),	  are	  up-­‐regulated	  
(Thiery	  2002).	  	  
4.3.1.1	  Characteristic	  expression	  response	  to	  miR-­429	  is	  temporary	  
For	  those	  genes	  that	  are	  differentially	  expressed	  across	  the	  time	  course,	  we	  noted	  a	  
characteristic	  gene	  expression	  response	  to	  the	  treatment	  with	  miR-­‐429.	  	  Expression	  
levels	  for	  many	  of	  these	  genes	  reach	  a	  maximum	  or	  minimum	  at	  24	  or	  48	  hours	  
(Figure	  4.1).	  We	  also	  noted	  that	  expression	  levels	  appeared	  similar	  at	  0	  and	  144	  
hours	  for	  many	  genes,	  so	  we	  asked	  if	  the	  average	  expression	  levels	  in	  miR-­‐429	  
treated	  Hey	  cells	  at	  0	  hour	  were	  significantly	  different	  from	  the	  average	  level	  at	  144	  
hours,	  corrected	  for	  the	  change	  in	  expression	  observed	  in	  the	  negative	  control-­‐
treated	  cells	  over	  the	  same	  time	  interval.	  By	  144	  hours,	  98.6%	  (3585	  out	  of	  3635)	  of	  
genes	  that	  were	  differentially	  expressed	  across	  the	  time	  course	  had	  returned	  to	  
expression	  levels	  that	  were	  not	  significantly	  different	  from	  their	  expression	  at	  0	  
hours	  (FDR	  =	  0.05)	  (Figure	  4.2).	  	  
4.3.1.2	  Small	  number	  of	  genes	  do	  not	  return	  to	  0	  hour	  expression	  levels	  following	  miR-­
429	  treatment	  
We	  were	  then	  interested	  in	  the	  function	  of	  those	  50	  genes	  that	  showed	  significantly	  
different	  average	  expression	  at	  144	  hours	  compared	  to	  their	  expression	  at	  0	  hours	  
(Table	  4.2).	  Of	  particular	  interest,	  for	  their	  potential	  involvement	  in	  EMT/MET,	  were	  
Wnt7A,	  IL-­1β,	  SERPINE1,	  and	  LAMC2	  (Figure	  4.3).	  Moreover,	  FGD6,	  which	  may	  
activate	  CDC42	  and	  play	  a	  role	  in	  cell	  cycle	  signaling,	  and	  DCLK1,	  a	  doublecortin	  and	  
calmodulin-­‐like	  kinase	  that	  shows	  expression	  in	  human	  hippocampal	  and	  cortical	  
tissue,	  are	  targets	  of	  miR-­‐429,	  though	  both	  genes	  show	  up-­‐regulated	  expression	  by	  
	  
Figure	  4.1	  Clustered	  fold-­change	  values	  of	  probes	  display	  a	  large	  change	  at	  48	  hours	  
The	  lines	  labeled	  as	  4	  show	  overall	  expression	  patterns	  common	  to	  our	  set	  of	  genes	  that	  are	  
significantly	  differentially	  expressed	  genes	  over	  the	  time	  course	  (0-­‐144	  hours).	  Partitioning	  
is	  performed	  by	  k-­‐means	  clustering	  on	  the	  fold-­‐change	  values	  of	  each	  gene	  into	  9	  groups.	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  4.2	  By	  144	  hours,	  most	  genes	  in	  miR-­429	  treated	  cells	  have	  the	  same	  average	  
expression	  as	  at	  0	  hours	  
Histogram	  of	  corrected	  differences	  of	  average	  expression	  at	  0	  hours	  compared	  to	  144	  hours	  
for	  all	  genes	  assayed.	  To	  correct	  for	  baseline	  changes,	  we	  subtracted	  the	  change	  in	  average	  
expression	  for	  cells	  treated	  with	  the	  negative	  control	  between	  0	  h	  and	  144	  h	  from	  the	  
change	  observed	  in	  cells	  treated	  with	  miR-­‐429	  during	  the	  same	  time.	  	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Table	  4.2	  Genes	  that	  do	  not	  return	  to	  their	  0	  hour	  expression	  levels	  by	  144	  hours	  post-­
transfection	  
	  
These	  genes	  showed	  a	  significantly	  large	  corrected	  difference	  of	  average	  expression	  at	  0	  
hours	  compared	  to	  144	  hours	  out	  of	  all	  genes.	  To	  correct	  for	  baseline	  changes,	  we	  
subtracted	  the	  change	  in	  average	  expression	  for	  cells	  treated	  with	  the	  negative	  control	  
between	  0	  h	  and	  144	  h	  from	  the	  change	  observed	  in	  cells	  treated	  with	  miR-­‐429	  during	  the	  
same	  time,	  listed	  here	  as	  the	  corrected	  difference.	  	  
	  
Probe ID Symbol 
Corrected 
difference p-value 
222108_at AMIGO2 -1.08 1.35E-06 
230875_s_at ATP11A -0.99 5.22E-05 
218723_s_at C13orf15 2.41 2.56E-07 
228193_s_at C13orf15 2.32 3.62E-07 
219010_at C1orf106 -1.00 1.01E-05 
230339_at CCDC138 -1.12 1.18E-05 
243864_at CCDC80 -1.10 4.73E-05 
223655_at CD163L1 -1.20 1.92E-06 
226187_at CDS1 1.54 2.16E-05 
1569183_a_at CHM -1.30 1.36E-05 
233396_s_at CSRP2BP -0.99 4.38E-05 
226393_at CYP2U1 -1.32 8.95E-06 
205399_at DCLK1 1.36 6.69E-07 
226281_at DNER -1.35 3.51E-06 
205741_s_at DTNA -0.85 4.29E-05 
228361_at E2F2 -1.14 4.33E-05 
200878_at EPAS1 1.51 9.11E-08 
213929_at EXPH5 1.06 1.13E-05 
223000_s_at F11R 0.97 2.91E-05 
241456_at FAM78B -1.78 3.43E-05 
1555137_a_at FGD6 1.72 2.13E-07 
219901_at FGD6 1.21 4.93E-05 
205014_at FGFBP1 2.79 1.57E-10 
204417_at GALC 1.42 3.32E-05 
215243_s_at GJB3 1.33 2.63E-06 
205490_x_at GJB3 1.50 6.98E-06 
214467_at GPR65 4.33 6.21E-12 
218537_at HCFC1R1 0.92 4.64E-05 
Table 4.2 (continued) 
39402_at IL1B 1.28 1.61E-06 
205067_at IL1B 1.25 3.37E-05 
228414_at KCNMA1 -1.61 2.93E-05 
202267_at LAMC2 1.15 6.43E-07 
222561_at LANCL2 -1.20 5.17E-07 
206483_at LRRC6 -1.13 1.79E-05 
204475_at MMP1 2.08 4.69E-08 
206186_at MPP3 -1.31 5.17E-05 
236718_at MYO10 -1.05 7.81E-06 
232317_at PLXNA4 -1.36 1.68E-06 
230015_at PRCD 1.42 1.40E-06 
232532_at QRICH2 -1.08 3.09E-05 
206884_s_at SCEL 2.36 1.86E-08 
232056_at SCEL 2.40 4.74E-07 
202627_s_at SERPINE1 0.99 2.21E-05 
222838_at SLAMF7 -1.32 9.55E-06 
202816_s_at SS18 -0.92 2.72E-05 
235086_at THBS1 -1.35 6.45E-07 
210248_at WNT7A 1.85 6.40E-06 
219836_at ZBED2 2.67 2.96E-06 
222016_s_at ZNF323 -1.79 4.35E-06 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Figure	  4.3	  Fold-­change	  over	  time	  of	  selected	  genes	  with	  significantly	  different	  expression	  at	  
144	  hours	  than	  at	  0	  hours	  
Expression	  patterns	  of	  genes	  that	  are	  thought	  to	  be	  involved	  in	  EMT	  or	  MET	  or	  otherwise	  
predicted	  targets	  of	  miR-­‐429,	  depicting	  fold-­‐change	  over	  the	  experimental	  time	  course.	  The	  
expression	  across	  time	  is	  indicate	  by	  the	  curve	  labeled	  “4”.	  
	  
	  
	  
Figure	  4.3	  (continued)	  
144	  hours	  in	  our	  treated	  samples	  (Havik	  et	  al.	  2012).	  Response	  gene	  to	  complement	  
32	  (C13orf15)	  is	  up-­‐regulated	  through	  the	  entire	  time	  course,	  and	  is	  known	  to	  
mediate	  EMT	  in	  human	  renal	  proximal	  cells	  (Huang	  et	  al.	  2009).	  	  E2F2	  is	  a	  
transcription	  factor	  involved	  in	  cell	  cycle	  regulation	  observed	  to	  be	  over-­‐expressed	  
in	  nonepithelial	  ovarian	  cancers	  compared	  to	  normal	  ovaries,	  and	  is	  down	  regulated	  
in	  our	  miR-­‐429-­‐treated	  samples	  (Vui-­‐Kee	  et	  al.	  2012).	  Lamin	  gamma	  2	  (LAMC2),	  a	  
component	  of	  the	  lamins	  that	  are	  a	  constituent	  of	  basement	  membranes	  and	  were	  
observed	  to	  be	  up-­‐expressed	  in	  ovarian	  metastatic	  tumors,	  are	  also	  up-­‐regulated	  in	  
our	  miR-­‐429	  treated	  cells	  (Schaner	  et	  al.	  2005).	  Also	  up-­‐regulated	  in	  our	  miR-­‐429	  
treated	  cells	  was	  wingless-­‐type	  MMTV	  integration	  site	  family	  member	  7A	  (WNT7A)	  
that	  has	  been	  shown	  to	  be	  abundant	  in	  the	  epithelium	  of	  serous	  ovarian	  carcinomas,	  
and	  lacking	  in	  benign	  tumors,	  normal	  ovaries,	  and	  endometrioid	  carcinomas	  
(Yoshioka	  et	  al.	  2012).	  Wnt	  signaling	  is	  of	  particular	  interest	  because	  it	  has	  been	  
shown	  to	  regulate	  Slug	  and	  EMT	  activity	  (Wu	  et	  al.	  2012).	  Plasminogen	  activator	  
inhibitor-­‐1	  (SERPINE1)	  a	  marker	  for	  EMT	  linked	  to	  metastasis	  was	  down-­‐regulated	  
at	  24	  hours,	  but	  was	  up-­‐regulated	  at	  144	  hours	  in	  miR-­‐429-­‐treated	  cells	  (Bajou	  et	  al.	  
1998).	  Interleukin	  1	  beta	  (IL-­1β)	  is	  a	  well-­‐characterized	  inflammatory	  cytokine	  that	  
was	  down	  regulated	  at	  24	  and	  48	  hours,	  but	  up	  regulated	  by	  144	  hours	  in	  our	  
treated	  cells.	  In	  peritoneal	  mesothelial	  cells,	  IL-­‐1β	  was	  shown	  to	  induce	  down	  
regulation	  of	  E-­‐cadherin	  and	  cytokeratin,	  and	  also	  induce	  NF-­‐κB	  translocation,	  
which	  is	  necessary	  for	  epithelial-­‐mesenchymal	  transitions	  in	  breast	  cancer	  
progression	  (Huber	  et	  al.	  2004;	  Strippoli	  et	  al.	  2008).	  
4.3.1.3	  miR-­429	  treated	  cells	  also	  return	  to	  a	  mesenchymal-­like	  phenotype	  at	  144	  
hours	  
We	  believe	  this	  pattern	  where	  expression	  reaches	  a	  maximum	  at	  24	  or	  48	  hours	  and	  
then	  returns	  to	  the	  same	  zero	  hour	  expression	  level	  by	  144	  hours	  represents	  the	  
direct	  impact	  of	  miR-­‐429	  on	  different	  transcription	  targets.	  This	  impact	  attenuates	  
as	  the	  miRNA	  degrades	  over	  time	  and	  is	  diluted	  through	  successive	  cell	  passaging	  at	  
48	  hours.	  The	  response,	  followed	  by	  return	  to	  0	  hour	  levels	  corresponds	  closely	  to	  
our	  observations	  of	  cell	  phenotypes	  over	  time,	  where	  the	  miR-­‐429	  transfected	  cells	  
change	  from	  a	  pre-­‐transfection	  (0	  hour)	  elongated	  fibroblast-­‐like	  morphology	  to	  
increasingly	  rounded,	  cobblestone	  epithelial-­‐like	  morphology	  at	  24	  and	  48	  hours	  
and	  then	  return	  to	  the	  fibroblast-­‐like	  morphology	  at	  144	  hours	  (Figure	  4.4).	  The	  
negative	  control	  transfected	  cells	  did	  not	  change	  from	  their	  original	  mesenchymal-­‐
like	  morphology	  during	  the	  0-­‐144	  hour	  time	  course,	  suggesting	  that	  these	  negative	  
control	  cells	  represent	  a	  stable	  baseline.	  	  
4.3.1.4	  Gene	  set	  enrichment	  and	  miR-­429	  predicted	  targets	  
Given	  the	  large	  number	  of	  differentially	  expressed	  genes,	  we	  then	  asked	  what	  
biological	  pathways	  and	  processes	  were	  over-­‐represented	  among	  our	  differentially	  
expressed	  genes.	  Gene	  set	  enrichment	  analysis	  using	  GeneGO	  demonstrated	  that	  the	  
significantly	  differentially	  expressed	  genes	  were	  significantly	  enriched	  for	  gene	  sets	  
related	  to	  cell	  adhesion,	  cytoskeletal	  remodeling,	  EGFR	  signaling,	  apoptosis,	  and	  
regulation	  of	  the	  epithelial-­‐mesenchymal	  transition,	  among	  others	  (Figure	  4.5).	  The	  
presence	  of	  significantly	  enriched	  gene	  sets	  suggests	  that	  miR-­‐429	  is	  not	  only	  
	  
	  
Figure	  4.4	  miR-­429	  transfection	  in	  HEY	  cells	  induces	  morphological	  changes	  characteristic	  of	  
MET	  and	  then	  EMT	  
Cells	  transfected	  with	  miR-­‐429	  displayed	  a	  change	  from	  the	  elongated	  mesenchymal-­‐like	  
morphology	  (0	  h)	  to	  a	  rounded,	  cobblestone	  epithelial-­‐like	  morphology	  (24,	  48	  h),	  which	  
later	  returned	  to	  the	  mesenchymal-­‐like	  morphology	  by	  144	  hours.	  No	  morphological	  
changes	  were	  observed	  in	  cells	  transfected	  with	  the	  negative	  control.	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causing	  the	  differential	  expression	  of	  individual	  genes,	  but	  also	  altering	  entire	  
pathways	  related	  to	  the	  epithelial-­‐mesenchymal	  transition.	  
We	  also	  asked	  which	  genes	  that	  are	  differentially	  expressed	  across	  the	  time	  
course	  are	  also	  predicted	  targets	  of	  miR-­‐429.	  Out	  of	  the	  3635	  genes	  that	  were	  
differentially	  expressed	  over	  the	  time	  course,	  261	  (7.1%)	  of	  these	  were	  predicted	  as	  
targets	  of	  miR-­‐429	  by	  miRanda	  (Table	  4.3).	  Among	  these	  known	  differentially	  
expressed	  miR-­‐429	  targets	  were	  transcription	  factors	  ZEB1	  and	  ZEB2	  that	  were	  
observed	  to	  be	  significantly	  down	  regulated.	  ZEB1	  and	  ZEB2	  are	  transcription	  
factors	  that	  play	  a	  key	  role	  in	  EMT	  by	  binding	  to	  E-­‐box	  elements	  and	  directly	  
repressing	  E-­‐cadherin	  expression	  and	  polarity	  factor	  genes	  (Gregory	  et	  al.	  2008a;	  
Korpal	  et	  al.	  2008).	  Among	  the	  up-­‐regulated	  genes	  was	  TSPAN13	  (tetraspanin-­‐13)	  
(p-­‐value	  =	  2.24x10-­‐6),	  an	  epithelial	  marker	  over-­‐expressed	  in	  many	  known	  subtypes	  
of	  epithelial	  ovarian	  cancer	  and	  shown	  to	  mediate	  trans-­‐membrane	  signaling	  events	  
(Huang	  et	  al.	  2007;	  Martin	  et	  al.	  2009).	  The	  low	  fraction	  of	  differentially	  expressed	  
genes	  that	  are	  also	  predicted	  targets	  of	  miR-­‐429	  confirms	  our	  previous	  studies	  
showing	  equally	  low	  fractions	  and	  implying	  the	  majority	  of	  molecular	  and	  
phenotypic	  changes	  are	  indirect	  effects	  of	  miR-­‐429	  transfection	  (Chen	  et	  al.	  2011;	  
Shahab	  et	  al.	  2011).	  
	  
4.3.2	  Expression	  changes	  before	  and	  after	  the	  48-­‐hour	  mark	  
We	  observed	  that	  the	  magnitude	  of	  phenotypic	  and	  gene	  expression	  changes	  is	  
greatest	  at	  the	  48	  hour	  mark	  in	  our	  time	  course,	  therefore	  we	  have	  split	  the	  time	  
course	  into	  two	  time	  spans	  to	  show	  that	  statistically	  significant	  gene	  expression	  
Table	  4.3	  Genes	  targeted	  by	  miR-­429,	  as	  predicted	  by	  miRanda,	  that	  are	  differentially	  
expressed	  over	  the	  time	  course	  (0-­144	  hours)	  
These	  genes	  are	  differentially	  expressed	  across	  the	  time	  course	  (0-­‐144	  hours)	  by	  maSigPro	  
(FDR	  =	  0.05),	  and	  are	  predicted	  targets	  of	  miR-­‐429	  by	  miRanda.	  The	  fold	  change	  values	  
compare	  the	  miR-­‐429-­‐treated	  cells’	  average	  expression	  to	  the	  negative	  control-­‐treated	  cells’	  
average	  expression	  at	  each	  time	  point	  (24,	  48,	  and	  144	  hours).	  	  
  
Fold change in miR-
429 treated cells   
Probe ID Symbol 
24 
hours 
48 
hours 
144 
hours p-value R-squared 
207819_s_at ABCB4 -0.42 -0.62 -0.39 2.67E-09 0.90 
1552731_at ABRA -0.42 -0.44 -0.85 2.20E-04 0.61 
218658_s_at ACTR8 -0.24 -0.40 -0.54 3.15E-07 0.80 
1552519_at ACVR1C 0.08 0.30 0.47 1.99E-04 0.62 
202952_s_at ADAM12 1.02 1.50 -1.34 8.13E-07 0.82 
201346_at ADIPOR2 -0.83 -0.51 -0.13 2.34E-07 0.77 
202820_at AHR 0.62 0.36 -0.05 9.15E-06 0.67 
203180_at ALDH1A3 1.30 1.25 0.38 6.68E-05 0.71 
219649_at ALG6 0.44 0.10 -0.10 4.36E-05 0.67 
205621_at ALKBH1 0.13 -0.12 -0.33 5.43E-08 0.83 
205609_at ANGPT1 -1.24 -0.52 -0.78 5.12E-05 0.61 
206385_s_at ANK3 -0.20 -2.16 -0.05 7.68E-04 0.62 
1556361_s_at ANKRD13C 0.00 -0.09 -0.77 7.21E-07 0.78 
218158_s_at APPL1 1.42 1.04 0.01 5.91E-05 0.71 
205239_at AREG 1.56 2.02 0.52 3.56E-09 0.90 
203264_s_at ARHGEF9 0.98 0.96 0.09 5.51E-10 0.92 
221230_s_at ARID4B -0.02 -0.36 -0.36 2.34E-09 0.88 
202641_at ARL3 0.00 0.00 0.21 1.72E-05 0.70 
217852_s_at ARL8B 0.91 0.75 -0.09 2.58E-07 0.84 
218862_at ASB13 -1.18 -1.06 0.05 1.91E-09 0.88 
201855_s_at ATMIN -0.53 -0.82 -0.48 3.29E-06 0.70 
203188_at B3GNT1 -2.13 -1.03 -0.04 9.41E-08 0.79 
37549_g_at BBS9 -0.09 -0.51 -0.13 1.27E-05 0.66 
205433_at BCHE -0.53 -1.29 -0.08 1.83E-08 0.82 
203140_at BCL6 -0.56 -0.74 -0.21 5.98E-06 0.77 
203840_at BLZF1 0.88 0.89 0.01 1.63E-06 0.80 
201849_at BNIP3 -0.41 -0.16 0.02 7.38E-04 0.62 
218024_at BRP44L -0.55 -0.48 -0.36 2.45E-05 0.74 
205548_s_at BTG3 1.59 1.14 0.18 1.80E-04 0.67 
203944_x_at BTN2A1 -0.04 -0.44 0.03 1.25E-04 0.69 
217905_at C10orf119 0.36 -0.01 -0.54 2.91E-06 0.75 
218867_s_at C12orf49 -0.56 -0.32 -0.87 3.23E-07 0.76 
219099_at C12orf5 0.25 0.13 0.23 9.96E-09 0.86 
1552310_at C15orf40 0.37 0.29 -0.25 2.58E-05 0.74 
219439_at C1GALT1 0.67 0.85 -0.07 5.35E-07 0.83 
220992_s_at C1orf25 0.64 0.28 -0.01 1.73E-04 0.67 
219706_at C20orf29 -0.61 -0.14 -0.27 1.88E-05 0.70 
1552740_at C2orf15 0.40 0.89 0.06 6.36E-07 0.74 
Table 4.3 (continued) 
218646_at C4orf27 -0.73 -0.60 0.17 2.23E-10 0.88 
205500_at C5 0.05 0.10 -0.69 1.08E-04 0.64 
220032_at C7orf58 -0.33 -0.22 0.19 1.74E-04 0.67 
217873_at CAB39 1.17 0.59 -0.08 8.16E-05 0.70 
1552682_a_at CASC5 0.06 -0.04 -0.76 8.18E-05 0.65 
1554785_at CCDC82 0.66 0.71 -0.63 6.49E-04 0.62 
219226_at CDK12 0.08 0.05 -0.71 1.24E-10 0.91 
204604_at CDK14 1.48 1.51 -0.17 5.43E-05 0.71 
204029_at CELSR2 1.79 1.06 -0.12 6.38E-07 0.82 
218566_s_at CHORDC1 0.17 0.17 -0.34 2.38E-07 0.84 
219944_at CLIP4 0.20 0.14 0.49 1.98E-08 0.85 
203291_at CNOT4 -0.22 -0.23 -0.61 1.24E-04 0.64 
1552344_s_at CNOT7 -0.11 -0.48 -0.63 2.27E-06 0.76 
203642_s_at COBLL1 -0.04 -0.15 -0.34 6.01E-06 0.73 
211981_at COL4A1 0.05 0.26 0.20 5.36E-07 0.79 
203551_s_at COX11 -0.32 -0.02 -0.20 4.53E-08 0.84 
201117_s_at CPE 0.10 -0.84 -0.37 7.38E-09 0.89 
201990_s_at CREBL2 -0.13 -0.28 -0.24 5.07E-06 0.74 
205630_at CRH 0.20 0.60 0.30 2.23E-05 0.64 
201380_at CRTAP -1.69 -1.64 -0.11 1.92E-11 0.94 
220753_s_at CRYL1 -0.73 -0.64 -0.35 2.42E-05 0.64 
221139_s_at CSAD 0.09 0.50 -0.03 1.00E-03 0.60 
201112_s_at CSE1L 0.13 0.21 -0.04 4.22E-05 0.72 
219179_at DACT1 0.37 -0.41 0.66 5.14E-05 0.67 
202250_s_at DCAF8 0.12 -0.09 0.19 3.49E-10 0.90 
205399_at DCLK1 1.08 2.08 1.36 1.23E-12 0.94 
206752_s_at DFFB 0.96 0.14 -0.31 3.21E-04 0.65 
203791_at DMXL1 0.50 0.23 -0.19 5.71E-04 0.63 
213853_at DNAJC24 -0.88 -0.84 -0.01 2.12E-06 0.80 
208499_s_at DNAJC3 -0.76 -0.28 -0.15 5.79E-10 0.92 
205545_x_at DNAJC8 -1.32 -0.79 -0.15 5.90E-04 0.63 
217976_s_at DYNC1LI1 0.27 0.16 -0.06 3.55E-06 0.79 
202023_at EFNA1 0.31 0.45 0.53 3.45E-06 0.70 
208112_x_at EHD1 -1.18 -1.06 -0.15 1.80E-05 0.65 
201632_at EIF2B1 -0.34 -0.27 -0.07 1.10E-04 0.69 
220161_s_at EPB41L4B 0.47 0.03 0.09 2.91E-06 0.75 
206114_at EPHA4 -0.77 -1.12 -0.81 8.60E-04 0.61 
208394_x_at ESM1 -1.47 -1.23 0.47 6.21E-06 0.68 
219121_s_at ESRP1 0.80 2.68 0.74 6.32E-08 0.79 
207981_s_at ESRRG -0.48 -0.57 -0.23 1.64E-07 0.85 
201574_at ETF1 1.13 0.65 -0.07 4.23E-04 0.64 
1555355_a_at ETS1 -0.18 -0.29 -0.53 6.66E-08 0.74 
1569024_at FAM13A 0.09 -0.71 -0.68 2.00E-06 0.76 
218518_at FAM13B 0.68 -0.07 -0.71 3.86E-05 0.62 
1553749_at FAM76B 0.62 0.62 0.31 2.69E-04 0.66 
203420_at FAM8A1 -0.95 -0.44 0.42 7.50E-06 0.77 
Table 4.3 (continued) 
201911_s_at FARP1 -1.01 -0.58 -0.08 4.12E-05 0.62 
219901_at FGD6 1.85 2.03 1.21 7.79E-13 0.96 
203033_x_at FH 0.27 0.62 -0.01 3.59E-05 0.73 
218530_at FHOD1 -1.31 -0.64 0.02 2.24E-05 0.74 
204359_at FLRT2 0.06 -0.19 -0.65 8.65E-06 0.67 
205935_at FOXF1 -0.53 -1.46 -0.16 2.40E-04 0.66 
206377_at FOXF2 -0.31 -0.44 -0.38 1.70E-04 0.62 
202724_s_at FOXO1 0.90 0.61 -0.02 3.63E-08 0.87 
208475_at FRMD4A -0.31 -0.51 0.09 1.51E-06 0.81 
201564_s_at FSCN1 -0.59 -0.10 0.59 6.55E-09 0.87 
219683_at FZD3 0.51 0.52 -0.61 1.25E-05 0.66 
203706_s_at FZD7 1.30 0.41 0.16 6.61E-05 0.60 
218885_s_at GALNT12 -0.38 -1.14 -0.66 2.71E-06 0.79 
205848_at GAS2 0.03 -0.91 -0.77 1.77E-06 0.76 
203925_at GCLM -0.27 -0.62 -0.66 1.71E-07 0.81 
205498_at GHR -0.19 -0.12 -0.42 1.72E-05 0.70 
219467_at GIN1 0.27 0.38 0.00 2.91E-06 0.70 
201576_s_at GLB1 -0.47 -0.25 0.19 2.99E-06 0.79 
202382_s_at GNPDA1 -0.65 -0.47 -0.26 2.82E-05 0.73 
201057_s_at GOLGB1 -0.04 0.22 0.21 5.09E-06 0.74 
220264_s_at GPR107 -0.51 -1.99 -0.36 8.23E-06 0.77 
220265_at GPR107 -0.52 -1.68 -0.43 3.85E-05 0.72 
205862_at GREB1 -1.20 -1.55 -0.64 8.91E-07 0.82 
205930_at GTF2E1 -0.77 -1.19 -0.07 3.95E-08 0.80 
203138_at HAT1 0.31 0.15 0.06 7.11E-06 0.77 
202815_s_at HEXIM1 0.56 0.25 -0.30 1.68E-06 0.80 
205466_s_at HS3ST1 0.45 1.50 0.49 2.59E-05 0.63 
204569_at ICK 0.56 0.23 -0.37 2.89E-04 0.66 
206693_at IL7 -0.08 -0.61 -0.33 5.29E-08 0.83 
202859_x_at IL8 -1.14 -3.13 0.28 3.84E-06 0.79 
208193_at IL9 -0.17 -0.19 0.26 8.94E-05 0.70 
223681_s_at INADL 0.81 1.41 0.15 4.21E-07 0.75 
1559716_at INO80C 0.76 0.70 -0.38 1.81E-08 0.88 
218905_at INTS8 -0.36 -0.32 0.13 1.04E-06 0.81 
204686_at IRS1 0.42 0.86 0.02 2.72E-08 0.87 
204301_at KBTBD11 -0.13 -0.97 -0.63 4.28E-06 0.69 
219479_at KDELC1 -1.56 -1.55 -0.09 2.07E-08 0.81 
200040_at KHDRBS1 0.09 0.16 -0.05 3.41E-05 0.73 
203288_at KIAA0355 -0.17 -0.59 -0.14 1.34E-09 0.91 
219570_at KIF16B 1.06 0.33 -0.06 4.48E-05 0.72 
219657_s_at KLF3 0.87 1.42 0.84 3.71E-05 0.62 
221221_s_at KLHL3 0.22 -0.76 -0.75 7.84E-06 0.73 
218604_at LEMD3 0.52 0.49 -0.09 2.82E-07 0.84 
202594_at LEPROTL1 0.04 0.01 -0.32 1.30E-04 0.63 
218326_s_at LGR4 -0.07 0.00 0.28 1.93E-05 0.70 
218656_s_at LHFP -1.24 -2.09 -0.26 1.44E-11 0.91 
Table 4.3 (continued) 
219399_at LIN7C 0.19 -0.15 -0.47 1.84E-06 0.76 
1559433_at LOC149773 1.03 0.61 -0.64 1.12E-08 0.86 
204298_s_at LOX -0.80 -0.63 -0.46 5.32E-04 0.63 
218577_at LRRC40 -0.21 -0.68 0.03 4.65E-07 0.75 
203804_s_at LUC7L3 0.08 -0.38 0.07 2.11E-04 0.67 
206584_at LY96 -0.47 -1.39 -0.58 2.78E-08 0.81 
207292_s_at MAPK7 -1.02 -0.60 -0.13 4.48E-04 0.64 
206091_at MATN3 -0.85 -1.45 -0.39 1.24E-04 0.69 
220195_at MBD5 -0.10 -0.96 0.12 9.04E-04 0.61 
201930_at MCM6 0.12 0.17 -0.09 6.89E-05 0.71 
223780_s_at MED13 -0.66 -0.39 -0.55 1.85E-05 0.70 
202016_at MEST 1.20 0.94 0.06 1.03E-06 0.81 
1552312_a_at MFAP3 1.29 1.50 -0.51 3.11E-07 0.84 
218259_at MKL2 0.37 0.26 -0.36 2.72E-08 0.87 
217883_at MMADHC 0.31 0.30 0.09 1.50E-07 0.85 
219265_at MOBKL2B 0.31 0.69 -0.31 2.15E-08 0.88 
200600_at MSN -0.66 -0.51 0.28 2.03E-05 0.74 
216095_x_at MTMR1 0.05 -0.38 -0.08 6.49E-11 0.93 
221250_s_at MXD3 -0.24 -0.51 0.13 2.26E-06 0.80 
201798_s_at MYOF 0.15 0.17 0.29 2.15E-04 0.61 
204823_at NAV3 -0.11 -1.19 0.02 2.52E-05 0.69 
201384_s_at NBR1 -0.44 -0.43 0.15 3.35E-10 0.92 
207760_s_at NCOR2 -0.51 -0.37 -0.05 1.01E-05 0.67 
218266_s_at NCS1 -0.63 -0.48 -0.16 3.21E-04 0.65 
203039_s_at NDUFS1 0.07 0.11 0.16 4.85E-06 0.74 
219031_s_at NIP7 -0.32 -0.04 -0.43 9.48E-07 0.78 
218902_at NOTCH1 -0.08 -0.42 -0.11 2.09E-04 0.67 
202679_at NPC1 -0.21 -0.41 0.62 3.45E-10 0.92 
205440_s_at NPY1R 0.32 -0.24 -0.84 9.17E-06 0.72 
204791_at NR2C1 0.50 0.47 0.35 1.48E-04 0.68 
1560204_at NT5DC4 0.36 0.73 0.44 3.93E-04 0.64 
205729_at OSMR -0.28 0.00 -0.37 1.81E-04 0.62 
218196_at OSTM1 -2.09 -2.78 -0.66 9.77E-15 0.97 
219160_s_at PAPOLG -0.18 0.09 -0.45 2.30E-05 0.69 
205534_at PCDH7 0.38 0.87 -0.21 1.16E-05 0.66 
202731_at PDCD4 0.84 0.35 0.81 1.57E-04 0.63 
205078_at PIGF 0.37 0.46 -0.47 1.62E-06 0.80 
204269_at PIM2 -0.32 -0.73 -0.55 2.52E-08 0.87 
205570_at PIP4K2A -0.60 -0.32 0.08 2.02E-06 0.80 
201081_s_at PIP4K2B 0.10 0.24 -0.74 2.31E-05 0.74 
221027_s_at PLA2G12A 0.72 0.80 0.38 1.26E-10 0.93 
201682_at PMPCB 0.29 0.54 -0.11 7.81E-06 0.77 
205878_at POU6F1 -0.40 -0.56 0.05 6.31E-07 0.82 
219195_at PPARGC1A 0.48 0.63 -0.23 3.55E-05 0.73 
203063_at PPM1F -1.72 -1.69 -0.03 6.63E-12 0.91 
202166_s_at PPP1R2 0.71 0.42 0.08 5.25E-07 0.83 
Table 4.3 (continued) 
204507_s_at PPP3R1 0.34 -0.13 -0.39 2.79E-05 0.63 
208004_at PROL1 0.27 0.61 -0.09 5.11E-05 0.61 
218040_at PRPF38B 0.35 -0.37 -0.49 2.55E-05 0.69 
201053_s_at PSMF1 -0.19 -0.50 -0.53 3.22E-06 0.70 
219654_at PTPLA -0.29 -0.36 -0.31 7.14E-06 0.73 
205438_at PTPN21 -0.41 -0.83 -0.28 2.35E-04 0.61 
203884_s_at RAB11FIP2 -0.75 -0.76 0.03 4.70E-09 0.84 
203885_at RAB21 0.15 -0.38 -0.39 8.24E-06 0.72 
219210_s_at RAB8B -0.45 -0.58 -0.57 4.22E-07 0.83 
218668_s_at RAP2C -0.68 -0.95 0.03 2.31E-04 0.66 
203097_s_at RAPGEF2 -0.16 -0.95 -0.27 4.04E-05 0.62 
219286_s_at RBM15 -0.13 -0.29 -0.31 3.18E-05 0.63 
205407_at RECK -1.66 -1.87 -0.25 1.66E-06 0.72 
204365_s_at REEP1 -0.45 -0.30 -0.93 1.04E-07 0.82 
218430_s_at RFX7 0.07 0.26 -0.43 1.21E-04 0.69 
220483_s_at RNF19A -0.01 -0.21 -0.33 1.40E-04 0.63 
205215_at RNF2 -0.82 -0.70 -0.46 3.27E-06 0.70 
203161_s_at RNF8 -0.05 0.06 -0.49 1.29E-07 0.82 
204208_at RNGTT -0.14 -0.33 -0.03 4.50E-13 0.96 
1554080_at RQCD1 -0.34 -0.33 -0.20 1.75E-08 0.88 
218370_s_at S100PBP -0.43 -0.33 -0.04 1.68E-06 0.80 
202797_at SACM1L -0.15 -0.23 -0.05 8.12E-06 0.77 
218346_s_at SESN1 -1.03 -0.78 0.15 9.24E-06 0.76 
205933_at SETBP1 -0.40 -0.32 -0.86 5.74E-06 0.62 
201811_x_at SH3BP5 -0.08 0.08 0.66 8.05E-13 0.95 
219493_at SHCBP1 -2.10 -1.96 -0.30 2.79E-08 0.87 
219083_at SHQ1 -0.10 -0.35 -0.45 3.43E-08 0.87 
219159_s_at SLAMF7 -0.34 -0.55 -0.93 1.05E-09 0.89 
204404_at SLC12A2 -0.16 -0.27 -0.55 7.10E-05 0.66 
204462_s_at SLC16A2 -0.90 -1.46 -1.09 5.27E-05 0.61 
204587_at SLC25A14 0.38 0.34 -0.35 1.44E-04 0.68 
203306_s_at SLC35A1 1.18 1.11 0.22 1.51E-08 0.88 
207440_at SLC35A2 -0.96 -0.83 -0.07 1.87E-06 0.80 
207678_s_at SOX30 -0.42 0.00 -0.50 5.19E-09 0.87 
220456_at SPTLC3 0.35 0.34 -0.77 1.51E-06 0.77 
206095_s_at SRSF10 0.17 0.02 -0.35 1.41E-05 0.71 
217790_s_at SSR3 -0.63 -0.49 0.12 1.70E-08 0.82 
220979_s_at ST6GALNAC5 0.93 2.14 0.40 1.84E-10 0.93 
234140_s_at STIM2 0.47 0.40 -0.29 7.69E-04 0.62 
214512_s_at SUB1 0.11 0.21 0.30 4.15E-10 0.90 
201838_s_at SUPT7L 0.98 0.33 -0.35 3.85E-06 0.79 
219156_at SYNJ2BP 0.57 0.82 -0.14 5.85E-05 0.60 
200976_s_at TAX1BP1 0.18 0.39 0.24 2.91E-10 0.92 
219682_s_at TBX3 -0.05 -0.38 -0.59 4.41E-08 0.84 
202720_at TES 0.61 0.37 0.15 7.34E-04 0.62 
205016_at TGFA 1.62 1.67 0.48 9.31E-09 0.89 
Table 4.3 (continued) 
201506_at TGFBI -0.28 -0.40 -0.66 2.48E-04 0.61 
219122_s_at THG1L 0.14 -0.30 -0.42 9.18E-05 0.65 
219950_s_at TIAM2 0.31 0.71 0.36 2.99E-05 0.73 
203046_s_at TIMELESS 0.03 0.48 -0.25 4.33E-04 0.64 
1558487_a_at TMED4 -0.60 -1.02 -0.57 3.80E-07 0.76 
218962_s_at TMEM168 0.30 0.15 -0.17 3.44E-04 0.65 
218113_at TMEM2 2.08 1.95 0.11 1.46E-07 0.85 
217743_s_at TMEM30A 0.90 0.33 -0.01 9.56E-06 0.67 
219449_s_at TMEM70 0.32 0.12 -0.22 2.47E-09 0.90 
205611_at TNFSF12 -1.08 -1.01 -0.30 9.02E-09 0.89 
201519_at TOMM70A -0.33 -0.30 -0.16 1.07E-05 0.76 
203786_s_at TPD52L1 0.25 0.44 0.28 4.76E-08 0.87 
202478_at TRIB2 1.66 1.48 -0.32 2.94E-04 0.65 
217979_at TSPAN13 0.21 0.27 0.33 2.24E-06 0.76 
203894_at TUBG2 -0.27 0.35 0.55 1.20E-04 0.64 
222989_s_at UBQLN1 0.18 0.19 -0.17 2.85E-07 0.84 
215983_s_at UBXN8 -0.46 -0.90 -0.47 1.02E-07 0.78 
219960_s_at UCHL5 0.13 0.60 -0.07 1.47E-04 0.68 
218257_s_at UGGT1 -0.37 -0.13 -0.20 3.63E-06 0.75 
203583_at UNC50 -0.26 -0.28 -0.16 4.24E-05 0.72 
201672_s_at USP14 -0.14 -0.22 -0.19 6.19E-05 0.66 
1552678_a_at USP28 -0.21 -0.72 -0.74 1.72E-06 0.76 
1562238_at USPL1 -0.08 0.81 -0.02 7.24E-07 0.82 
202829_s_at VAMP7 -0.21 -0.41 0.01 1.70E-06 0.76 
219060_at WDYHV1 -0.45 -0.40 0.15 1.23E-04 0.69 
206067_s_at WT1 -0.05 -0.27 -0.71 3.82E-09 0.87 
206537_at XIAP 0.02 -0.04 -0.46 2.53E-04 0.61 
218753_at XKR8 -1.35 -1.22 -0.30 6.18E-06 0.68 
210813_s_at XRCC4 0.61 1.36 0.21 6.71E-09 0.89 
205340_at ZBTB24 -0.19 -0.03 -0.50 1.39E-04 0.63 
1554470_s_at ZBTB44 0.61 0.70 0.06 5.19E-04 0.63 
221193_s_at ZCCHC10 0.12 -0.11 -0.29 7.26E-07 0.78 
218249_at ZDHHC6 -0.03 -0.30 -0.17 5.83E-07 0.82 
212764_at ZEB1 -1.29 -1.72 -0.14 1.33E-07 0.78 
239952_at ZEB1 -1.17 -1.36 -0.20 1.33E-05 0.66 
203603_s_at ZEB2 -0.43 -1.12 -0.33 2.14E-05 0.74 
1553736_at ZFC3H1 -0.05 -0.57 -0.53 4.51E-07 0.75 
219778_at ZFPM2 -0.86 -1.09 -0.44 5.71E-08 0.80 
207920_x_at ZFX 0.27 0.24 -0.63 1.92E-05 0.70 
207753_at ZNF304 -0.30 -0.34 -0.12 3.32E-08 0.87 
1553718_at ZNF548 0.30 -0.74 -1.25 3.51E-07 0.80 
1553719_s_at ZNF548 0.15 -0.72 -0.55 1.98E-07 0.81 
	  
	  
	  
	  
changes	  are	  occurring	  around	  this	  time	  point	  even	  when	  each	  span	  is	  considered	  by	  
itself:	  0	  to	  48	  hours	  and	  48	  to	  144	  hours.	  Here	  we	  used	  a	  linear	  model	  time	  course	  
fitting	  to	  determine	  which	  genes	  are	  differentially	  expressed,	  treating	  each	  time	  
span	  as	  a	  separate	  time	  course	  and	  correcting	  for	  the	  gene	  expression	  change	  
observed	  in	  our	  negative	  control-­‐treated	  cells.	  
4.3.2.1	  Expression	  changes	  between	  0	  to	  48	  hours	  
Across	  the	  0	  to	  48	  hour	  time	  span,	  1339	  genes	  in	  the	  miR-­‐429-­‐treated	  cells	  were	  
differentially	  expressed	  (FDR	  <	  0.1)	  compared	  to	  the	  negative	  control-­‐treated	  cells	  
(Table	  4.4).	  Among	  these	  are	  FN1,	  a	  mesenchymal	  marker	  that	  was	  down	  regulated.	  
CAV2	  and	  DSP,	  both	  epithelial	  markers,	  were	  up	  regulated.	  β-­catenin,	  required	  for	  
the	  creation	  of	  epithelial	  cell	  layers,	  was	  also	  up	  regulated.	  MMP9,	  involved	  in	  the	  
breakdown	  of	  basement	  membranes	  in	  EMT,	  was	  down	  regulated.	  SMAD7	  is	  down	  
regulated.	  ZEB1	  and	  ZEB2	  were	  both	  down	  regulated.	  Gene	  set	  enrichment	  analysis	  
showed	  that	  the	  significantly	  differentially	  expressed	  genes	  across	  this	  time	  span	  
were	  significantly	  enriched	  for	  gene	  sets	  related	  to	  the	  regulation	  of	  EMT,	  
extracellular	  matrix	  (ECM)	  remodeling,	  cell	  adhesion,	  TGF-­‐β-­‐dependent	  induction	  of	  
EMT	  via	  RhoA,	  PI3K,	  and	  ILK,	  the	  EGFR	  signaling	  pathway,	  and	  others	  (Figure	  4.6).	  
Out	  of	  the	  total	  of	  1339	  differentially	  expressed	  genes	  118	  (8.8%)	  differentially	  
expressed	  genes	  were	  predicted	  targets	  of	  miR-­‐429	  by	  miRanda.	  Among	  these	  are	  
ZEB1,	  ZEB2	  and	  MSN	  (moesin).	  
4.3.2.2	  Expression	  changes	  between	  48	  to	  144	  hours	  
Across	  the	  48-­‐144	  hour	  time	  span,	  772	  genes	  in	  miR-­‐429-­‐treated	  cells	  were	  
differentially	  expressed	  (FDR	  =	  0.1)	  compared	  to	  the	  negative	  control-­‐treated	  cells	  
Table	  4.4	  Selected	  genes	  differentially	  expressed	  in	  the	  miR-­429	  treated	  cells	  during	  the	  0	  to	  
48	  hour	  time	  span	  
These	  selected	  genes	  are	  those	  that	  are	  known	  to	  be	  involved	  in	  EMT	  or	  MET	  processes,	  are	  
differentially	  expressed	  across	  the	  MET-­‐like	  time	  span	  (0-­‐48	  hours)	  by	  Limma	  (FDR	  =	  0.1).	  
The	  fold	  change	  values	  compare	  the	  miR-­‐429-­‐treated	  cells’	  average	  expression	  to	  the	  
negative	  control-­‐treated	  cells’	  average	  expression	  at	  each	  time	  point	  (24,	  48,	  and	  144	  
hours).	  	  
  
Fold change in 
miR-429 treated 
cells  
0-48 hour time 
span 
ID Symbol 
24 
hours 
48 
hours 
144 
hours p-value 
1552721_a_at FGF1 0.81 0.96 -0.41 0.001634427 
1558683_a_at HMGA2 -1.20 -0.06 -0.01 0.000131942 
1561633_at HMGA2 -0.92 -0.14 0.00 0.000717811 
1568765_at SERPINE1 -2.48 -0.83 -0.51 0.000303968 
200606_at DSP 1.20 1.49 0.86 1.78E-06 
201533_at CTNNB1 0.90 0.78 -0.01 0.00213969 
202011_at TJP1 1.04 0.89 0.04 2.82E-05 
202627_s_at SERPINE1 -0.78 0.11 0.99 0.000742481 
203323_at CAV2 2.21 2.21 0.67 6.45E-09 
203324_s_at CAV2 0.69 0.95 0.35 0.001389587 
203603_s_at ZEB2 -0.43 -1.12 -0.33 0.001528935 
203780_at MPZL2 -0.14 1.00 0.22 0.001227715 
203936_s_at MMP9 -0.16 -1.08 -0.23 0.002371341 
204422_s_at FGF2 1.62 1.71 -0.04 1.40E-07 
204619_s_at VCAN 0.89 0.92 0.22 0.000139842 
204620_s_at VCAN 0.95 0.95 0.14 0.002186291 
204790_at SMAD7 0.82 -0.14 -0.82 0.000517814 
205014_at FGFBP1 1.94 1.60 2.79 2.93E-07 
205122_at TMEFF1 0.40 -0.80 0.14 0.001217298 
209552_at PAX8 -1.10 -0.04 0.38 0.00327345 
209875_s_at SPP1 -0.10 -1.03 -0.38 0.001039589 
210495_x_at FN1 -1.65 -2.70 -0.13 2.71E-09 
211719_x_at FN1 -1.70 -2.66 -0.12 1.24E-09 
212464_s_at FN1 -1.68 -2.76 -0.05 2.72E-09 
212764_at ZEB1 -1.29 -1.72 -0.14 4.75E-06 
213891_s_at TCF4 -0.48 -0.74 -0.26 0.00195207 
214702_at FN1 -0.67 -1.66 -0.33 0.002989896 
216442_x_at FN1 -1.58 -2.63 -0.11 5.79E-09 
221029_s_at WNT5B -1.33 -1.14 -0.23 0.001165162 
221731_x_at VCAN 0.65 0.97 0.18 0.001740123 
228333_at ZEB2 -1.21 -0.51 -0.25 0.001361533 
239952_at ZEB1 -1.17 -1.36 -0.20 0.001502772 
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(Table	  4.5).	  Among	  these	  are	  fibronectin	  (FN1)	  and	  ZEB1	  that	  were	  up	  regulated	  
during	  this	  time	  span.	  FGF1,	  FGF2,	  and	  CAV2	  were	  down	  regulated.	  Gene	  set	  
enrichment	  analysis	  showed	  that	  the	  significantly	  differentially	  expressed	  genes	  
across	  this	  time	  span	  were	  significantly	  enriched	  for	  gene	  sets	  related	  to	  the	  
regulation	  of	  EMT,	  TGF-­‐β-­‐dependent	  induction	  of	  EMT	  via	  RhoA,	  PI3K,	  and	  ILK,	  
chemokines	  and	  adhesion,	  the	  EGFR	  signaling	  pathway,	  IL-­15	  signaling,	  IL-­1	  
signaling,	  PEDF	  signaling,	  and	  others	  (Figure	  4.6).	  Out	  of	  the	  772	  genes	  that	  were	  
differentially	  expressed	  across	  the	  48-­‐144	  time	  span,	  59	  (7.6%)	  differentially	  
expressed	  genes	  were	  predicted	  targets	  of	  miR-­‐429	  by	  miRanda.	  Among	  these	  are	  
ZEB1	  and	  MSN	  (moesin).	  
	   Immune	  response	  pathways	  are	  strongly	  represented	  in	  the	  gene	  set	  
enrichments	  for	  both	  time	  spans,	  due	  in	  large	  part	  to	  the	  differential	  expression	  of	  
IL1β,	  IL6,	  IL8,	  and	  MAPK	  proteins	  that	  are	  part	  of	  the	  EMT	  pathway.	  The	  three	  
interleukins	  are	  all	  down	  regulated	  by	  48	  hours	  and	  have	  previously	  been	  noted	  to	  
be	  potential	  inducers	  and	  maintainers	  of	  EMT	  through	  autocrine	  loops	  (Lee	  et	  al.	  
2004a;	  Palena	  et	  al.	  2012;	  Xie	  et	  al.	  2012).	  	  
	  
4.3.3.	  Regulation	  of	  EMT	  through	  TGF-­‐β/Smads/MAPK	  signaling	  axis	  
One	  of	  our	  primary	  interests	  in	  miR-­‐429	  is	  its	  impact	  on	  the	  regulation	  of	  EMT	  and	  
its	  potential	  role	  in	  altering	  the	  diverse	  signaling	  pathways	  leading	  to	  EMT.	  In	  our	  
enrichment,	  we	  see	  up-­‐regulation	  of	  TGF-­‐β	  signaling	  components,	  as	  well	  as	  up-­‐
regulation	  of	  downstream	  elements	  such	  as	  MAPK,	  SMAD	  family	  member	  proteins,	  
and	  PI3K	  that	  are	  important	  in	  TGF-­‐β-­‐dependent	  induction	  of	  EMT	  (Massague	  2000;	  
Table	  4.5	  Selected	  genes	  differentially	  expressed	  in	  the	  miR-­429	  treated	  cells	  during	  the	  48	  to	  
144	  hour	  time	  span	  
These	  selected	  genes	  are	  those	  that	  are	  known	  to	  be	  involved	  in	  EMT	  or	  MET	  processes,	  are	  
differentially	  expressed	  across	  the	  EMT-­‐like	  time	  span	  (48-­‐144	  hours)	  by	  Limma	  (FDR	  =	  
0.1).	  The	  fold	  change	  values	  compare	  the	  miR-­‐429-­‐treated	  cells’	  average	  expression	  to	  the	  
negative	  control-­‐treated	  cells’	  average	  expression	  at	  each	  time	  point	  (24,	  48,	  and	  144	  
hours).	  	  
	  
  
Fold change in miR-429 
treated cells 
 Time span 
ID Symbol 
24 
hours 
48 
hours 
144 
hours p-value 
1552721_a_at FGF1 0.81 0.96 -0.41 7.98E-05 
200600_at MSN -0.66 -0.51 0.28 0.00129774 
201389_at ITGA5 -0.63 -0.41 0.45 0.00165984 
202011_at TJP1 1.04 0.89 0.04 0.000560457 
202627_s_at SERPINE1 -0.78 0.11 0.99 0.001365373 
203323_at CAV2 2.21 2.21 0.67 5.79E-06 
204422_s_at FGF2 1.62 1.71 -0.04 4.32E-06 
205014_at FGFBP1 1.94 1.60 2.79 0.001405309 
205122_at TMEFF1 0.40 -0.80 0.14 0.000856437 
210495_x_at FN1 -1.65 -2.70 -0.13 2.04E-08 
211719_x_at FN1 -1.70 -2.66 -0.12 1.95E-08 
212464_s_at FN1 -1.68 -2.76 -0.05 1.08E-08 
212758_s_at ZEB1 -1.54 -1.54 -0.07 0.000615458 
212764_at ZEB1 -1.29 -1.72 -0.14 3.89E-06 
216442_x_at FN1 -1.58 -2.63 -0.11 2.39E-08 
220016_at AHNAK -0.63 -0.35 0.95 0.000141059 
221729_at COL5A2 0.05 -0.61 0.21 0.000594582 
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
	  
Zavadil	  and	  Bottinger	  2005;	  Bierie	  and	  Moses	  2006).	  Included	  in	  this	  pathway	  are	  
epithelial	  markers	  DSP,	  KRT19,	  and	  KRT8	  that	  are	  up-­‐regulated,	  and	  mesenchymal	  
markers	  COL1A1,	  FN1,	  and	  TPM1	  that	  are	  down-­‐regulated	  (Table	  4.6).	  	  
4.3.3.1	  TGF-­β	  signaling	  
The	  signaling	  pathways	  involved	  in	  EMT	  include	  TGF-­β	  and	  its	  downstream	  
transcription	  factors	  and	  signaling	  proteins.	  Members	  of	  the	  TGF-­‐β	  family	  are	  
known	  major	  inducers	  and	  maintainers	  of	  EMT	  in	  carcinoma,	  although	  in	  normal	  
cells	  they	  suppress	  cell	  proliferation	  and	  are	  involved	  in	  the	  induction	  of	  apoptosis	  
(Shipley	  et	  al.	  1985;	  Derynck	  et	  al.	  1987;	  Massague	  2008).	  In	  our	  study,	  TGF-­β2	  is	  up	  
regulated	  across	  the	  time	  course,	  as	  is	  the	  transmembrane	  receptor	  TGF-­βR1.	  
Malignant	  cells	  are	  able	  to	  circumvent	  the	  tumor-­‐suppressive	  effects	  of	  the	  TGF-­‐β	  
pathway	  by	  either	  inactivating	  TGF-­β	  or	  its	  receptor,	  or	  altering	  downstream	  
elements	  that	  are	  responsible	  for	  tumor	  suppression	  (Massague	  2008).	  Hey	  cells,	  
despite	  their	  derivation	  from	  the	  surface	  epithelia	  of	  human	  ovarian	  carcinoma,	  are	  
known	  to	  have	  functional	  TGF-­β	  and	  TGF-­β	  receptor	  expression	  by	  PCR	  and	  affinity	  
radio-­‐labeling	  (Jindal	  et	  al.	  1995).	  	  Since	  TGF-­‐β	  pathway	  components	  are	  unaltered	  
in	  Hey	  cells,	  the	  up-­‐regulation	  of	  TGF-­β	  is	  able	  to	  contribute	  to	  the	  induction	  of	  the	  
epithelial	  phenotype.	  
4.3.3.2	  Smads	  signaling	  
TGF-­‐β	  is	  known	  to	  propagate	  its	  signal	  via	  receptor-­‐regulated	  SMADs	  (Mothers	  
against	  decapentaplegic)	  family	  signal	  transducer	  proteins.	  In	  our	  miR-­‐429	  treated	  
samples,	  SMAD2	  and	  SMAD7	  were	  significantly	  down-­‐regulated.	  When	  TGF-­‐β	  is	  
bound,	  the	  TGF-­‐β	  II	  receptor	  activates	  the	  TGF-­‐βI	  receptor	  that	  is	  capable	  of	  
Table	  4.6	  Genes	  associated	  with	  regulation	  of	  the	  epithelial-­mesenchymal	  transition	  that	  are	  
differentially	  expressed	  over	  the	  time	  course	  (0-­144	  hours)	  
These	  selected	  genes	  are	  those	  that	  are	  known	  to	  be	  involved	  in	  EMT	  regulation	  and	  are	  
differentially	  expressed	  across	  the	  time	  course	  (0-­‐144	  hours)	  by	  maSigPro	  (FDR	  =	  0.05).	  
The	  fold	  change	  values	  compare	  the	  miR-­‐429-­‐treated	  cells’	  average	  expression	  to	  the	  
negative	  control-­‐treated	  cells’	  average	  expression	  at	  each	  time	  point	  (24,	  48,	  and	  144	  
hours).	  	  
 
Fold change in miR-429 
treated cells 
 Time course 
Symbol 24 hours 48 hours 
144 
hours p-value 
ACTG1 0.13 0.09 0.25 3.09E-08 
ADAM17 0.32 0.47 0.29 9.34E-06 
AKT2 -0.52 -0.46 0.01 5.53E-06 
AKT3 0.09 0.51 0.34 3.71E-10 
BCL2 0.43 0.09 -0.63 9.03E-06 
BMP2 -0.36 -0.52 0.27 1.36E-07 
CBL 0.10 0.26 -0.67 2.47E-06 
CDC42 -0.40 -0.13 0.11 2.93E-06 
CDH2 0.27 0.05 -0.14 0.000233764 
CFL1 0.95 0.18 0.56 2.56E-05 
CFL2 -1.24 -1.03 -0.21 2.93E-06 
CFL2 -2.28 -1.91 -0.15 3.46E-11 
CFL2 -1.84 -1.54 0.00 4.93E-06 
COL1A1 -0.56 -0.80 -0.42 5.60E-09 
COL1A1 -0.04 -0.39 -0.32 2.99E-09 
DSP 1.20 1.49 0.86 3.76E-10 
EGFR 0.03 -0.10 0.47 0.000228239 
ETS1 -0.18 -0.29 -0.53 6.66E-08 
FGF1 0.81 0.96 -0.41 2.33E-10 
FGF2 1.29 0.53 0.01 1.92E-08 
FGF2 1.62 1.71 -0.04 6.91E-12 
FGFR1 -0.24 -0.26 -0.48 2.84E-05 
FGG -0.40 -0.34 0.03 0.000370961 
FN1 -1.65 -2.70 -0.13 2.53E-06 
FN1 -1.70 -2.66 -0.12 1.31E-06 
FN1 -1.68 -2.76 -0.05 4.03E-06 
FN1 -0.67 -1.66 -0.33 7.10E-05 
FN1 -1.58 -2.63 -0.11 4.54E-06 
FOS 0.98 1.05 0.02 4.08E-05 
FOSL2 0.68 0.34 -0.25 0.000753844 
FRS2 0.32 0.55 -0.65 5.40E-05 
FRS2 0.18 -0.11 -0.81 2.78E-06 
Table 4.6 (continued) 
FZD1 0.22 -0.09 -0.33 2.19E-05 
FZD3 0.51 0.52 -0.61 1.25E-05 
FZD5 1.96 1.44 0.15 3.47E-05 
FZD7 1.02 0.47 0.02 8.02E-06 
FZD7 1.30 0.41 0.16 6.61E-05 
GAB2 -0.18 -0.86 0.22 4.13E-07 
GNAI1 0.33 0.35 -0.30 8.71E-06 
GNAQ 0.35 0.19 -0.09 0.001023096 
GSK3B 0.21 -0.03 -0.35 4.73E-10 
HIF1A 0.35 0.33 0.08 2.91E-07 
HMGA2 -0.92 -0.14 0.00 1.64E-05 
HMGA2 0.17 -0.36 -0.20 8.88E-16 
HSD17B2 -0.05 -1.08 -0.22 6.24E-09 
IKBKB -0.49 -0.89 -0.16 1.40E-10 
IL1B -1.65 -1.45 1.25 3.31E-05 
IL1B -1.59 -1.50 1.28 5.90E-06 
IL6ST 0.12 -0.25 -0.48 1.55E-11 
IL6ST -0.80 -0.49 0.19 1.22E-06 
ITGB1 -0.70 -0.93 -1.13 2.26E-06 
ITGB3 -0.63 -0.91 -0.26 6.94E-05 
KRT18 0.01 0.71 0.50 7.04E-05 
KRT8 0.29 0.90 0.68 9.49E-06 
LEF1 0.51 0.14 -0.77 5.79E-08 
LIFR 0.31 0.58 0.15 0.000851456 
LIMS1 -0.61 -0.42 -0.10 0.000780253 
LOX -0.80 -0.63 -0.46 0.000532485 
LOX -2.09 -2.73 -0.37 1.59E-11 
LOXL2 0.43 0.71 0.15 9.26E-12 
MAP2K3 0.00 0.22 0.20 0.000112092 
MAPK1 -0.01 -0.09 -0.26 5.01E-07 
MAPK14 -0.07 0.34 -0.16 0.000186127 
MAPK8 0.66 0.55 -0.26 5.76E-07 
MAPK8 1.53 1.12 -0.09 5.87E-05 
MAPK8 0.64 0.69 -0.28 1.70E-07 
MAPK8 0.94 0.99 -0.26 3.34E-07 
MAPK9 0.28 0.24 -0.12 2.44E-15 
MET 0.39 0.12 0.26 4.75E-05 
MKL2 0.37 0.26 -0.36 2.72E-08 
NES -0.57 -0.63 0.26 6.11E-06 
NFKBIA -0.04 -0.86 0.11 6.64E-10 
NOG 0.14 0.42 0.05 7.38E-05 
Table 4.6 (continued) 
NOTCH1 -0.08 -0.42 -0.11 0.000209242 
NOTCH4 -0.27 -0.44 0.06 2.80E-06 
NOX4 -0.04 -0.28 -1.04 4.28E-11 
NOX4 0.24 -0.29 -0.88 5.91E-06 
OSMR -0.28 0.00 -0.37 0.000181366 
PDPK1 0.53 0.78 -0.12 7.44E-05 
PIK3CD -0.36 -0.71 0.31 6.77E-10 
PPP3R1 0.34 -0.13 -0.39 2.79E-05 
PTEN -0.19 -0.10 -0.41 6.76E-07 
PTEN 0.44 0.29 -0.29 2.02E-06 
PTK2 0.17 0.27 0.07 0.000151619 
SERPINE1 -0.78 0.11 0.99 3.25E-06 
SMAD2 -0.49 -0.59 0.07 3.55E-09 
SMAD2 -0.28 -0.52 -0.23 0.000342423 
SMAD7 0.82 -0.14 -0.82 1.61E-07 
SOS1 -0.06 -0.22 -0.36 1.28E-07 
STAT1 0.04 -0.33 -0.17 1.26E-06 
STAT3 1.24 1.71 0.46 4.22E-12 
TCF3 -0.26 -0.17 -0.15 4.81E-05 
TCF3 -0.33 -0.21 -0.19 3.77E-05 
TCF3 -0.24 -0.21 -0.21 0.000526648 
TGFB1I1 -1.25 -0.76 0.04 6.28E-05 
TGFB2 1.31 0.67 -1.39 1.64E-10 
TGFB2 1.37 0.99 -0.83 2.32E-07 
TGFBR1 0.62 0.33 0.01 0.000396257 
TJP1 1.04 0.89 0.04 0.00108346 
TPM1 -0.43 -1.82 -0.62 5.55E-05 
TPM1 -0.63 -1.04 -0.34 0.000357113 
WNT10A -0.35 -0.48 -0.41 0.000354227 
WNT7A 0.39 1.71 1.85 5.34E-08 
ZEB1 -1.29 -1.72 -0.14 1.33E-07 
ZEB1 -1.17 -1.36 -0.20 1.33E-05 
ZEB2 -0.43 -1.12 -0.33 2.14E-05 
	  
	  
	  
	  
	  
	  
	  
phosphorylating	  Smads.	  Receptor-­‐phosphorylated	  Smads	  are	  then	  capable	  of	  
binding	  partner	  Smads	  and	  freely	  move	  into	  the	  nucleus	  where	  it	  can	  interact	  with	  
gene	  regulatory	  sites	  (Massague	  2000).	  Valcourt	  et	  al.	  examined	  the	  key	  regulatory	  
role	  of	  SMADs	  in	  TGF-­‐β-­‐dependent	  EMT	  using	  dominant-­‐negative	  forms	  of	  SMADs	  
and	  a	  TGF-­‐β	  I	  receptor	  that	  was	  incapable	  of	  activating	  SMADs	  or	  inducing	  EMT	  
alone,	  showing	  that	  SMAD	  signaling	  has	  a	  critical	  role	  in	  activating	  the	  signaling	  
network	  that	  induces	  EMT	  (Valcourt	  et	  al.	  2005).	  SMAD2	  may	  also	  serve	  to	  maintain	  
the	  epithelial	  phenotype,	  as	  suggested	  by	  studies	  where	  SMAD2	  knockout	  mouse	  
hepatocytes	  spontaneously	  transition	  to	  the	  mesenchymal	  phenotype	  when	  TGF-­‐β	  is	  
absent	  (Zavadil	  and	  Bottinger	  2005).	  SMAD7	  acts	  as	  an	  inhibitor	  of	  TGF-­‐β	  signaling,	  
where	  SMAD7	  down-­‐regulation	  by	  	  miR-­‐106b-­‐25	  has	  been	  shown	  to	  increase	  TGF-­‐β	  
signaling,	  inducing	  EMT	  in	  breast	  cancer	  cells	  (Smith	  et	  al.	  2012;	  Xia	  et	  al.	  2013).	  
4.3.3.3	  MAPK	  signaling	  
A	  number	  of	  mitogen-­‐activated	  protein	  kinases	  (MAPKs)	  are	  also	  differentially	  up	  
regulated	  in	  our	  miR-­‐429	  treated	  samples,	  including	  ERK2	  (MAPK1),	  JNK1	  (MAPK8),	  
MKK3	  (MAP2K3),	  and	  p38-­‐α	  (MAPK14).	  Although	  the	  canonical	  TGF-­‐β	  pathway	  does	  
not	  involve	  MAPK,	  there	  is	  strong	  evidence	  for	  signaling	  crosstalk	  between	  TGF-­‐β	  
signaling	  and	  the	  MAPK	  pathway	  in	  the	  induction	  of	  EMT	  (Yu	  et	  al.	  2002;	  Javelaud	  
and	  Mauviel	  2005).	  Specifically,	  when	  ERK	  activity	  is	  inhibited	  in	  human	  
keratinocytes	  in	  the	  presence	  of	  TGF-­‐β,	  the	  disassembly	  of	  adherens	  junctions	  and	  
subsequent	  cell	  mobility	  associated	  with	  EMT	  was	  also	  inhibited	  (Zavadil	  et	  al.	  
2001).	  Moreover	  in	  TGF-­‐β	  responsive	  mouse	  mammary	  epithelial	  cells,	  inhibition	  of	  
p38	  with	  SB203580	  completely	  blocks	  EMT,	  suggesting	  that	  TGF-­‐β-­‐activated	  p38	  
MAPK	  is	  required	  for	  EMT	  (Yu	  et	  al.	  2002).	  Likewise	  in	  mouse	  keratinocytes,	  
inhibition	  of	  c-­‐Jun	  N-­‐terminal	  kinase	  1	  (JNK1)	  with	  antisense	  oligonucleotides	  or	  
JNK	  inhibitor	  SP600125	  results	  in	  the	  suppression	  of	  fibronectin,	  and	  vimentin	  even	  
when	  exposed	  to	  TGF-­‐β1	  (Santibanez	  2006).	  	  Additionally,	  when	  normal	  mouse	  
keratinocytes	  are	  exposed	  to	  TGF-­‐β	  1,	  E-­‐cadherin	  is	  delocalized	  and	  lost	  from	  cell	  
contacts.	  This	  effect	  no	  longer	  occurs	  when	  JNK	  antisense	  oligonucleotides	  or	  
inhibitor	  is	  added,	  indicating	  JNK’s	  importance	  in	  TGF-­‐β-­‐induced	  EMT.	  Our	  finding	  
of	  up-­‐regulated	  MAPK	  in	  our	  miR-­‐429	  treated	  sample	  appears	  to	  contradict	  their	  
role	  in	  promoting	  EMT,	  as	  MAPK	  expression	  peaks	  at	  the	  same	  time	  our	  miR-­‐429	  
treated	  cells	  display	  the	  strongest	  epithelial	  phenotype.	  This	  may	  be	  explained	  by	  
the	  down-­‐regulation	  of	  integrin	  β1	  (ITGB1)	  in	  our	  miR-­‐429	  treated	  cells.	  ITGB1	  
signaling	  is	  known	  to	  be	  necessary	  for	  TGF-­‐β-­‐activation	  of	  p38	  MAPK	  leading	  to	  EMT	  
in	  mouse	  mammary	  epithelial	  cells	  (Bhowmick	  et	  al.	  2001).	  
4.3.3.4	  TGF-­β/Smads/MAPK	  signaling	  before	  and	  after	  the	  48	  hour	  mark	  
Because	  of	  the	  apparent	  cyclic	  nature	  of	  expression	  levels	  and	  the	  change	  in	  cell	  
morphology	  from	  mesenchymal-­‐like	  to	  epithelial-­‐like	  and	  back	  again,	  we	  
hypothesize	  that	  the	  same	  pathways	  we	  observe	  being	  differentially	  expressed	  from	  
0	  to	  48	  hours	  then	  return	  to	  their	  original	  expression	  levels	  between	  48	  to	  144	  
hours.	  Thus	  it	  is	  not	  a	  different	  set	  of	  pathways	  that	  are	  responsible	  for	  returning	  
these	  Hey	  cells	  to	  a	  mesenchymal-­‐like	  state.	  To	  this	  end	  we	  examined	  the	  
significantly	  enriched	  TGF-­‐β/Smads/MAPK	  pathways	  and	  their	  constituents	  in	  each	  
time	  span.	  
4.3.3.4.1	  TGF-­β	  signaling	  
We	  examined	  the	  TGF-­‐β	  pathway	  because	  of	  its	  strong	  involvement	  in	  both	  EMT	  
signaling	  in	  carcinoma	  and	  maintenance	  of	  epithelial	  characteristics	  in	  normal	  cells.	  
In	  our	  study,	  signaling	  cytokine	  TGF-­β2	  is	  differentially	  expressed	  in	  both	  time	  
spans.	  	  It	  is	  up	  regulated	  during	  the	  0-­‐48	  hour	  and	  down	  regulated	  during	  the	  48-­‐
144	  hour	  time	  courses.	  At	  24	  hours	  post-­‐transfection	  the	  fold	  change	  of	  expression	  
levels	  for	  TGF-­β2	  in	  miR-­‐429	  treated	  cells	  compared	  to	  negative-­‐control-­‐treated	  
cells	  is	  at	  its	  highest	  across	  the	  entire	  144	  hour	  observation	  period.	  Additionally	  
TGF-­‐β	  receptor	  type	  II	  is	  up	  regulated	  in	  the	  0-­‐48	  hour	  span.	  	  
4.3.3.4.2	  Smads	  and	  MAPK	  signaling	  
When	  examining	  downstream	  pathways	  from	  TGF-­‐β	  receptor	  signaling,	  SMADs	  
were	  not	  differentially	  expressed	  in	  either	  time	  span,	  but	  elements	  of	  the	  MAPK	  
pathway	  for	  EMT	  were	  differentially	  expressed,	  including	  MAPK1	  (ERK1/2),	  MAPK8	  
(JNK),	  MAPK11	  (p38	  MAPK),	  and	  MAP3K7	  (TAK1).	  	  ERK1/2,	  p38	  MAPK,	  and	  JNK	  were	  
significantly	  up	  regulated	  during	  the	  0-­‐48	  hour	  time	  span,	  while	  only	  JNK	  was	  
significantly	  down	  regulated	  during	  the	  48-­‐144	  hour	  time	  span.	  In	  the	  case	  of	  JNK,	  
both	  the	  expression	  values	  and	  fold	  changes	  appeared	  to	  reach	  a	  maximum	  at	  24	  
hours.	  TAK1	  and	  ERK1/2	  have	  peak	  expression	  at	  48	  hours,	  but	  have	  fold	  change	  
peaks	  at	  24	  hours.	  p38	  MAPK	  was	  significantly	  down	  regulated	  during	  the	  0-­‐48	  hour	  
time	  span.	  While	  the	  up-­‐regulation	  of	  MAPK	  elements	  suggests	  an	  increased	  role	  in	  
signaling,	  without	  information	  on	  the	  phosphorylation	  status	  of	  MAPKs	  its	  effect	  on	  
EMT/MET	  is	  ambiguous.	  
	   	  
4.3.3.4.3	  FGF1	  and	  FGF2	  signaling	  
FGF1	  (heparin-­‐binding	  growth	  factor	  1),	  which	  was	  detected	  at	  the	  edge	  of	  
nephrogenic	  growth	  zones	  where	  mesenchyme	  transitioned	  into	  epithelium,	  is	  
thought	  to	  promote	  MET	  in	  renal	  development	  (Cancilla	  et	  al.	  1999).	  In	  our	  miR-­‐429	  
treated	  cells,	  FGF1	  was	  up-­‐expressed	  during	  the	  0-­‐48	  hour	  time	  span,	  and	  down-­‐
expressed	  during	  the	  48-­‐144	  hour	  time	  span,	  and	  showed	  a	  fold	  change	  peak	  at	  48	  
hours.	  Ramos	  et	  al.	  showed	  that	  FGF1	  was	  capable	  of	  reversing	  TGF-­‐β1-­‐induced	  
EMT	  in	  alveolar	  epithelial-­‐like	  cells	  (Ramos	  et	  al.	  2010).	  Epithelial	  cells	  cultured	  in	  
the	  presence	  of	  TGF-­‐β1	  assumed	  an	  elongated,	  spindle	  shape	  with	  fibroblast-­‐like	  
morphology,	  and	  displaying	  the	  down-­‐regulation	  of	  E-­‐cadherin	  and	  up-­‐regulation	  of	  
α-­‐smooth	  muscle	  actin	  that	  is	  characteristic	  of	  EMT.	  Once	  treated	  with	  FGF1,	  the	  
morphology	  of	  these	  cells	  reverted	  to	  a	  cobblestone-­‐like	  epithelial	  shape,	  and	  the	  
expression	  levels	  of	  these	  markers	  were	  restored	  to	  nearly	  their	  untreated	  levels.	  
Ramos	  (2010)	  also	  showed	  that	  FGF1-­‐induced	  reversion	  mainly	  occurred	  through	  
the	  MEK/ERK	  pathway,	  major	  components	  of	  which	  are	  up-­‐expressed	  in	  our	  miR-­‐
429	  treated	  samples	  as	  detailed	  above.	  This	  signaling	  through	  the	  MEK/ERK	  
pathway	  eventually	  inhibits	  Smad2	  phosphorylation,	  blocking	  the	  usual	  pathway	  for	  
TGF-­‐β1-­‐induced	  Smad-­‐mediated	  EMT.	  Our	  observation	  of	  increased	  FGF1	  
expression	  at	  48	  hours	  thus	  suggests	  an	  alternative	  pathway	  by	  which	  MET	  may	  
have	  been	  induced	  in	  our	  miR-­‐429	  treated	  cells	  even	  if	  TGF-­‐β	  signaling	  is	  
circumvented.	  
FGF2	  (basic	  fibroblast	  growth	  factor)	  is	  known	  to	  promote	  EMT	  in	  renal	  
development,	  inducing	  cell	  motility	  across	  basement	  membranes	  in	  cultured	  
proximal	  tubular	  epithelium	  while	  down-­‐regulating	  E-­‐cadherin	  and	  cytokeratins	  
(Strutz	  et	  al.	  2002).	  In	  our	  miR-­‐429	  treated	  cells,	  FGF2	  was	  up-­‐expressed	  during	  the	  
0-­‐48	  hour	  time	  span,	  and	  down-­‐expressed	  during	  the	  48-­‐144	  hour	  time	  span.	  FGF2-­‐
induces	  EMT	  by	  activating	  PI3K	  that	  then	  mediates	  a	  number	  of	  small	  GTPases	  (Rho,	  
Rac,	  and	  Cdc42),	  leading	  to	  actin	  cytoskeletal	  remodeling	  (Lee	  and	  Kay	  2006).	  While	  
we	  would	  expect	  up-­‐expression	  of	  FGF2	  to	  result	  in	  EMT,	  PI3K	  (phosphoinositide-­‐3-­‐
kinase)	  is	  down-­‐expressed	  in	  our	  miR-­‐429	  treated	  samples,	  possibly	  acting	  as	  a	  
gatekeeper	  on	  FGF2’s	  induction	  of	  EMT.	  
	  
4.4.	  Discussion	  
Previous	  studies	  have	  established	  a	  role	  for	  miR-­‐200	  family	  microRNAs	  and	  miR-­‐
429	  in	  particular	  in	  the	  induction	  of	  MET	  in	  ovarian	  cancer	  cells	  with	  differing	  
metastatic	  potentials	  (Bendoraite	  et	  al.	  2010;	  Chen	  et	  al.	  2011).	  These	  studies	  relied	  
on	  assays	  of	  gene	  expression	  levels	  taken	  from	  a	  single	  time	  point.	  However	  gene	  
expression	  is	  a	  temporal	  process,	  and	  EMT	  and	  MET	  are	  controlled	  by	  multiple	  
regulatory	  and	  structural	  elements	  that	  are	  known	  to	  change	  expression	  levels.	  
Capturing	  this	  increased	  dimensionality	  demands	  time	  course	  studies,	  where	  the	  
strong	  autocorrelation	  between	  successive	  time	  points	  can	  be	  used	  to	  reveal	  the	  full	  
set	  of	  involved	  genes	  and	  expression	  differences	  that	  would	  not	  otherwise	  be	  
significant	  at	  single	  time	  points.	  We	  examined	  the	  dynamics	  of	  the	  MET	  process	  in	  
mesenchymal-­‐like	  Hey	  cells	  initiated	  by	  a	  single	  miR-­‐429	  transfection,	  assaying	  
gene	  expression	  across	  multiple	  time	  points	  following	  the	  transfection.	  
	   We	  observed	  significant	  change	  in	  cell	  morphology	  and	  molecular	  profiles	  in	  
the	  24	  to	  48	  hours	  following	  transfection	  with	  miR-­‐429,	  confirming	  the	  results	  from	  	  
our	  previous	  single-­‐time	  point	  transfection	  study	  (Chen	  et	  al.	  2011).	  Mesenchymal	  
markers	  like	  fibronectin	  (FN1)	  are	  significantly	  down	  regulated	  in	  this	  time	  period,	  
while	  N-­‐cadherin	  (CDH2)	  is	  slightly	  up	  and	  vimentin	  is	  not	  significantly	  differentially	  
expressed	  across	  the	  time	  span.	  	  Epithelial	  markers	  like	  caveolin	  2	  (CAV2),	  
cytokeratin	  8	  (KRT8),	  and	  desmoplakin	  (DSP)	  are	  up-­‐regulated	  during	  the	  24	  to	  48	  
hour	  period	  and	  are	  significantly	  differentially	  expressed	  across	  the	  time	  span.	  We	  
also	  note	  the	  characteristic	  down-­‐regulation	  of	  ZEB1	  and	  ZEB2,	  previously	  noted	  as	  
an	  effect	  of	  miR-­‐429.	  And	  we	  note	  gene	  enrichment	  among	  these	  significantly	  
differentially	  expressed	  genes	  for	  multiple	  pathways	  related	  to	  the	  mechanisms	  of	  
MET	  and	  EMT.	  
	   In	  our	  miR-­‐429	  transfected	  cells	  we	  observed	  a	  shift	  in	  cell	  morphology	  from	  
mesenchymal-­‐like	  at	  0	  hours	  to	  more	  epithelial	  at	  24	  and	  48	  hours	  followed	  by	  a	  
return	  to	  a	  mesenchymal-­‐like	  morphology	  by	  144	  hours.	  We	  also	  observed	  that	  
nearly	  all	  genes	  (98.6%)	  that	  show	  differential	  expression	  across	  the	  0	  to	  144	  hour	  
time	  span,	  return	  to	  an	  average	  expression	  level	  by	  144	  hours	  that	  is	  not	  
significantly	  different	  from	  their	  average	  expression	  level	  at	  0	  hours.	  This	  suggests	  
that	  most	  of	  the	  changes	  induced	  by	  the	  miR-­‐429	  transfection	  both	  in	  cell	  
morphology	  and	  gene	  expression	  are	  reversible	  and	  non-­‐permanent.	  The	  nature	  of	  
the	  genetic	  reprogramming	  that	  stabilizes	  a	  mesenchymal-­‐like	  phenotype	  in	  Hey	  
cells	  is	  not	  well	  understood,	  but	  Gregory	  et	  al.	  (2008)	  propose	  that	  a	  TGF-­‐β	  
autocrine	  loop	  indirectly	  regulated	  by	  miR-­‐200	  family	  miRNAs	  could	  increase	  ZEB	  
expression,	  resulting	  in	  the	  repression	  of	  E-­‐cadherin	  and	  other	  polarity	  genes	  and	  
establishing	  a	  mesenchymal	  phenotype	  in	  a	  reversible	  manner	  (Gregory	  et	  al.	  
2008b).	  
	   We	  hypothesized	  that	  the	  same	  pathways	  we	  observe	  being	  differentially	  
expressed	  from	  0	  to	  48	  hours,	  then	  return	  to	  their	  original	  expression	  levels	  
between	  48	  to	  144	  hours,	  rather	  than	  different	  pathways	  being	  responsible	  for	  
returning	  these	  Hey	  cells	  to	  a	  mesenchymal-­‐like	  state.	  Our	  observation	  that	  98.6%	  
of	  genes	  that	  show	  differential	  expression	  across	  the	  0	  to	  144	  hour	  time	  period	  
return	  to	  0	  hour	  expressions	  levels	  at	  144	  hours	  reinforces	  our	  hypothesis.	  
However,	  the	  abundance	  of	  differentially	  expressed	  genes	  enriched	  for	  pathways	  
involved	  in	  both	  EMT	  and	  MET,	  coupled	  with	  a	  lack	  of	  functional	  data	  about	  
signaling	  states	  or	  baseline	  function	  of	  specific	  pathways	  leaves	  us	  unable	  to	  
eliminate	  the	  possibility	  that	  a	  different	  set	  of	  pathways	  is	  responsible	  for	  the	  EMT-­‐
like	  process	  that	  is	  observed	  after	  48	  hours.	  Our	  examination	  of	  the	  TGF-­‐B/Smads	  
signaling	  pathway,	  and	  its	  potential	  crosstalk	  with	  MEK/ERK	  pathways	  and	  FGF1	  
leaves	  open	  both	  possibilities.	  	  Our	  findings	  underscore	  the	  challenges	  facing	  the	  
therapeutic	  use	  of	  miRNAs:	  the	  wide	  range	  of	  pathway	  expression	  altered	  by	  miR-­‐
429,	  significant	  temporal	  dependence	  of	  its	  impact,	  and	  need	  for	  further	  functional	  
study.	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CHAPTER	  5	  
CONCLUSION	  
	  
	  
	  
5.1.	  Firefighter	  coronary	  risk	  factor	  study	  
	   In	  this	  study,	  we	  asked	  if	  changes	  in	  common	  accepted	  thresholds	  for	  
assessing	  coronary	  artery	  disease	  (Framingham	  Risk	  Scores)	  could	  be	  brought	  into	  
better	  concordance	  with	  well-­‐established	  non-­‐invasive	  measures	  of	  atherosclerosis.	  
Individuals	  with	  clinically	  significant	  amounts	  of	  coronary	  calcification	  (CAC)	  and	  
carotid	  intima-­‐medial	  thickening	  (CIMT)	  are	  known	  to	  have	  elevated	  risk	  of	  major	  
adverse	  cardiac	  events	  (Nambi	  et	  al.	  2010;	  Baldassarre	  et	  al.	  2012;	  Budoff	  et	  al.	  
2013).	  By	  comparing	  non-­‐invasive	  measurements	  with	  calculated	  risk	  scores	  in	  190	  
asymptomatic	  firefighters,	  we	  were	  able	  to	  identify	  a	  significant	  sub-­‐population	  of	  
individuals	  who	  had	  high	  atherosclerotic	  burden	  or	  significant	  thickening	  of	  carotid	  
arteries	  despite	  having	  low	  to	  medium	  Framingham	  Risk	  Scores	  (<20%).	  Receiver	  
operator	  characteristic	  (ROC)	  analysis	  suggested	  thresholds	  of	  7%	  for	  calcification	  
and	  9%	  for	  intima-­‐medial	  thickness,	  which	  improved	  the	  sensitivity	  of	  FRS	  from	  
17%	  to	  58%	  and	  40%	  to	  67%,	  respectively.	  We	  then	  asked	  if	  adding	  an	  age-­‐based	  
smoking	  adjustment	  for	  all	  individuals,	  regardless	  of	  smoking	  status,	  to	  reflect	  
particulate	  exposure	  over	  time	  could	  also	  improve	  the	  sensitivity	  of	  FRS.	  	  Combined	  
with	  threshold	  optimization	  using	  ROC,	  prediction	  by	  an	  FRS	  threshold	  of	  12%	  
yielded	  a	  sensitivity	  improvement	  to	  43%	  for	  CAC	  and	  75%	  for	  CIMT.	  Our	  
optimizations	  of	  FRS	  thresholds	  using	  ROC	  show	  that	  the	  sensitivity	  of	  traditional	  
measures	  can	  be	  improved	  to	  capture	  those	  at-­‐risk	  individuals	  who	  would	  
otherwise	  be	  scored	  as	  negative.	  It	  is	  of	  particular	  interest	  to	  us	  that	  those	  
individuals	  with	  CAC	  scores	  and	  CIMT	  in	  the	  highest	  quartile	  fall	  into	  the	  low	  to	  
middle	  risk	  categories	  by	  Framingham	  Risk	  Scores.	  Although	  much	  criticized,	  the	  
recommendations	  of	  the	  Adult	  Treatment	  Panel	  III	  Committee	  are	  still	  widely	  used.	  
Given	  that	  even	  with	  our	  improved	  thresholds	  a	  number	  of	  affected	  individuals	  are	  
still	  called	  as	  negative,	  we	  suggest	  that	  firefighting	  as	  a	  profession	  may	  be	  viewed	  as	  
a	  risk	  equivalent	  in	  the	  Framingham	  risk	  assessment	  on	  the	  same	  level	  as	  a	  family	  
history	  of	  coronary	  disease	  or	  diabetes.	  	  
	   As	  a	  follow-­‐up	  to	  our	  study,	  we	  would	  recommend	  increasing	  the	  number	  of	  
sampled	  individuals,	  as	  well	  as	  sampling	  a	  non-­‐firefighter	  age	  and	  disease-­‐state	  
matched	  population.	  This	  would	  enable	  us	  to	  more	  clearly	  distinguish	  risk	  factors	  
specific	  to	  firefighters.	  Moreover,	  a	  five	  and	  ten	  year	  follow-­‐up	  survey	  of	  assayed	  
individuals	  would	  enable	  us	  to	  link	  risk	  factors	  more	  directly	  to	  the	  incidence	  of	  
major	  adverse	  coronary	  events,	  as	  tracked	  by	  the	  Framingham	  Study.	  The	  current	  
suite	  of	  non-­‐invasive	  measures	  provides	  a	  soft	  demarcation	  when	  describing	  
affected	  and	  unaffected	  individuals.	  Moreover,	  the	  combination	  of	  long	  term	  event	  
data	  and	  more	  sampled	  individuals	  would	  permit	  us	  to	  develop	  a	  novel	  total	  risk	  
score	  for	  this	  subpopulation.	  	  
	  
5.2.	  Drug	  eluting	  stent	  gene	  expression	  study	  
	   In	  this	  study	  we	  asked	  if	  coronary	  stents	  eluting	  rapamycin-­‐derived	  
compounds	  actually	  stopped	  the	  progress	  of	  restenosis	  resulting	  from	  stent	  
implantation	  following	  angioplasty,	  or	  if	  it	  only	  delayed	  the	  onset	  of	  in-­‐stent	  
restenosis	  as	  suggested	  by	  a	  number	  of	  clinical	  reports	  (Dangas	  et	  al.	  2010;	  Garg	  and	  
Serruys	  2010;	  Kuriyama	  et	  al.	  2011).	  We	  compared	  the	  arteries	  of	  pigs	  implanted	  
with	  traditional	  bare	  metal	  stents	  with	  the	  arteries	  of	  pigs	  implanted	  with	  sirolimus	  
and	  zotarolimus-­‐eluting	  stents	  using	  high-­‐density	  microarray	  gene	  expression	  
assays.	  Arterial	  tissue	  samples	  surrounding	  the	  implanted	  stents	  were	  harvested	  at	  
28	  days	  post-­‐implantation.	  Zotarolimus-­‐eluting	  stents	  (ZES)	  exhaust	  90%	  of	  their	  
payload	  by	  14	  days,	  while	  sirolimus-­‐eluting	  stents	  (SES)	  reach	  that	  point	  by	  28	  days.	  
In	  our	  studies,	  we	  looked	  at	  genes	  differentially	  expressed	  in	  SES,	  in	  ZES,	  and	  both	  
SES	  and	  ZES.	  Among	  those	  genes	  significantly	  differentially	  expressed	  in	  SES	  we	  
observed	  up	  regulation	  of	  genes	  associated	  with	  extracellular	  matrix	  degradation,	  
specifically	  matrix	  metalloproteases,	  and	  a	  down	  regulation	  of	  genes	  for	  ion	  
channels	  that	  has	  been	  previously	  observed	  in	  vascular	  smooth	  muscle	  cells	  shifting	  
from	  the	  contractile	  to	  proliferative	  state.	  While	  among	  the	  genes	  significantly	  
differentially	  expressed	  in	  ZES,	  we	  observed	  an	  up	  regulation	  of	  genes	  associated	  
with	  basement	  membrane	  growth	  and	  structural	  markers	  known	  to	  accompany	  the	  
contractile	  state	  in	  vascular	  smooth	  muscle	  cells	  and	  neointimal	  growth.	  For	  both	  
SES	  and	  ZES,	  there	  were	  significantly	  differentially	  expressed	  inflammatory	  
response	  genes	  that	  are	  known	  players	  in	  the	  extravasation	  that	  occurs	  at	  the	  
restenotic	  wound	  site.	  When	  taken	  together	  with	  the	  timeline	  for	  restenosis	  that	  has	  
been	  well	  characterized	  in	  histological	  and	  molecular	  assays,	  this	  is	  consistent	  with	  
a	  timeline	  where	  SES	  and	  ZES	  have	  delayed	  restenosis	  in	  their	  respective	  arteries	  up	  
until	  drug	  payload	  exhaustion,	  whereupon	  the	  process	  resumes.	  Alternatively,	  the	  
data	  we	  observed	  may	  also	  be	  consistent	  with	  a	  timeline	  where	  SES	  and	  ZES	  stalls	  
the	  restenotic	  process	  in	  the	  smooth	  muscle	  cell	  migration	  and	  proliferation	  phase.	  
	   Our	  analysis	  of	  the	  gene	  expression	  data	  relied	  solely	  on	  statistical	  tests,	  
abandoning	  prior	  reliance	  on	  fold	  change	  as	  an	  arbitrary	  threshold	  for	  determining	  
significant	  differential	  expression.	  When	  analyzing	  a	  large	  number	  of	  data	  points,	  be	  
they	  tens	  of	  thousands	  of	  genes	  or	  hundreds	  of	  gene	  sets,	  multiple	  testing	  correction	  
is	  critical	  to	  minimize	  false	  positive	  results.	  To	  correct	  the	  Student’s	  t-­‐test	  we	  used	  
to	  compare	  individual	  gene	  expression	  levels	  between	  groups,	  we	  used	  a	  beta-­‐
uniform	  mixed	  modeling	  approach	  (BUM)	  designed	  to	  correct	  high	  dimensionality	  
data	  sets	  like	  gene	  expression	  microarrays	  (Allison	  et	  al.	  2002;	  Pounds	  and	  Morris	  
2003).	  BUM	  models	  the	  observed	  p-­‐value	  distribution	  as	  a	  mixture	  of	  a	  uniform	  
distribution	  corresponding	  to	  true	  null	  values,	  and	  a	  beta	  distribution	  
corresponding	  to	  false	  null	  values.	  This	  model	  can	  then	  be	  used	  to	  adjust	  the	  p-­‐value	  
threshold	  for	  significance	  to	  generate	  different	  false	  positive	  and	  false	  negative	  
rates.	  For	  normalized	  enrichment	  scores	  (NES)	  calculated	  by	  Gene	  Set	  Enrichment	  
Analysis	  (GSEA),	  false	  discovery	  rate	  (FDR)	  estimates	  are	  calculated	  for	  each	  gene	  
set.	  For	  a	  given	  observed	  NES,	  the	  probability	  of	  that	  observed	  NES	  being	  a	  false	  
positive	  is	  calculated	  by	  permuting	  phenotype	  labels	  to	  generate	  a	  null	  distribution	  
(Subramanian	  et	  al.	  2005).	  We	  are	  then	  able	  to	  choose	  a	  threshold	  for	  an	  acceptable	  
level	  of	  false	  positives	  based	  on	  these	  estimates.	  Both	  the	  BUM	  and	  FDR	  approach	  
provide	  false	  positive	  and	  false	  negative	  rate	  estimates	  that	  allow	  us	  to	  adjust	  
significance	  thresholds	  for	  different	  data	  sets.	  Particularly	  in	  these	  cases	  where	  we	  
expect	  the	  total	  number	  of	  positives	  to	  be	  small,	  this	  enables	  investigators	  to	  weigh	  
changes	  in	  the	  rate	  of	  false	  positives	  against	  gains	  in	  statistical	  power	  and	  discovery.	  	  
	   Our	  study	  has	  its	  greatest	  limitation	  in	  the	  single	  time	  point	  when	  arterial	  
samples	  were	  harvested.	  	  To	  improve	  resolution	  of	  the	  time	  course	  and	  drug	  effects	  
over	  time	  would	  require	  additional	  time	  points	  over	  a	  longer	  time	  frame	  and	  more	  
animals	  per	  time	  point.	  Adding	  an	  angioplasty-­‐only	  animal	  series	  would	  also	  allow	  
us	  to	  establish	  a	  clear	  base	  line	  response	  for	  bare	  metal	  stent	  implantation	  at	  a	  high-­‐
density	  microarray	  resolution.	  Finally,	  measuring	  drug	  concentration	  directly	  in	  
tissue	  using	  a	  pharmacological	  assay	  would	  permit	  us	  to	  adjust	  for	  differential	  
effects	  due	  to	  local	  drug	  delivery.	  
	   	  
5.3.	  miR-­429	  treatment	  of	  ovarian	  cancer	  cell	  study	  
	   In	  this	  study,	  we	  asked	  how	  ovarian	  cancer	  cells	  with	  a	  mesenchymal	  
metastatic	  cell	  phenotype	  reacted	  at	  the	  molecular	  level	  to	  a	  single	  treatment	  with	  
microRNA,	  miR-­‐429.	  miR-­‐429	  previously	  had	  been	  characterized	  as	  a	  member	  of	  the	  
miR-­‐200	  family	  that	  was	  capable	  of	  inducing	  decreased	  migration,	  suppression	  of	  
anchorage-­‐independent	  growth,	  as	  well	  as	  morphological	  changes	  when	  over-­‐
expressed	  in	  HEY	  cells.	  To	  further	  characterize	  the	  effect	  of	  miR-­‐429	  in	  Hey	  cells,	  we	  
treated	  these	  cells	  with	  miR-­‐429	  and	  took	  molecular	  “snapshots”	  at	  24,	  48,	  and	  144	  
hours,	  a	  time	  interval	  over	  which	  we	  had	  previously	  observed	  significant	  
morphological	  changes.	  By	  utilizing	  a	  time	  course	  analysis	  approach,	  we	  were	  able	  
to	  not	  only	  capture	  significant	  time	  point-­‐to-­‐time	  point	  changes,	  but	  also	  more	  
subtle	  changes	  that	  occurred	  across	  the	  entire	  time	  course	  while	  compensating	  for	  
changes	  observed	  in	  our	  negative	  control.	  	  
Consistent	  with	  prior	  studies,	  we	  observed	  morphological	  changes	  in	  miR-­‐
429-­‐treated	  Hey	  cells,	  where	  cells	  changed	  from	  a	  pre-­‐transfection	  (0	  hour)	  
elongated	  fibroblast-­‐like	  state	  to	  a	  rounded,	  cobblestone	  epithelial-­‐like	  state	  by	  24	  
and	  48	  hours,	  eventually	  returning	  to	  a	  fibroblast-­‐like	  state	  by	  144	  hours.	  Negative	  
control-­‐treated	  cells	  showed	  no	  morphological	  changes	  at	  any	  time	  point.	  Across	  
this	  time	  course,	  3635	  genes	  displayed	  significantly	  differential	  expression	  across	  
the	  entire	  time	  course	  when	  compared	  to	  the	  negative	  control	  treated	  Hey	  cells.	  
Mesenchymal	  markers	  like	  fibronectin	  were	  down	  regulated,	  while	  epithelial	  
markers	  like	  caveolin	  2,	  catenin,	  keratin,	  and	  desmoplaking	  were	  up	  regulated	  
across	  the	  time	  course.	  Transition	  of	  cancer	  cells	  from	  the	  drug-­‐resistant	  
mesenchymal	  phenotype	  to	  drug-­‐sensitive	  epithelial	  phenotype	  may	  permit	  miR-­‐
429	  to	  be	  used	  as	  a	  co-­‐therapeutic	  in	  chemotherapy	  (Chen	  et	  al.	  2011).	  
The	  return	  of	  morphological	  features	  to	  their	  0-­‐hour	  state	  at	  144	  hours	  led	  
us	  to	  ask	  if	  individual	  gene	  expression	  levels	  followed	  the	  same	  pattern.	  We	  
determined	  that	  98%	  of	  differentially	  expressed	  genes	  did	  not	  have	  significantly	  
different	  average	  expression	  levels	  at	  144	  hours	  than	  they	  did	  at	  0	  hours,	  corrected	  
for	  the	  change	  in	  expression	  observed	  in	  negative	  control-­‐treated	  cells	  across	  the	  
same	  time	  interval.	  Out	  of	  the	  2%	  that	  did	  show	  significantly	  different	  average	  
expression	  levels	  at	  144	  hours,	  we	  noted	  genes	  that	  were	  associated	  with	  
EMT/MET,	  such	  as	  Wnt7A,	  Serpine1	  and	  LAMC2.	  This	  plasticity	  may	  prove	  to	  be	  a	  
double-­‐edged	  sword	  when	  translating	  miR-­‐429’s	  potential	  as	  a	  co-­‐therapeutic.	  The	  
brevity	  of	  response	  may	  necessitate	  more	  treatments	  to	  develop	  a	  sustained	  effect,	  
but	  it	  may	  also	  allow	  patients	  to	  escape	  unwanted	  side	  effects	  more	  quickly	  once	  
therapy	  has	  been	  delivered.	  More	  testing	  on	  other	  cell	  types	  may	  be	  necessary	  to	  
gauge	  miR-­‐429’s	  long-­‐term	  effects.	  	  
Finally,	  out	  of	  the	  3635	  genes	  that	  were	  differentially	  expressed	  following	  
miR-­‐429	  treatment,	  only	  261	  genes	  are	  predicted	  targets	  of	  miR-­‐429	  by	  miRANDA.	  
This	  highlights	  the	  previously	  described	  highly	  indirect	  nature	  of	  the	  miR-­‐200	  
family	  in	  affecting	  gene	  expression.	  While	  the	  261	  predicted	  gene	  targets	  are	  in	  fact	  
enriched	  for	  genes	  having	  to	  do	  with	  EMT	  and	  MET	  processes,	  the	  non-­‐predicted	  
genes	  are	  part	  of	  the	  wider	  secondary	  effects	  from	  miR-­‐429	  treatment,	  highlighting	  
the	  need	  for	  network	  analysis	  of	  highly	  inter-­‐connected	  genes.	  This	  may	  also	  
represent	  a	  shortcoming	  in	  miRANDA’s	  ability	  to	  correctly	  predict	  targeting	  by	  this	  
microRNA.	  Our	  ability	  to	  research	  miR-­‐429	  and	  other	  microRNAs	  as	  therapeutics	  
may	  be	  greatly	  improved	  by	  further	  work	  in	  system	  biological	  approaches	  to	  
studying	  microRNA	  activity	  and	  microRNA	  targeting	  prediction.	  	  
Additional	  downstream	  studies	  to	  improve	  our	  understanding	  of	  this	  plastic	  
response	  include	  expanding	  the	  sampling	  time	  points	  beyond	  144	  hours	  to	  see	  if	  
genes	  that	  did	  not	  return	  to	  0-­‐day	  expression	  levels	  in	  this	  study	  do	  return	  on	  a	  
longer	  time	  scale	  (as	  well	  as	  confirming	  the	  long	  term	  stability	  of	  those	  genes	  that	  
appear	  to	  return	  to	  their	  0-­‐day	  levels).	  We	  may	  also	  desire	  to	  investigate	  cell	  
migration	  and	  other	  phenotypic	  response	  at	  all	  time	  points	  to	  determine	  if	  the	  
plastic	  response	  in	  gene	  expression	  levels	  and	  morphology	  are	  also	  reflected	  in	  the	  
cells	  functional	  responses.	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